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Abstract 
Gamma-herpesviruses can cancers. For example, Epstein-Barr virus (EBV) causes B cell 
Burkitt’s lymphoma and nasopharyngeal carcinoma. EBV infection is endemic world-wide 
with a sero-prevalence of 75-95%. Our understanding of how EBV infects in vivo and how 
it might be controlled is limited. For example, how EBV enters the host is still a contested 
debate. This has made vaccination a distant challenge. Vaccine trials to date have 
reduced the symptoms of primary infection (infectious mononucleosis) but not the long-
term viral loads that likely lead to cancers. The species specificity of EBV has made new 
vaccines difficult to develop.  
 
Murid-herpesvirus 4 (strain MHV-68), readily infects inbred laboratory mice, and has 
provided an accessible way to understand gamma-herpesvirus infection and control. Like 
EBV, it persists in memory B cells. Live-attenuated MHV-68 that lacks the ORF73 open 
reading frame, and so is deficient in latency and persistence, protects mice against long-
term wild type infection. Dissecting natural and vaccine-induced infection control has 
identified distinct roles for CD4+ T cells, CD8+ T cells and antibody. CD4+ T cells play a 
particular role in controlling chronic lytic infection. As yet, the immune effectors responsible 
for controlling latency remain ill-defined. CD8+ T cells specific for latent viral antigens play 
some role, but vaccination to prime these cells has not reduced long-term viral loads.  
 
Recently, cytomegaloviruses have gained prominence as vaccine vectors. To test 
protection by CD4+ T cell priming, a recombinant murine cytomegalovirus that expresses 
membrane bound ovalbumin from the viral genome was used to vaccinate against a 
recombinant MHV-68 that expresses the same membrane bound ovalbumin from a lytic 
promoter. Vaccinated mice controlled lytic infection but failed to reduce long-term infection. 
Nor was a combination of CD4+ and CD8+ T cell priming fully effective. In trying to improve 
recombinant cytomegalovirus-based priming, MHC class II down-regulation was noted in 
infected cells, along with relatively weak CD4+ T cell priming. This down-regulation was 
found to depend on the viral M78 gene. M78-deficient MCMV was characterised in vitro 
and in vivo. More than one defect was identified, but a significant component was found to 
be CD4+ T cell-dependent. This represents a possible future basis for better 
cytomegalovirus-mediated CD4+ T cell priming, and so better protection against long-term 
gamma-herpesvirus infection.  
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i.v Intravenous 
LCMV Lymphocytic choriomeningitis virus 
LMP2 Latent membrane protein 2 
MOI multiplicity of infection 
MHV-68 Murine Herpesvirus-68 
mRNA Messenger ribonucleic acid  
MS Multiple sclerosis 
NF-Y Nuclear factor Y 
pp65 Phosphoprotein 65 (MCMV) 
QPCR Quantitative (real-time) polymerase chain 
reaction 
RFX Regulatory factor X 
RPM Rotation per minute 
RNA Ribonucleic acid 
Rta Replication and transcription factor 
RT-PCR Reverse transcription polymerase chain 
reaction 
RT Room temperature 
ORF Open reading frame 
oriP Origin of replication 
OVA Ovalbumin 
SP Spleen 
SCLN Superficial cervical lymph node 
MLN Mediastinal lymph node 
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PMBC Peripheral blood mononuclear cell 
PCR Polymerase chain reaction 
PEL Primary effusion lymphoma  
TCR T cell receptor 
TNFα Tumour necrosis factor alpha 
JAK Janus kinase 
K181 MCMV Perth laboratory strain 
Kb Kilobase 
KDa Kilo Daltons  
NK Natural Killer cells 
p.i Post infection 
PFU Plaque forming units 
SEM Standard error of mean 
SG Salivary glands 
IM Infectious mononucleosis  
Vac Vaccinia virus 
Cont Control 
PTLD Post-transplant lymphoproliferative 
APC Allophycocyanin 
FITC Fluorescein isothiocyanate 
PE Phycoerythrin  
Per CP Cy5.5 Peridinin chlorophyll protein complex 
Cyanine 5.5 
BV421 Brilliant Violet 421 
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CHAPTER 1: INTRODUCTION 
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1.1 Significance 
Epstein-Barr virus (EBV) is an oncogenic virus that infects more than 95% of adults world-
wide (1) with no licenced preventative or therapeutic vaccine. It is associated with African 
Burkitt’s lymphoma and nasopharyngeal carcinoma in which nearly all tumour cells contain 
EBV genomes (2). Burkitt’s lymphoma is the most common childhood cancer of sub-
Saharan Africa while nasopharyngeal carcinoma is prevalent in Southern China (2, 3). The 
median age of developing Burkitt’s lymphoma in Africa is 8 years (4). The virus infects 
approximately 50% of children by the age of 1 and is generally asymptomatic (4). In 
developed countries, primary EBV infection is delayed in young adults and is the main 
cause of infectious mononucleosis (IM) (5). 
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1.2 Aims 
The overall aim of this thesis is to test whether a recombinant murine cytomegalovirus can 
vaccinate against MHV-68, using ovalbumin as a shared model antigen. 
1.2.1 Specific aims 
a) Characterise T cell mediated immune control against MHV-68 in; 
i. BALB/c mice, that make a strong CD4+ T cell response to ovalbumin 
ii. C57BL/6 mice, which make a strong CD8+ T cell response to ovalbumin 
and a weak CD4+ T cell response.  
iii. F1 mice (BALB/c x C57BL/6), that make comparable CD4+ and CD8+ T 
cell responses to ovalbumin. 
b) Determine whether a recombinant vaccinia virus expressing the MHV-68 gH/gL can 
protect.  
c) Understand how MCMV limits antigen presentation to CD4+ T cells, and how this 
contributes to host colonisation. 
d) Using ORF73-deficient, ovalbumin+ MHV-68, to track antigen-specific CD4+ T cells 
in an established protection model. 
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1.3 Literature Review 
This review will cover vaccine initiatives against EBV and the use of animal models to 
understand virus-host interactions that are important for protection against 
infection.  There are many elegant reviews that detail the physical structure, genetic and 
replicative properties of EBV (2, 6-13) and these are not detailed in this thesis.  
1.3.1 Clinical background 
EBV pathology is associated with primary infection or reactivating virus in 
immunocompromised hosts and is the major cause of post-transplant lymphoproliferative 
disorder (PTLD). PTLD is a complication of solid organ transplants and haematopoietic cell 
transplants (14-16). PTLDs from solid organ transplants originate from recipient lymphoid 
cells while in bone-marrow or stem cell transplant, PTLDs are usually of donor origin (15). 
Most PTLDs studied are of B cell origin, particularly germinal centre B cells and may 
develop at different times after organ transplant (15, 17, 18). Early onset of PTLDs are 
usually EBV driven after an episode of primary infection or virus reactivation where EBV 
oncogenes drive polyclonal B cell proliferation. Late onset of PTLDs which are not always 
associated with EBV infection are predominately monoclonal lymphoid malignancies (19-
21). In EBV driven lymphoproliferation, infected cells are immune targets (22). In these 
patients, immune function can be restored by administrating Rituximab (anti-CD20) which 
eliminates B cells that harbour virus, thus reducing virus load (23). Chemotherapy can also 
be used when Rituximab fails or if tumours are EBV negative (23).   
1.3.2 EBV pathogenesis 
1.3.2.1 Infectious mononucleosis 
Primary EBV infection in children is asymptomatic but in adults manifests as IM, a benign 
lymphoproliferative disorder characterised by expansion of EBV infected B-lymphoid blasts 
(24) and proliferation of activated T cells (25). IM symptoms range from; fever, skin 
lesions, pneumonitis, hepatitis, encephalitis, hemolysis, leukopenia, and thrombocytopenia 
(13, 26). 
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1.3.2.2 Burkitt’s lymphoma  
B cell Burkitt’s lymphoma was first characterised by Dr Denis Burkitt while working as a 
surgeon in Uganda (27, 28). Burkitt’s lymphoma is an aggressive form of non-Hodgkin B 
cell lymphoma derived from germinal center B cells (29). It is characterised by uncontrolled 
proliferation of malignant cells due to translocation of the c-MYC gene (30). BL is sub-
divided into three clinical classification; endemic, sporadic, and immunodeficiency-
associated variants distinguishable only by their clinical and geographical presentations 
(31). Endemic Burkitt’s lymphoma occurs predominately in children aged 5 to 8 years 
along the equatorial part of Africa and Papua New Guinea and accounts for 74% of 
childhood non-Hodgkin’s lymphoma (32). In adults, the sporadic form occurs in Western 
Europe and in the United States and accounts for 1-2% of all adult lymphomas (33). HIV 
associated Burkitt’s lymphoma accounts for 30-50% of all EBV positive lymphomas 
worldwide (34). This increase has been attributed to the HIV epidemic (35). Onset of 
Burkitt’s lymphoma leads to the development of high titer IgG antibodies to Burkitt’s 
lymphoma cell line Jiyoye when used as source of antigen (36) and the EBV viral capsid 
antigen (37). 
1.3.2.3 Nasopharyngeal carcinoma 
This is a carcinoma associated with the presence of monoclonal EBV episomes in 
epithelial cells of the nasopharynx (38, 39) and is a major health problem in Southern and 
Eastern Asia (40). In Southern China and Southeast Asia, the incidence of NPC is 
relatively high, about 25% compared to the rest of the world, where the incidence is below 
1/100,000 per year, in Caucasians from North America and Western Europe (38). NPC 
peaks at 50-60 years of age but can also be observed in childhood (41). It is more 
prevalent in men that in women and is independent of race or ethnicity (42). EBV induced 
NPC is classified in three forms, keratinising squamous cell carcinoma (SCC) type I, a 
non-keratinising differentiated type II and non-keratinising undifferentiated type III 
according to the World Health Organisation (WHO) classification of NPCs based on 
tumour cell morphology by light microscopy (3, 43). Type II (23%) and III (60%) account for 
most NPC cases worldwide with type 1 accounting for less than 20% of all NPC cancers 
(38). In NPC, EBV exists in its latent form (3). Patients with type II and type III NPC but not 
type I also develop high titer IgG and IgA to viral capsid antigens, and EBV early antigen 
(44). Currently, the standard treatment for NPC is radiotherapy but patients can also 
undergo chemotherapy or combined chemoradiation therapy in cases of advanced 
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disease (45, 46). The response to radiation or chemotherapy varies with NPC type (39). In 
Southeast Asia, particularly in Indonesia, patients diagnosed with type III but not type I 
NPC at the time of radiotherapy had an overall survival of 70%-80% and 3 years of event 
free NPC (40).  
1.3.2.4 EBV associated gastric carcinoma 
The association between EBV and gastric carcinoma (EBVaGC) was first proposed in the 
early 1990s when DNA from paraffin-embedded block of an undifferentiated 
lymphoepithelial gastric carcinoma was positive for EBV genome by PCR and was 
histologically distinct from other carcinomas of the stomach (47, 48). EBVaGC represents 
10% of all gastric carcinomas worldwide and is predominately found in males (49, 50). 
EBV exists as episomes in infected gastric carcinoma cells without active replication (51). 
How EBV causes gastric carcinogenesis is still not well understood. Nonetheless, there is 
growing evidence that like Helicobacter Pylori (H.pylori), EBV is a co-factor in gastric 
carcinomas (51-53). EBV is also thought to be associated with a number of other 
malignancies for example acquired immune deficiency syndrome associated B-cell 
lymphomas, NK/T cell lymphoma, Hodgkin lymphoma. These are critically reviewed 
elsewhere (9, 11, 34) and not included in this thesis.  
1.3.2.5 Multiple sclerosis  
The link between EBV and multiple sclerosis (MS) was first proposed in the early 1980s 
when patients with a history of infectious mononucleosis (IM) developed MS (54). In the 
early 1990s, relapsing chronic or acute demyelinating disease following IM in five patients 
was attributed to EBV infection (55). MS risk factors are thought to be high levels of EBV-
specific antibodies and onset of IM (56, 57). This was found to be age dependent, with 
higher titers to EBNA-1 by 25 or later in life predictive of MS (58, 59). Despite these 
etiological studies, no direct brain infection has been demonstrated raising interesting 
questions; for example why is MS not prevalent despite EBV infections being common in 
the population and what causes MS in EBV seronegative patients? (60). Genetic 
predisposition and age at primary infection or infection with other microbes are possible 
factors (57). Thus, a cause and effect and a better understanding of the mechanism of 
how EBV drives or leads to MS is critical particularly in EBV seronegative patients (57, 60).  
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1.3.3 Transmission 
How EBV enters the host is still a matter of debate. Why is this important? Virus entry is 
the first essential process for the virus to begin replication. Blocking entry into the first 
target cell subsequently suppresses virus load and provides an attractive vaccination 
strategy. This was the reasoning behind the glycoprotein 350 (gp350) vaccine to target 
complement receptor type 2 required for B cell entry (61) as a prophylactic vaccine. This 
vaccine failed to prevent transmission and persistence associated with EBV pathogenesis. 
This showed epithelial cell infection precedes B cell infection. And the high prevalence of 
EBV suggests transmission efficiency between individuals is high. Oral transmission is 
thought to be the main route of entry because of the presence of virus in the saliva (13, 18, 
62). In the mid-1980s to early 1990s when EBV DNA was detected in cervical secretions 
of women and in urethral discharge of men, sexual transmission was proposed as an 
alternative route of transmission (63, 64). Thus, identifying a consensus route of entry can 
inform vaccine design and strategies to block entry and prevent transmission.  
1.3.4 Epidemiology of EBV 
Identifying risk groups provide key vaccine targets. Epidemiological studies into the risks of 
acquiring EBV showed an association between sexual intercourse and EBV sero-positivity 
that correlated with sexual partners in a study of university and college students (13, 65, 
66). No study has yet demonstrated a direct link between the presence of EBV in sexually 
active individuals to either sexual intercourse, kissing or oral-genital contact suggesting 
that, kissing or sexual intercourse play a role in EBV transmission 
1.3.5 EBV replication 
EBV is thought to infect and initiate lytic replication in epithelial cells of the oral mucosa  
that drives viral DNA replication and lytic antigen expression (1). Naïve infiltrating B cells 
or lymphocytes around the lymphoid tissue that surrounds the oropharynx (67) are then 
infected and induced to proliferate. This expands the latent pool of infected cells that either 
differentiate into memory or plasma cells (67). In memory B cells, EBV is transcriptionally 
silent, and is invisible to the immune system particularly cytotoxic T cell lymphocytes (68). 
The virus can sporadically reactivate from latency when memory B cells differentiate into 
plasma cells. What triggers this reactivation is currently unknown? Plasma cells (20) then 
re-enter the circulation and circulate to peripheral sites to establish latency in epithelial or 
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B cell sites (1, 69). Latent form of EBV is maintained as a stable viral genome (22) with no 
detection of lytic replication (2). Immunosuppressed individuals tend to have expansive 
latently infected memory B cells in the blood than in healthy carriers (68) suggesting 
frequent reactivation.  
1.3.6 Immune responses 
T cells are essential to control EBV (67). Innate and adaptive immunity play 
complementary roles in EBV control. In this thesis, the focus is on cell mediated immunity 
particularly CD4+ and CD8+ T cells and the vaccine strategies that have been tried.  
1.3.6.1 CD8+ T cell responses 
In immunocompetent hosts, symptomatic infection that manifests as IM elicits a strong 
CD8+ T cell response that is effective at limiting virus load. Cytotoxic CD8+ T cells target 
EBV immediate-early or early lytic proteins (BZLF1, BRLF1 and BMLF1) and to some 
extent latent proteins (EBNA3A, 3B, 3C and LMP2). These protein targets were identified 
using in vitro assays involving rechallenging polyclonal CD8+ T cell lymphocytes isolated 
from peripheral blood or by direct detection using peptide-specific MHC I tetramers (22, 
70-73). How CD8+ T cells restrict virus replication in immunosuppressed individuals, is not 
clear. During latency as virus load decreases, CD8+ T cells become less effective, in part 
due to immune evasion. EBV encodes several genes that interfere with HLA-1 processing 
and antigen presentation; BNLF2a inhibits peptide and ATP binding of TAP (74), BGLF5 
shuts off host protein synthesis (75) and BILF1 downregulates HLA-1 (76). These 
processes interfere with HLA-I antigen presentation and modulate the CD8+ T cell immune 
responses to EBV. However, whether these genes directly influence the CD8+ T cell 
response in vivo remains to be determined. 
1.3.6.2 CD4+ T cell responses 
CD4+ T cell responses to EBV are not well characterised but are predominately directed to 
enhancing B cell maturation and differentiation necessary for high affinity antibody 
production (22) and in generating and maintaining memory CD8+ T cells (77). Cytotoxic 
CD4+ T cells have been reported to EBV lytic (78) and latent epitopes LMP1 and LMP2 
(79). These have been characterised in vitro using vaccinia viruses expressing lytic or 
latent EBV proteins on B lymphoblastoid cell lines (B-LCL) or dendritic cells (DCs) or EBV-
transformed LCL established by infecting peripheral blood lymphocytes (78). Attempts to 
30 
 
determine the CD4+ T cell cytotoxic response to EBNA1 found no cytotoxic activity when 
B-LCL cells were infected with vaccinia virus expressing EBNA1. CD4+ CTLs were unable 
to lyse EBV-infected B cells suggesting that EBNA1 may not be endogenously processed 
and presented to the host CD4+ CTL (80). Whether these cytotoxic CD4+ T cells are even 
readily detectable in vivo remains to be determined. CD4+ T cells from patients with IM 
showed a burst in frequency of effector CD4+ T cells that declined with a small proportion 
persisting during chronic infection (81). Expansion and inflation of EBV-specific CD4+ T 
cells was found to correlate with peripheral blood EBV load suggesting CD4+ T cell 
responses to EBV are antigen driven (82).  
1.3.6.3 Vaccination 
Glycoprotein 350 (gp350) as a prophylactic vaccine failed to prevent transmission and 
persistence associated with EBV pathogenesis (23). In China, a single dose of gp350 
expressed by a vaccinia virus conferred no protection to EBV seronegative vaccinated 
children (83). A single-phase two trial of a recombinant subunit gp350 vaccine reduced the 
rate of IM in healthy EBV seronegative young adults but could not prevent asymptomatic 
infection (84, 85). Similarly, vaccination of children with chronic kidney disease awaiting 
organ transplant was found to be ineffective (86).  
The failure of EBV glycoprotein gp350 to confer protection has led to alternative 
approaches to improve efficacy or use peptides directed against other EBV proteins to 
elicit cellular mediated immune responses. Thus,  a CD8+ T cell epitope based vaccine 
against a latency associated protein EBNA3 was well tolerated with no side effects (87). 
Four out of eight EBV seronegative vaccinees seroconverted and had no symptoms of IM 
(87). Ex vivo IFN-γ ELISPOT confirmed vaccine induced response in three of the 
vaccinees. However, due to the small sample size, it is difficult to correlate protection to 
immune response induced by the vaccine.  
Other EBV glycoproteins such as gp42 that binds to HLA class II molecules as a receptor 
(88) and gH/gL that is thought to interact with integrin receptors (89) have also been 
shown to be targets for neutralisation. Monoclonal antibodies directed against gp42 
inhibited B cell infection while gH/gL inhibited epithelial cell infection (90). Recently a 
tripartite nano-particle based vaccine targeted against gH/gL/ gp42 showed promising 
results in vitro and generated high titer antibodies in mice (91). No human trials have been 
performed to date.  
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1.4 Animal model systems for EBV vaccination studies. 
To understand how new vaccine combinations work, and which vaccine platforms to use, 
animal models are critical as proof of concept and to reveal mechanisms of control since 
host specificity has hindered vaccine design.    
1.4.1 Rhesus Lymphocryptovirus  
EBV, unlike all gamma-1-herpesviruses (lymphocryptovirus) is not present in all primates 
(92, 93). Gamma-2-herpesviruses (rhadinoviruses), which includes KSHV and MHV-68, 
occur in all mammals (94). Rhesus lymphocryptovirus is the main primate model for EBV 
and reproduces key aspects of human EBV infection; atypical lymphocytosis, 
lymphadenopathy, latent infection in peripheral blood, and virus persistence in 
oropharyngeal secretion (95). Vaccination of rhesus monkeys with soluble gp350 to mimic 
gp350 vaccinations in humans, reduced the level of LCV DNA loads in blood months after 
LCV infection (96). In contrast, rhesus monkeys that received virus like replicon particles to 
latent antigens EBNA-3A and EBNA-3AB to model CD4+ and CD8+ T cell induced 
protection, were ineffective in reducing virus loads (96). The results showed that although 
gp350-specific responses targeted lytic infection they had no effect on persistent infection. 
Priming CD4+ and CD8+ T lymphocytes against latent epitopes had no anti-viral effect. 
These findings are consistent with human EBV vaccine trials and demonstrates the low 
antigenicity and limited efficacy of epitope and soluble vaccines.  
1.4.2 Live attenuated vaccines 
Live attenuated vaccines have now been shown to be effective and have had major impact 
on human health against acute virus infections, particularly influenza, rotavirus, measles, 
mumps, yellow fever and polio (97). Developing vaccines against persistent viruses have 
posed significant challenges throughout history because of safety concerns. The only 
successful herpesvirus vaccine against a persistent virus is the live attenuated vaccine 
against varicella zoster virus, a herpesvirus related to herpes simplex 1 and 2. The vaccine 
was slow to develop because of technical difficulties, identifying markers for virus 
attenuation, evaluating the risk of vaccine morbidity and mortality in healthy individuals and 
the duration of immunity following vaccination (98). The anti-viral treatment of choice, 
acyclovir, provides minimal benefits, reinforcing the need for prevention-based therapy 
using a vaccine that was safe and effective. In 1974, the first clinical trial of a live 
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attenuated varicella zoster Oka strain in 70 healthy individuals was tested in Japan (99). 
Subsequently, the vaccine was licenced for general use in 1988 and showed promise in 
immunocompromised individuals (99, 100). It was then licenced in the US in 1995 for 
persons 12 months of age and older (101). The mechanism of action is still not well 
understood. Protection is thought to be mediated by antibody directed against structural 
glycoproteins, nucleocapsid and tegument proteins based on in vitro neutralising assays 
(98). Nevertheless, more than 90% of vaccine responders maintain antibody for at least 6 
years (99) and it is well tolerated and safe (101).  
A live attenuated EBV vaccine has not yet been tried. Since EBV is an oncogenic virus, a 
live attenuated vaccine poses potential risk. Thus, a replication deficient recombinant 
vaccine vector targeting lytic and latent epitopes of EBV seems essential. This is difficult to 
do in humans. The poor characterisation of EBV infection processes and host specificity 
further hinders vaccine design and testing. Thus, to develop strategies, animal models are 
critical to elucidate the biology of vaccine targets, vaccine vectors, mechanism of action 
and demonstrate safety.  
1.4.3 Murine gamma-herpesvirus 68 
Murine gamma-herpesvirus 68 (MHV-68) also known as (Murid Herpesvirus-4) was first 
isolated from bank voles in Slovakia and found to cause cytopathic effects (CPE) in 
epithelial and fibroblast cell lines (102). MHV-68 infects B cells and becomes latent with 
sporadic reactivation. This was demonstrated in NSO, a mouse myeloma cell line, and 
A20, a B cell hybridoma cell line derived from lymphoma in vitro (103). Similar to EBV, 
MHV-68 causes IM like syndrome, splenomegaly (enlargement of the spleen due to B cell 
expansion), lymphoproliferative disease (proliferation of B cells in the lymph nodes), 
persists in memory B cells and causes CD8+ T cell peripheral lymphocytosis (103-105). It 
is a naturally occurring herpesvirus of wild rodents and readily infects laboratory mice, the 
least expensive, easy to handle and ethically less challenging animal model to work with to 
develop a basic understanding of what could work against EBV (105). MHV-68 is also 
genetically related to Epstein-Barr virus (105). About 80% of their genes are close 
homologs (106). However, due to host adaptation, these viruses have evolved divergent 
functions specific to their respective hosts. Thus, MHV-68 as an EBV model is limited to 
understanding mechanisms of host colonisation and protection but not efficacy or safety of 
vaccines.  
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1.4.3.1 Normal infection 
How MHV-68 colonises the host has been characterised. The virus infects via the upper 
respiratory track causing epithelial nose infection, specifically the olfactory neuroepithelium 
(107-109). The neuroepithelium is a poorly characterised site, but is targeted by HSV-
1(110) and MCMV (111) suggesting, it is an important site for herpesvirus entry. The virus 
can also infect alveolar epithelial cells in the lungs after lower respiratory tract intranasal 
inoculation under anaesthesia (105, 107, 112). MHV-68 causes no infection when given 
orally (107). Sexual transmission has recently been demonstrated in naïve males caged 
with latently infected females (113).This raises interesting questions on whether sexual 
transmission is a normal route of transmission for all gamma-herpesviruses as postulated 
for EBV. However, this is unlikely to be the most common natural route of infection.  
To model natural EBV infection in humans, MHV-68 is given via the i.n route without 
anaesthesia, delivery is inefficient, most of the virus gets swallowed and infection is slow 
to develop while in anesthetised mice, virus delivery to the lungs is more controlled as 
delivery is effective (107, 109). In this thesis, both upper and lower respiratory tract 
inoculations are used, with lower respiratory tract infection serving as a positive control 
because of its convenience and reproducibility to better understand immune responses. 
Acute primary lytic infection in the nose or lung, seeds the virus to the superficial cervical 
lymph nodes that drain the nose or the mediastinal lymph nodes (SCLN or MLN) that 
drains the lungs. In these lymph nodes, B cell proliferation is induced by cells that traffic 
virus from the nose or lung (107, 114, 115). Infection then progresses to the spleen where 
there is extensive B cell proliferation (103). The timing is dependent on dose and route of 
infection (107, 109). After lung inoculation, spleen infection peaks 13 to 14 days post 
infection and reaches steady state by day 30 (109, 116) . After nose infection however, 
peak spleen infection occurs after 20 days (109). MHV-68 persists in memory B cells 
(117). Most of this infection is latent, the genome is stably maintained without new virus 
production. B cell differentiation to plasma cells lead to sporadic reactivation in 
submucosal sites, but what triggers reactivation is unknown. During latency, macrophages 
and dendritic cells have a less stable form of latency, with strong tendencies to reactivate 
(118, 119). Epithelial and fibroblast infections are predominantly lytic in vitro. In vivo, virus 
behaviour in these cell types is still not well characterized. B cell infection seeds MHV-68 
to the bone marrow (120). Whether it infects myeloid stem cells in the bone marrow to 
establish a more stably persistent myeloid infection is unknown. Immature B cells isolated 
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from the bone marrow have shown to exhibit high frequencies of stable latent infection. 
Interestingly, circulating mature B cells detected in the BM, 15, 42 and 48 days post i.n or 
i.p infection show that developing B cells harbor viral genome through persistent infection 
and then immigrate to the periphery and seed tissues (120).  
1.4.3.2 Immune response to MHV-68 
The normal immune response to MHV-68 will be addressed with emphasis on CD8+, 
CD4+, antibody response and IFN-γ which indirectly or directly influence responses 
required to develop vaccine strategies against EBV.   
1.4.3.3 CD8+ T cell responses 
In CD4+ T cell depleted or CD4+ deficient mice, CD8+ T cells have little effect on lymphoid 
infection and provide no protection against lytic infection (112, 116, 121). This is despite 
large numbers of CD8+ T cells responding to lytic epitopes p56 and p79 (122). Similar to 
EBV, MHV-68 expresses a number of immune evasion genes, particularly K3 and M3 that 
interfere with virus clearance during lytic infection (123, 124). K3 is a viral gene that 
encodes a zinc-finger-containing protein. It reduces the half-life of newly synthesised MHC 
I molecules, hence blocking antigen presentation to CD8+ T cells, while M3 binds a board 
spectrum of host chemokines which may block recruitment of CD8+ T cells into lymphoid 
organs. These inhibitory effects restrict CD8+ cytotoxic T lymphocytes, particularly during 
expansion of latently infected B cells (123, 124). The long-term importance of CD8+ T cells 
was addressed by infecting beta-2-microglobulin-deficient mice. These mice had increased 
lymphoid infection and developed B cell lymphomas (125). MHV-68 was not present in all 
tumours, a sharp contrast to EBV where essentially all tumour cells have EBV genomes. 
These studies show that CD8+ T cells are required to limit latent infection during lytic 
infection and are subjected to multiple viral evasive strategies similar to those described 
for EBV.  
1.4.3.4 CD4+ T cell responses 
A major function for CD4+ T cells is to provide B cell help in the production of virus-
neutralising antibody responses (103, 126). CD4+ T cells  can also direct effector functions 
via cytokine secretion (IFN-γ and TNF-alpha) and kill infected cells via fas/fas-ligand 
interaction (121, 127). However, a further complication with MHV-68 is the observed 
exploitation of CD4+ T cell help to drive non-specific B cell lymphoproliferation following in 
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vivo infection (103, 128, 129). This effect was ablated in CD40L deficient mice and in 
chimeric mice lacking MHC II specifically in B cells (128), implying CD4+ T cells require 
cognate antigen binding to drive B cell maturation and proliferation. The specificities of 
CD4+ T cells that drive virus-specific and non-specific B cell proliferation are unknown. 
Furthermore, how CD4+ T cells control infection at the site of entry- the nasal 
neuroepithelium is also not yet characterised.   
In the lungs of immunocompetent BALB/c mice, virus is cleared after 7 to 10 days while in 
CD4+ T cell depleted mice, virus is cleared after 10 to 20 days (112). In CD4+ and CD8+ 
depleted mice, MHV-68 infection is fatal (112), demonstrating that CD4+ and CD8+ T cells 
are important in controlling lytic infection. In the spleen, virus replication in CD4+ T cell 
depleted mice is reduced but there is no effect on long term latency while in CD8+ T cell 
depleted mice, virus titer in the spleen increased. This was attributed to B cell driven 
lymphoproliferation (112, 129). Using a C57BL/6 C2D mice genetically deficient for the H-
1Ab gene (lacks classical CD4+ T cells), CD8+ T cells were found to control acute lytic 
replication in the lungs but were unable to control long term infection compared to wild 
type mice (103, 116). These mice also had reduced splenomegaly and a low-grade, 
chronic lytic infection because of their lack of antibody response. This study further 
showed that, for effective control of chronic infection, CD4+ and CD8+ T cells are both 
important. 
A mechanism of how CD4+ T cells control infection was demonstrated in B cell deficient 
mice. Neutralising IFN-γ in these mice diminished CD4+ T cell response and increased 
lytic infection that increased mortality (121). This showed that in the absence of B cells, 
mice could recover from MHV-68 and keep the infection latent. It was only when IFN-γ was 
neutralised that mice began to die. Since IFN-γ is important for CD4+ T cell effector 
function, direct CD4+ T cell engagement with infected cells may be the important arm in 
dealing with gammaherpesvirus infections. 
This was further shown in IFN-γ receptor-deficient BALB/c mice (130). However, the 
absence of IFN-γ in C57BL/6 mice had no effect on latency (131) potentially due to 
difference in their genetic background or complex unknown interaction between MHV-68 
and IFN-γ in C57BL/6 mice (132).  
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1.4.3.5 Antibody 
Antibody mediated control of MHV-68 could be important when virus reactivates from 
latency and undergoes lytic infection. Thus, preformed antibody to MHV-68 is likely to 
block lytic infection (132). Adoptive transfer of neutralising and non-neutralising antibody 
during lytic infection in normal mice and in B cell deficient mice, reduced lytic infection 
(126, 133). This was mediated by IgG Fc receptor dependent cytotoxicity (133) suggesting 
that, antibody targets epithelial cell infection. 
1.4.3.6 Vaccine strategies in animal models 
1.4.3.7 Glycoprotein subunit vaccines 
The first vaccination in BALB/c mice to model EBV gp350 used a recombinant vaccinia 
virus expressing MHV-68 glycoprotein gp150. Glycoprotein gp150 is a positional 
homologue of gp350 and is expressed during lytic infection (134, 135). This vaccine 
provided no protection against persistent infection but protected mice against virus 
induced mononucleosis (136) consistent with EBV gp350 vaccination outcomes in humans 
and in primate models.  
1.4.3.7.1 CD4+ T cell specific epitopes 
Subunit MHV-68 vaccines that target CD4+ T cell lymphocytes was trialled. Vaccination 
with gp15067–83 peptide was found to stimulate CD4+ T cells but showed minimal protection 
against lytic infection in the lungs of C57BL/6 mice (137) and had no protection against 
latency in BALB/c or C57BL/6 (136-138). The fact that latency was not controlled suggests 
this peptide is either not abundantly expressed during lytic infection to prime CD4+ T cells 
or it is not expressed by infected B cells during latency.  
1.4.3.7.2 CD8+ T cell specific epitopes 
Vaccination against MHV-68 CD8+ T cell lytic epitopes gB604-612, ORF6487-495, ORF61524-531 
and p56 provided acute protection in the lungs of C57BL/6 mice against lytic infection (137, 
139). Virus replication in lymphoid organs (MLN and spleen) of p56 vaccinated C57BL/6 
mice was delayed, but long-term infection was not prevented (139). An attempt to 
vaccinate against M2, a latently expressed protein, to protect against long-term infection 
failed (140).  
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1.4.3.8 Live attenuated MHV-68 vaccine 
Using a similar approach to varicella zoster virus, a live attenuated MHV-68 engineered by 
removing latency associated genes was highly effective at reducing lytic infection and long 
term latent loads in both BALB/c and C57BL/6 mice (141-143). Protection was long lived, 
suggesting CD4+, CD8+ and B cells were are all important. Disrupting this T cell-B cell 
balance likely impairs protection.  
1.4.3.9 Vaccine vectors 
Controlling persistent infection requires live attenuated vaccine as demonstrated for 
varicella zoster virus. The use of cytomegaloviruses as vaccine vectors against HIV has 
gathered momentum. A live attenuated RhCMV vaccine expressing multiple proteins of 
SIV (Gag, Rev-Tat-Nef and Env) provided robust life-long SIV-specific CD4+ and CD8+ 
effector memory T cells even in RhCMV+ macaques. The macaques upon repeated 
intrarectal challenge, showed resistance to acquisition of SIV compared to controls (144). 
Interestingly, a recombinant adenovirus vaccine expressing the same proteins provided no 
protection (145). The CD8+ T cell responses elicited in the RhCMV/SIV vectors, 
particularly to gag, derive from unconventional antigen presentation via unconventional 
MHC –E and is under the genetic control of CMV (146, 147).  
The vaccine results described above have shown that targeting lytic or latent epitopes 
alone do not work in preventing MHV-68 infection. Inducing virus-specific antibody only 
limits the severity of disease in both humans and in animal models. Notably, a live 
attenuated ORF73 mutant protected mice against persistent infection via an unknown 
mechanism of action. ORF73 is a latency associated viral gene that regulates viral gene 
expression and maintains MHV-68 genome as episomes in latently infected dividing B 
cells (148-153). Further in vivo studies of how live attenuated vaccine vectors work is a 
timely and tractable strategy to evaluate their potential as vaccine candidates. 
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2.1 Reagents and consumables 
Reagents were purchased from the following companies: Qiagen, Fisher Scientific, 
Invitrogen, Roche, Sigma-Aldrich (sigma), Thermo Scientific and Mirus. Materials for cell 
culture and plastic ware were purchased from BD Biosciences, Corning and Sigma. 
Molecular biology reagents and enzymes were obtained from Roche, Clontech, Southern 
Biotec, New England BioLabs and Promega. 
2.2 Media and solutions 
Some solutions were prepared by Research assistants Kimberley Bruce and Clara Lawler 
 
Table 1: Reagents 
Name Company Composition 
Luria-Bertani (LB) broth Sigma 40 g of LB powder in 2 L water 
2xTY broth In house 16 g Tryptone, 10 g Yeast extract, NacI 5 g in 
1 L pH 6.8  
Antibiotics for selection Sigma 12.5 µg/mL or 10 µg/mL of Chloramphenicol, 
Kanamycin, Puromycin and Zeocin 
Agar  Sigma Variable  
DMEM Sigma Dulbecco’s Modified Eagle’s Medium 
(DMEM), supplemented with 2 mM 
glutamine, 100U/mL penicillin, 100 µg/mL 
streptomycin and 10% fetal calf/bovine serum 
RPMI Sigma RPMI 1640 medium supplemented with 10% 
heat-inactivated fetal calf serum, 2 mM L-
glutamine, 25 mM HEPES (pH 7.2), 50 μM 2-
mercaptoethanol, penicillin (100 U/mL), and 
streptomycin (100 μg/mL).  
CCMB buffer In house 11.8 g CaCL2, 4.0 g MnCL2, 2.0 g MgCL2, 0.7 
g KCL, 100mL glycerol, 1 L water and filter 
sterilise 
2xTY glycerol In house 16 g Tryptone, 10 g Yeast extract, NacI 5 g 
+7% (w/v) glycerol  
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Freezing solution In house 10% DMSO and 90% heat inactivated 
FBS/FCS 
Carboxymethylcellulose 
(CMC) 
In house 15 g High viscosity CMC + 15 g Low viscosity 
CMC + 400 mL water + 600 mL PBS, 
autoclaved at 121oC for 15 minutes 
PBS In house PBS tablets dissolved in water and 
autoclaved 
0.1% Tween-20/PBS 
(PBS/T) 
In house 2 mL Tween-20, 200 mL 10X PBS and 1798 
mL water 
0.05% Tween-20/PBS 
(PBS/T) 
In house 1mL Tween-20, 200mL 10X PBS and 1799 
mL water 
TE buffer In house 1X of 10X (108g Tris base and 55g of boric 
acid in 900mL water and 0.5M EDTA (pH 8.0) 
and adjusted to 1L with water 
TAE buffer In house 1X of 50X (242 g of Tris base and 37.2 g of 
Na2EDTA.(2H2O) in 900 mL water and 57.1 
mL of glacial acetic acid, final volume 
adjusted to 1 L with water) 
0.1% thiol Blue In house 1 g thiol blue in 1 L water 
4% PFA/PBS In house Dilute 1/4 (4%PFA) in X volume of PBS 
1% agarose  In house 0.5 g agarose in 50 mL TBEE 
 
2.3 Bacteria 
2.3.1 Bacterial strain 
Escherichia coli DH10B (Invitrogen) was used to propagate the BAC+ ORF73 deletion 
mutant (BAC+ Δ73) obtained from the UK. 
2.3.2 Growth and storage 
Liquid cultures of E.coli containing plasmids pA M3 sOVA and BAC+ Δ73 were grown in LB 
broth containing kanamycin or chloramphenicol antibiotics at 30oC or 37oC respectively on 
an orbital shaker at 180 rpm. These cultures were further used for DNA extractions. 
Bacterial stocks for long-term storage were derived from overnight cultures as above and 
stored at -80oC in 1 mL 2xTY broth containing 7% (v/v) glycerol. Bacteria were streaked 
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onto nutrient agar plates and grown overnight at either 30oC, 37oC or 42oC. Single 
colonies were then picked for subsequent manipulation. 
2.4 Making recombinant BAC+ Δ73 mutant using BAC technology 
2.4.1 Construction and analysis of shuttle vector and BAC plasmid DNA 
Plasmid DNA (containing pA M3 sOVA) was extracted using QIAGEN Miniprep kit from 
E.coli grown on LB broth containing kanamycin. To check for sucrose sensitivity and 
presence of kanamycin resistant gene in the pA M3 sOVA plasmid, colonies were grown 
on agar plate containing either 50% sucrose or kanamycin. BAC plasmid DNA was 
isolated from E.coli cultures using an alkaline lysis procedure involving phenol-chloroform, 
DNA was precipitated with isopropanol, washed with 70% ethanol and resuspended in Tris 
buffer (10 mM Tris-HCI-1mM EDTA, pH 7.5). 10 μL of purified plasmid DNA was digested 
using EcoRI, run on 1% agarose gel in TBEE buffer for 1 hr at 110V. 42 μL BAC plasmid 
DNA was digested using EcoRI and BstEII restriction enzymes and run on 0.8% agarose 
in TAEE buffer overnight at 30 V.    
2.4.2 Preparation of competent DH10B E.coli containing BAC+ Δ73 
5 mL overnight culture of DH10B E.coli containing BAC+ Δ73 were grown in LB broth 
containing chloramphenicol at 37oC with shaking was diluted 1/100 and further grown at 
37oC with shaking until log phase. The bacteria were pelleted at 908 x g for 15 minutes at 
4oC. The pellet was resuspended in pre-chilled CCMB buffer- ¼ of the starting culture 
volume. The bacteria  were then incubated on ice for at least 3 hrs. After incubation, the 
bacteria  were pelleted at 4oC and resuspended in CCMB buffer- 1/12 of the starting 
culture volume. Aliquots of 100 μL were snap frozen on dry ice and stored at -80oC for 
future use. 
2.4.3 Recombination MHV-68 BAC+ Δ73 sOVA 
For transformation, 100 ng purified psk pA sOVA M3 plasmid DNA which contains the 
recA gene that allows for replication in recA deficient DH10B E.coli and SacB, a negative 
selection marker in sucrose containing agarose was electroporated into competent E.coli 
DH10B containing the BAC+ Δ73 mutant using heat shock (30 min on ice, 42oC for 90 
secs, on ice 2 minutes). 900 μL of SOB broth were added to the transformed bacteria and 
cells were incubated for 30 minutes at 30oC with shaking. 100 μL of the transformed 
bacterial culture were then plated onto chloramphenicol and kanamycin containing agar 
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plates and incubated overnight at 30oC. Colonies were replated on chloramphenicol-
kanamycin containing or kanamycin containing plates and grown overnight at 42oC. 
Colonies picked from chloramphenicol-kanamycin plates were again replated on 
chloramphenicol-sucrose, kanamycin-chloramphenicol and chloramphenicol plates 
overnight at 30oC. Colonies picked from chloramphenicol-sucrose plate were plated onto 
chloramphenicol and kanamycin containing plates and grown on LB broth containing 
chloramphenicol. Plasmid DNA from single cultured colonies were extracted as mentioned 
above to analyse mutants. 
2.4.4 Reconstitution MHV-68 BAC+ Δ73 sOVA 
BHK-21 cells were transfected with 3 µg of BAC DNA (clone 2, 6, 13, 14, 21 and 24) using 
TransIT®-LT1 transfection reagent. Briefly, BHK-21 cells were seeded in six well plates in 
complete DMEM medium overnight at 37oC, 5% CO2. Complete DMEM medium was 
replaced with DMEM (containing no streptomycin or penicillin) and incubated for 30 
minutes at 37oC, 5% CO2. 2 mL warm Opti-MEM was added in 2 mL labelled test tubes. 
To these tubes, 13 μL of lipid mix was added and left for 1 minute at room temperature 
(RT) and 300 μL of this mix added to labelled 1.5 mL test tubes containing 10 μL of 300 
ng/µl BAC plasmid DNA (clone 2, 6, 13, 14, 21 and 24) and incubated for 30 minutes at 
RT. After 30 minutes, 310 μL of total mix was added to each six well plate and incubated 
for 2 days. After 2 days, the BHK-21 cells were split. After 3 days, plaques expressing the 
GFP formed in clones 13, 14 and 21 and complete CPE was observed a day later. 
Supernatant and cells of reconstituted BAC+ Δ73 sOVA recombinant virus constructs 
(Clones 13, 14 and 24) were harvested by scrapping off cells in 2 mL cryovials using 1 mL 
pipette tips and stored in -80oC as stocks. 
2.4.5 Removal of BAC cassette 
To remove the BAC cassette sequence, 2x105 NIH-3T3 expressing Cre were seeded in six 
well plates and infected with 1 μL or 10 μL of BAC+ Δ73 sOVA (clones 13 and 14).  After 5 
days, the cells were monitored for GFP expression and CPE. Absence of GFP expression 
confirmed loss of loxP-flanked by the BAC/eGFP cassette removed by Cre recombinase. 
Wells with complete CPE were harvested by scrapping cells and supernatant in 1.5 mL 
cryovials and stored in -80oC as master stocks. 
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2.5 Mice 
2.5.1 Facility 
C57BL/6 (IA +/-), C57BL/6 back crossed (IA -/-) (MHC II-), BALB/c, F1 (C57BL/6 crossed 
with BALB/c), CD169-DTR (diphtheria toxin receptor) and DO11.10 transgenic mice were 
either bred or housed at the UQ Biological facility at Australian Institute for Bioengineering 
and Nanotechnology (AIBN), University of Queensland Centre for Clinical Research 
(UQCCR), School of Chemistry and Molecular Biosciences (SCMB) and Herston Medical 
Research Centre (HMRC). All procedures and experiments were approved by the 
University of Queensland Animal Ethics Committee in accordance with the Australian 
National Health and Medical Research Council guidelines (projects 301/13 and 479/15). 
2.5.2 Infections 
6 to 12 week old adult male and female mice were sex matched and infected via the 
intranasal route (i.n) under anaesthesia (isoflurane) with 3x104 (p.f.u/30 μL) in DMEM to 
study lower respiratory tract infection or without anaesthesia with 1x105 (p.f.u/5 μL) to 
study upper respiratory tract infection in parallel where necessary. For vaccination or to 
directly study splenic infection, mice were injected via the intraperitoneal (i.p) route with 
104-106 (p.f.u/100µL). Adoptive transfer was performed by intravenous injection (i.v). 
2.5.3 In vivo depletions and anti-IFN-γ administration 
CD4+ and CD8+ T cells were depleted using rat anti-mouse CD4 clone GK1.5 and rat anti-
mouse CD8α clone 2.43 at 200 µg/mouse by i.p injection at 96 hrs, 48 hrs before infection 
and at the time of infection and every 48 hrs until the time of harvest. IFN-γ clone XMG1.2 
was administered via i.p injection (200 µg/mouse) at the time of infection and every 48 hrs 
until the time of harvest. Depletions were confirmed by either flow cytometry or histology 
using rat anti-mouse CD4 (RM4-4) and rat anti-mouse CD8β (H35-17.2) and rat anti-
mouse IFN-γ XMG1.2. 
2.6 Mammalian cell culture 
2.6.1 Cell lines 
Cells and cell lines used or generated in this thesis are described in the table below 
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 Table 2: Cell and cell lines 
Cells Description 
BHK-21 Syrian hamster fibroblast cell line obtained from rapidly growing 
primary culture of newborn hamster kidney tissue (154). 
MEF Fibroblast cell line isolated from mouse embryos in house by 
Helen Farrell and is stored in liquid nitrogen. Routinely used for 
MCMV plaque assays or immunofluorescence.  
NIH-3T3 Embryonic immortalised fibroblasts (ATCC). This cell line is used 
to propagate MCMV. 
NIH-3T3 CRE Embryonic fibroblast cell line that expresses a Cre-recombinase. 
It is used for the removal of the intervening DNA as Cre-
recombines paired loxP sites (155). 
BALB/c-3T3  Fibroblast cell line isolated from BALB/c mouse used as a 
negative control for MHC II expression. 
BALB/c-3T3-C2TA Transduced with C2TA transactivator using retrovirus 
RAW 264.7 A monocyte/macrophage cell line isolated from a tumor induced 
by Abelson murine leukemia virus in adult male BALB/c mice 
(ATCC).  
RAW 264.7 (RAW-
C2TA) 
Transduced with C2TA transactivator using retrovirus to express 
MHC II. This is used to study effects of infection on MHC II and 
characterise recombinant OVA viruses in an antigen presentation 
assay. 
NMuMG An epithelial cell line isolated from the mammary gland of 
NAMRU female mouse (ATCC).  
293T An epithelial cell line that is a highly transfectable human cell line 
derived from the 293-human embryonic kidney (HEK) cell line by 
insertion of the temperature sensitive gene for SV40 T antigen 
(American Type culture collection- ATCC). 
DO11.10 CD4+ T 
cell hybridoma cells 
A fusion of BW5147 cells with a T cell expressing a T cell 
receptor that recognises OVA323-339 in the context of I-Ad. It is 
useful to detect expression of the OVA epitope (156). 
Cell lines  
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BALB/c-3T3-C2TA-
M78 4 
Transduced with M78 amplified from K181 viral DNA using 
retrovirus. 
BALB/c-3T3-C2TA-
M78 2 
Transduced with M78 amplified from a plasmid expressing M78 
using retrovirus. 
RAW-C2TA-M78 4 Transduced with M78 amplified from K181 viral DNA using 
retrovirus. 
RAW-C2TA-M78 2 Transduced with M78 amplified from a plasmid expressing M78 
using retrovirus. 
RAW-C2TA-M78 
Clone E6 
Clone generated from the parent line RAW-C2TA-M78 2. 
 
2.6.2 Cell culture 
Cells were maintained in Dulbecco’s Modified Eagle’s Medium, supplemented with 2 mM 
glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin and 10% fetal calf/bovine serum 
using flat tissue 75 cm or 150 cm culture flasks. Primary cells particularly for interferon 
gamma (IFN-γ) responses  were maintained in RPMI 1640 medium supplemented with 
10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 25 mM HEPES (pH 7.2), 50 μM 
2-mercaptoethanol, penicillin (100 U/mL), and streptomycin (100 μg/mL). Cells were 
passaged by washing confluent monolayers with PBS, detached by incubation with 0.25% 
(w/v) trypsin/0.004% (w/v) EDTA for 2 minutes at 37oC. Macrophage cells were 
occasionally detached by scrapping off cells using a scrapper. For trypsin-based 
detachment, reaction was stopped by adding complete 10% DMEM, and the cells were 
centrifuged at 536 x g for 5 minutes. The cell pellet was resuspended in fresh complete 
10% DMEM and seeded in a new flask at either 1/5 or 1/10 or 1/20 of the total volume. 
2.7 Viruses 
Viruses used in this thesis are described. All MHV-68 viruses used were derived from 
strain MHV-68 (102) and MCMV from K181 Perth strain. Unless otherwise stated, all the 
MHV-68 and vaccinia recombinant viruses were provided by Dr Philip Stevenson, MCMV 
OVA+ viruses by Alec Redwood and MCMV WT and mutants by Helen Farrell and Dr 
Nicholas Davis-Poynter.   
 
46 
 
Table 3: Viruses used in the thesis 
Gamma-herpesvirus Description 
WT MHV-68 Lacks the loxP-flanked BAC/GFP cassette removed from by 
passing through NIH-3T3-CRE cells (157). 
WT eGFP+ MHV-68  Retains the BAC cassette (155, 157). 
WT gM eGFP+ MHV-68 Expresses GFP attached to the C terminus of gM (158).  
ORF73- eGFP+ M3 
sOVA 
Retains the BAC cassette. GFP expression is driven by the 
M3 promotor (unpublished data described in chapter 5). 
ORF73- eGFP- M3 
sOVA 
Lacks the BAC cassette removed by passing through NIH-
3T3-CRE cells. GFP expression is also driven by the M3 
promotor (unpublished data described in chapter 5). 
WT M3 mOVA  MHV-68 Expresses a fusion protein of OVA with the transferrin 
receptor transmembrane domain, which is efficiently 
processed and presented to both CD4 and CD8 T cells 
(159). 
WT M3 sOVA MHV-68 Expresses full-length OVA, including its signal sequence 
under the M3 lytic promotor (160).  
WT IiOVA MHV-68 Expresses OVA323-339 peptide in place of the CLIP peptide 
of mouse invariant chain. OVA323-339 is driven by ORF73 
(160). 
EFla-eGFP MHV-68 BAC-negative eGFP expressing virus. GFP is expressed 
under a cellular promoter for polypeptide chain elongation 
factor 1 alpha (EF1a). Expression is independent of lytic or 
latent infection (161).  
Beta herpesvirus  
WT K181 Perth strain. 
β-gal recombinants  
WT Expresses β-gal from the M33 intron driven by HCMV IE1 
promoter (unpublished). 
M78- Expresses β-gal cassette under the HCMV IE1 protomer at 
genomic coordinate 111681 within M78 ORF disrupting M78 
expression (162). 
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M33- Expresses β-gal cassette flanked by HCMV IE1 promoter 
and poly(A) signals inserted in the M33 coding region (163). 
gO- Expresses β-gal cassette within the gO ORF disrupting M74 
(unpublished). 
gL- Expresses β-gal cassette under the control of HCMV 
promoter inserted within gL ORF by homologous 
recombination (164). 
M131- Expresses β-gal within the m131 ORF driven by the HCMV 
IE promoter (165). 
M78_CΔ155 Made by inserting β-gal cassette in the ORF of M78 (M78-), 
then using M78 null as the parent to generate recombinant 
M78_cΔ155 (162). 
HA tagged   
HAM78 (REV) M78- revertant that express N-terminal HA-tagged onto M78 
via homologous recombination (162). 
HAM78 c∆155 Express N-terminal HA-tagged onto M78 via homologous 
recombination. The virus lacks 155 amino acids from the C-
terminus (162). 
GFP  
WT Expresses GFP from the M131 intron under the HCMV IE 
promoter (166). 
M78- Made by homologues recombination, deleting ORF 
(coordinates 111084-112499) and expresses GFP from the 
M131 intron under the HCMV IE promoter. 
Independent mutants  
M131-1 Has a premature stop codon in the m131 ORF (165). 
M78 orf deletion Made by homologues recombination, deleting ORF 
(coordinates 111084-112499) (unpublished). 
Vaccinia virus  
Vaccinia gH/gL Expresses MHV-68 glycoprotein gH/gL. 
Vaccinia control Expresses an irrelevant protein. 
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2.8 Preparation of virus stocks 
2.9 MHV-68 
Virus stocks were prepared by infecting BHK-21 cells at a multiplicity of infection (MOI) 
0.01 for 4 to 5 days or until CPE was complete. The cells were frozen, thawed and virions 
pelleted down by ultracentrifugation (33,000 x g, 2 hrs at 4oC) using Beckman Coulter 
Avanti-J-26 XP1 centrifuge, and supernatants discarded. Virus pellet was resuspended in 
6 mL 10% or 2% complete DMEM and spun down using a low speed centrifugation (245 x 
g for 5 min at 4°C) to remove cellular debris. Supernatants were stored in aliquots at 
−80°C. Virus titers were determined by plaque assay on BHK-21 cells.  
2.10 MCMV 
2.10.1 Working stocks 
Virus stocks were prepared by infecting NIH-3T3 cells in 6 well plates at a MOI 0.01 for 3 
days or until CPE was complete. The cells were frozen, thawed and supernatant added to 
a 175 flask. After 3 days, the flask was frozen, thawed and supernatants were centrifuged 
at low speed (581 x g for 30 minutes) to pellet cells. Supernatants were stored as working 
stocks and tittered by plaque assay on MEFs.  
2.10.2 Concentrated clean stocks 
To prepare concentrated stocks, a 175 cm2 flask of NIH-3T3 cells were infected at MOI 
0.01 for 3 days or until CPE was complete. The cells were frozen, thawed and supernatant 
added to six 175 cm2 flasks. After 3 days, the flasks were frozen, thawed and supernatants 
and cells were ultracentrifuged to pellet virions (33,000 x g for 2 hrs at 4oC) using 
Beckman Coulter Avanti-J-26 XP1 centrifuge, and supernatants discarded. Virus pellet 
was resuspended in 6 mL 2% complete DMEM and spun down at low speed (545 x g for 5 
minutes at 4°C) to remove cellular debris. Supernatants were stored in aliquots at −80°C 
and titer determined by plaque assay on MEFs.  
2.10.3 Virion detection stocks 
To prepare concentrated stocks, a 175 cm2 flask of NIH-3T3 cells were infected at MOI 
0.01 for 3 days or until CPE was complete. The cells were frozen, thawed and supernatant 
added to six 175 cm2 flasks. After 3 days, the flasks were frozen, thawed and 
supernatants and cells were ultracentrifuged to pellet virions (33,000 x g for 2 hrs at 4°C) 
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using Beckman Coulter Avanti-J-26 XP1 centrifuge, and supernatants discarded. Virus 
pellet was resuspended in 6 mL complete DMEM and spun down using a low speed 
centrifugation (545 x g for 5 minutes at 4°C) to remove cellular debris. Supernatants were 
stored in aliquots at −80°C. Virus titers were determined by plaque assay on monolayer of 
MEF cells. Briefly, ten-fold MCMV serial dilutions were added onto MEFs. After 60 minutes 
of incubation at 37°C, 5% CO2, complete DMEM medium containing 0.3% CMC was 
added. After 3 days, cells were fixed in 1%PFA/PBS and stained with 0.1% toluidine blue 
solution to determine plaque numbers. 
2.11 In vitro growth kinetics 
2.12 Multi-step growth kinetics- low multiplicity of infection 
2.12.1 MHV-68 
BHK-21 and RAW-C2TA cells were infected in suspension with BAC- WT or BAC- Δ73 
sOVA at low MOI 0.01. The production of infectious virus was monitored over a course of 
seven days. At different times post infection, cells and supernatants were harvested and 
stored at -80oC. 500 μL of ten-fold MHV-68 serial dilutions were added onto BHK-21 cells. 
After 2 hrs of incubation at 37°C, 5% CO2, complete DMEM medium containing 0.3% CMC 
was added. After 4 days, cells were fixed in 1% PFA/PBS and stained with 0.1% toluidine 
blue solution to determine plaque numbers. Virus titer was determined by multiplying the 
number of plaques by the dilution factor and then by the ratio of volume plated in 1 mL 
(plaques x dilution factor x 1 mL/0.5 mL). 
2.12.2 MCMV 
Monolayers of RAW 246.7 and RAW-C2TA cells were infected in triplicates in 24 well 
plates with WT or M78-  at low MOI 0.01 for 1 hr at 37oC 5% CO2. The cells were then 
washed twice in PBS and fresh 2% complete DMEM medium added.  The production of 
infectious virus was monitored over a course of seven days. At different times post 
infection, cells and supernatants were harvested and stored at -80oC for later analysis by 
plaque assay. 
2.13 Multi-step growth kinetics- high multiplicity of infection 
2.13.1 MCMV 
Monolayers of RAW-C2TA were infected in triplicates in 24 well plates with WT or M78- at 
high MOI 1 and centrifuged (536 x g for 30 minutes). The cells were incubated for 1 hr at 
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37oC 5%CO2. After 1 hr, culture media was aspirated, and the cells were incubated in citric 
acid for 1 minute and washed twice in PBS. 2% complete DMEM medium was added and 
the cells were incubated at 37oC 5% CO2. Production of infectious virus was monitored 
over a course of 48 hrs. At different times post infection, cells and supernatants were 
harvested and stored at -80oC for later analysis by plaque assay. 
2.14 Single-step growth kinetics 
2.14.1 MCMV 
Monolayers of BHK-21, MEFs, NMUMG, NIH-3T3 and RAW-C2TA (seeded at 106 
cells/well) were left uninfected or infected at different MOI (0.1, 0.3 and 1) with WT GFP or 
M78- for 18 hrs at 37oC 5% CO2. For RAW-C2TA cells, infection was enhanced by 
centrifugation (536 x g for 30 minutes) and left for 24, 48 and 72 hrs. To determine level of 
infection, the cells were washed once in PBS, scrapped off using a pipette and centrifuged 
(500 x g for 5 minutes). The cell pellets were then resuspended in 200 µL ice-cold PBS 
and analysed using BD Accurri C6 flow cytometer.  
2.15 Viral infectivity assays 
2.16 Plaque assay- measure of lytic virus 
At different times post infection, organs of interest from infected mice were harvested in 1 
mL 10% complete DMEM, frozen at -80oC, thawed at 37oC and homogenised in stainless 
steel strainers or tissue glass dounce homogenizers. 
2.16.1 MHV-68 
For MHV-68, ten-fold serial dilutions of organ homogenates were co-cultured with BHK-21 
cells. After 1 to 2 hrs of incubation at 37°C, 5% CO2, 10% complete DMEM medium 
containing 0.3% CMC was added. After 4 days, cells were fixed in 1% PFA/PBS for 1 hr or 
overnight and stained with 0.1% toluidine blue solution to determine plaque numbers. 
2.16.2 MCMV 
For MCMV, homogenates prepared as above were briefly centrifuged (8,000 x g for 1 
minute) to pellet debris. 200 µL of five-fold serial dilutions of organ homogenates were 
then added onto monolayers of MEFs seeded overnight in 24 well plates and centrifuged 
(536 x g for 30 minutes at 28oC). After centrifugation, the cells were incubated for 1 hr at 
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37°C, 5% CO2. After 1-hr incubation at 37°C, 5% CO2, the medium was aspirated and 
fresh 2% complete DMEM medium containing 0.3% CMC was added. After 3 days, cells 
were fixed in 1% PFA/PBS and stained with 0.1% toluidine blue solution to determine 
plaque numbers. 
2.17 Infectious centre assay- measure of latently infected reactivating cells 
Latent virus was measured by infectious centre assay, a measure for B cell reactivation in 
permissive cells. Briefly, for MHV-68, at different times post infection, harvested organs 
were homogenised in 1 mL complete DMEM using stainless steel strainers. Ten-fold serial 
dilution of homogenates were co-cultured with BHK-21 cells for 1 to 2 hrs and 4 mLs of 
0.3% CMC was then added. After 4 days, the medium was aspirated, and wells fixed in 
1% PFA/PBS for 1 hr or overnight and stained in 0.1% toluidine for plaque counting.   
2.18 Determining virus titer in infected cells and tissues 
Virus titer was determined by multiplying the number of plaques by the dilution factor and 
then by the ratio of volume plated in 1 mL to determine virus titer per organ per mouse or 
per mL. Formulae (no of plaques *dilution factor)/ (volume plated/1 mL) 
2.19 DNA extraction protocols 
2.19.1 Plasmid DNA extraction- miniprep 
5 mL overnight cultures of E.coli grown in LB broth were centrifuged 908 x g for 15 
minutes at RT to pellet cells. DNA was extracted according to manufacturer’s instructions 
(QIAGEN). Briefly, pelleted E.coli was resuspended in 250 µL buffer P1 and transferred to 
a 1.5 mL microfuge tube. 250 µL buffer P2 was then added and mixed by inverting the 
tube gently 4 to 6 times. 350 µL buffer N3 was then added and again mixed by inverting 
the tube 4 to 6 times and centrifuged for 10 minutes at 11,000 x g. 800 µL of supernatant 
was added to a spin column and centrifuged for 60 secs at 11,000 x g. The flow through 
was discarded and the column was washed with 500 µL buffer PB and centrifuged at 
11,000 x g, 60 secs. The flow through was discarded and washed again in 750 µL buffer 
PE and centrifuged at 13000 for 1 minute to remove residual wash buffer. To elute DNA, 
50 µL Buffer EB (10 mM Tris-CI, pH 8.5) was added, left to stand for a minute and 
centrifuged (11,000 x g for 1 min). The plasmid DNA was then used for subsequent 
manipulations.      
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2.19.2 BAC DNA extraction- Alkaline/SDS lysis 
200 μL ice-cold P1 (50 mM Tris-Cl, pH 8.0, 10 mM EDTA, 100 µg/mL RNase A) was 
added to 5 mL overnight cultures of E.coli cell pellet and left at RT for 30 minutes. 300 μL 
P2 (200 mM NaOH, 1% SDS) was then added, the tube was inverted to mix and left to 
incubate for 5 minutes at RT. 300 μL ice-cold P3 (3.0 M potassium acetate, pH 5.5 ) was 
then added, to mix the tubes were inverted a few times and left on ice for 5 to 10 minutes. 
The samples were then centrifuged (11,000 x g, 10 minutes) and the supernatant was 
transferred to a new 1.5 mL tube and 500 μL phenol/chloroform added. To mix, the tube 
was inverted a few times and left at RT for 2 minutes, then centrifuged (11,000 x g, for 5 
minutes). The aqueous phase was transferred to a new 1.5 mL tube and 800 μL RT 
isopropanol added and inverted a few times to mix and left to incubate for 5 minutes at RT 
and then centrifuged (11,000 x g, for 10 minutes). The supernatant was discarded, and the 
white pellet washed in 70% ethanol and then centrifuged (11,000 x g, 5 minutes). The 
ethanol was aspirated, and the pellet left to air dry at RT for 30 minutes. The pellet was 
then resuspended in 100 μL 10 mM Tris-HCI, pH 8.5.  
2.19.3 Viral DNA extraction from cell free virion stocks 
Viral DNA from working or concentrated cell free virion stocks was extracted using 
NucleoSpin® DNA extraction kit (MACHEREY-NAGEL). Briefly, 500 μL of virus (MCMV 
WT, MCMV mOVA, MCMV sOVA, Vaccinia IiOVA, MHV-68 sOVA, MHV-68 mOVA, MHV-
68 IiOVA, MHV-68 Δ73 sOVA and MHV-68 WT) was added to 1.5 mL tubes and spun 
down (1hr, 11,000 x g at 4oC). Supernatant was discarded, and viral pellet resuspended 
(200 μL lysis buffer T1, 25 μL Proteinase K solution, 200 μL binding buffer B3), vortex and 
incubated at 70oC for 10 minutes to denature DNA. 210 μL 100% ethanol was then added, 
vortexed and applied to NucleoSpin® Tissue Column and centrifuged (11,000 x g, for 1 
min). Flow through was discarded and 500 μL of wash buffer (BW) added and centrifuged 
(11,000 x g, for 1 min). This was repeated using 600 μL of wash buffer (BW). The 
NucleoSpin® Tissue Column was dried (11,000 x g, 1 min), 100 μL Buffer BE added and 
incubated for 1 min at RT.  DNA was eluted in 1.5 mL tube (11,000 x g, 1 min) and 
resuspended in TE buffer. DNA yield was determined using nanodrop. 
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2.19.4 Genomic DNA extraction from tissues 
Genomic DNA was extracted from mouse tissues using a wizard genomic DNA extraction 
kit according to manufacturer’s instructions (Promega). Briefly, 300 μL of thawed tissue 
homogenates from the nose (N), salivary glands (SG), lungs (L), lymph modes (MLN and 
CLN), spleen (SP) and bone marrow (BM) was added to 1.5 mL labelled test tubes. To 
this, 600 μL of ice-cold Nuclei lysis solution (120 μL 0.5M EDTA solution pH 8.0, 500 μL of 
Nuclei lysis solution, 17.5 μL 20mg Proteinase K) was added and incubated at 55oC for 3-
hrs. The homogenate was vortexed once every 1 hr and allowed to cool to RT for 5 to10 
minutes. Once cooled, 200 μL of Protein Precipitation Solution was added and vortexed 
vigorously at high speed for 20 seconds and incubated on ice for 5 minutes. The sample 
was then centrifuged for 4 minutes at 11,000 x g, and 600 μL of supernatant containing 
DNA was carefully removed and transferred to a new 1.5 mL test tube containing 600 μL 
of RT isopropanol. The sample was mixed by inverting the tube several times until white 
thread-like strands of DNA forming a visible mass was observed. DNA was pelleted by 
centrifugation at 11,000 x g for 1 minute. The pellet was washed in 600 μL RT 70% 
molecular grade ethanol by inverting the tube several times and centrifuged at 11,000 x g 
for 1 minute. 70% ethanol was gently aspirated using a pipette and the DNA pellet left to 
air dry on a clean absorbent paper for 15 to 30 minutes. 100 μL rehydration solution was 
added to the DNA pellet and incubated overnight at 4oC. 
2.19.5 Genomic DNA extraction from blood 
Genomic DNA from blood of infected mice was extracted using Promega DNA extraction 
kit according to manufacturer’s instructions. Briefly, 150 to 300 μL of blood was collected in 
1.5 mL test tubes containing 20 μL 0.5M EDTA to prevent clotting. The tube was gently 
rocked to thoroughly mix the blood and then 900 μL of cell lysis buffer was added. The 
tube was inverted 5-6 times and incubated at RT for 10 minutes to lyse red blood cells. 
The tubes were then centrifuged for 20 seconds at 11,000 x g. The supernatant was 
discarded and the whole process was repeated twice or until white pellets were observed. 
The pellet was then resuspended in 300 μL of nuclei lysis. To lyse the white blood cells, 
the solution was pipetted 5 to 6 times and incubated at 37oC for 1 hr until clumps were 
disrupted. The solution was allowed to cool at RT for 5 to 10 minutes. Once cooled, 300 μL 
of Protein Precipitation Solution was added and vortexed vigorously at high speed for 20 
seconds and then centrifuged for 3 minutes at 11,000 x g. 300 μL of the supernatant 
containing DNA was carefully removed and transferred to a new 1.5 mL test tube 
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containing 300 μL of RT isopropanol. The sample was mixed by inverting the tube several 
times until white thread-like strands of DNA forming a visible mass was observed. DNA 
was pelleted by centrifugation at 11,000 x g for 1 minute. The pellet was washed in 300 μL 
RT 70% molecular grade ethanol by inverting the tube several times and centrifuged at 
11,000 x g for 1 minute. 70% ethanol was gently aspirated using a pipette and the DNA 
pellet left to air dry on a clean absorbent paper for 15 to 30 minutes. 100 μL rehydration 
solution was added to the DNA pellet and incubated overnight at 4oC. 
2.20 RNA extraction protocol 
1x106 to 2x106 RAW-C2TA, thioglycollate stimulated peritoneal macrophage cells and 
NIH-3T3 were left uninfected or infected with WT or M78- GFP at different MOI. Infection of 
RAW-C2TA and thioglycollate stimulated macrophage was enhanced by centrifugation 
(536 x g for 30 minutes at 28oC). After 18 hrs (NIH-3T3) or 24 hrs (peritoneal 
macrophages) or 48 hrs (RAW-C2TA), culture media was aspirated, and cells were 
harvested in PBS. 100-200 μL was reserved to determine level of infection by quantifying 
GFP expression using flow cytometry. The remaining cells were pelleted (500 x g for 5 
minutes). RNA was extracted using Trizol reagent according to manufacturer’s instructions 
(Life Technology- Invitrogen). Briefly, 400 μL Trizol reagent was added to cell pellet and 
pipetted up and down several times to homogenise and left to incubate for 5 minutes at 
RT. 200 μL chloroform was added to the lysate, vortexed for 15 seconds and incubated at 
RT for 3 minutes. The samples were then centrifuged for 15 minutes at 11,000 x g at 4oC. 
The colourless aqueous phase was transferred to a new 1.5 mL test tube containing 500 
μL RT isopropanol, incubated for 10 minutes at RT and then centrifuged for 10 minutes at 
11,000 x g at 4oC. The supernatant was discarded, and the white gel-like pellet washed in 
400 μL 70% ethanol by inverting the tube few times and centrifuged at 8,000 x g at 4oC for 
5 minutes at 4oC. The supernatant was discarded using a pipette and left to air dry for 10 
minutes at 37oC. The pellet was resuspended in 20 to 50 µL water by pipetting up and 
down and incubated at 55oC on a heat block for 15 minutes. 2 µL aliquot was then 
analysed for nucleic acid concentration using nanodrop. 
2.20.1 DNase 1 treatment 
50 ng to 1000 ng RNA was treated with DNase 1 (RNase free) prior to RT-PCR according 
to manufacturer’s instructions (New England BioLabs). Briefly, 50 ng 10 µg RNA was 
added to 10 µL 10X DNase buffer (100 mM Tris-HCI, 25 mM MgCI2, 5 mM CaCI2 pH 7.6, 
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at 25oC), 1 µL (DNase 2U/µL) and water to a volume of 100 µL. The samples were mixed 
and incubated at 37oC for 10 minutes. DNase 1 was inactivated by adding 1 µL 0.5 M 
EDTA (filtered using a 0.2 µM filter) to a final concentration 5 mM and incubated for 10 
minutes at 75oC. 
2.20.2 Single strand cDNA synthesis using reverse transcriptase  
First strand cDNA synthesis was performed using ProtoScript II First Strand cDNA 
Synthesis Kit according to manufacturer’s instructions (New England BioLabs). Briefly, 1 to 
4 µL of DNase treated template RNA (10 ng-1000 ng) was added to 10 µL 2X reaction 
mix, 2 µL oligo d(T)23 VN (50 µM), 2 µL of 10X enzyme mix and 2 µL to 4 µL of nuclease 
free water, to a total reaction volume of 20 µL. Control samples had no enzyme. The 
samples were mixed and incubated at 42oC in a water bath or heat block for 1 hr. To 
inactivate the enzyme, the samples were further incubated for 5 minutes at 80oC, then 
kept on ice, and stored at -20oC for later analysis. 
2.21 Spectrophotometry of nucleic acid 
2 µL DNA or RNA or DNase 1 treated RNA was quantified using nanodrop to determine 
DNA concentration. To equilibrate the machine, 2 μL of RNase-free water was applied and 
2 μL rehydration buffer or water used to blank. 2 μL of genomic DNA, RNA or DNase 1 
treated RNA was then quantified in ng/μL. Purity index 260/280 ratio was automatically 
determined during analysis. 
2.22 Transcription analysis using PCR 
MHC II, beta-2-microglobulin, M33 and IE1 were amplified in a 25 µL reaction to check 
specificity of the reverse transcriptase. 5 to 10 µL of 1/5 or 1/100 diluted cDNA synthesis 
with or without reverse transcriptase, 2.5 µL 10X buffer, 0.5 µL dNTPs (10 mM), 0.5 µL 
each of forward and reverse primers (10 µM), 0.125 µL Taq DNA polymerase. Water was 
added to a final reaction volume of 25 µL. The samples were run as follows (95oC 1 min, 
35 cycles at 95oC 15 secs, 55oC 15 sec, 72oC 30 secs, then 72oC for 7 minutes and 4oC 
indefinitely. 10 to 25 µL of PCR reaction was mixed in 2-5 µL 1X blue loading dye and run 
on a 1.5% agarose gel in TAE buffer at 70 to 110V. Bands were visualised using 
Carestream Gel Logic 212 Pro.  
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Table 4. RNA primer list 
RNA primers to 
target genes 
sequence 
M33 Forward 5’GAAACTTCTTAACCTTTCCAACGG 3’ 
M33 Reverse 5’ TCAGGATGATCACCGTGTTGATG 3’ 
IE1 Forward 5’CGATGCGCTCGAAGATATCATTG 3’ 
IE1 Reverse  5’AACCGTCCGCTGTGACCTGAC 3’ 
Beta-2-m Forward 5’ GAGACTGATACATACGCCTGCAG 3’ 
Beta-2-m Reverse  5’ TAGACCAAAGATGAGTAACTGCATC 3’ 
MHC II 5’CATCCACACAGCTTATTAGGAATG3’ 
MHC II 5’GATGCCGCTCAACATCTTGCTC3’ 
 
2.23 Polymerase Chain Reaction (PCR) 
Ovalbumin or M78 genes were amplified using PCR in 100 μL reaction (Taq DNA 
polymerase 1 μL, 10X buffer 10 μL, dNTPs (10 mM) 2 μL, purified DNA 5 μL, forward 
primer (100 µM) 1 μL, reverse primer (100 µM) 1 μL and 80 μL water). The samples were 
run as follows (95oC 5 minutes, 30 cycles at 95oC 1min, 55oC 1 min, 72oC 1 min 30 secs, 
then 72oC 10 minutes and 4oC indefinitely). 10 μL 2 log DNA ladder, amplified PCR 
products mixed in 8 μL orange loading dye were run on 1% agarose gel (0.5 g LE agarose, 
50 mL TBEE buffer, 110V). Bands were visualised using Carestream Gel Logic 212 Pro. 
Table 5. PCR primer list 
PCR primers to 
target genes 
Sequence 
OVA 1 Forward 5’CAAATAAATAAGGTTGTTCGCTTT3’ 
OVA 2 Reverse 5’CATCCACTCCAGCCTCTGCTG3’ 
OVA 3 Forward 5’TGCAGATGAGTGACCAGATTGG3’ 
M78 Forward 5’AAAGAATTCGTCGCCATGCCGACTTCATCGTG3’ 
M78 Reverse 5’AAAAGATCTCAGACAACAGAGGAGGAGGTAGGC3’ 
HAM78 Forward 
(independent) 
5’GTCGAATTCTCGCCATGCCGTACCCATAC3’ 
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2.24 Quantitative real-time PCR (QPCR) 
Genomic DNA was diluted to 5 ng/μL and a serial dilution of plasmid DNA of varying 
concentrations containing either K3 (MSCV GFP K3 plasmid) or M78 (B129) was used to 
generate a standard curve based on calculated copies per reaction. To detect MHV-68 in 
tissues, K3 primers were used to amplify K3 in MHV-68 infected tissues while M78 to 
detect MCMV infected tissues. For cellular controls, primers to mtitin was used to amplify 
connectin from genomic DNA of infected mice tissues. Water was used as no template 
control. The reaction was performed in a final volume of 20 μL as follows; 10 μL 2X Syber 
green (Roche), 1.2 μL of primer mix (Forward and Reverse at 10 µM), 6.8 μL sterile water 
and 2 μL genomic (10 ng) or plasmid DNA of varying dilutions as standards or water. 
Amplification and real-time green fluorescence detection was performed using Rotor gene 
6000 (Corbett Research) using a two-step amplification process using the following 
protocol: an initial denaturation and polymerase activation step of 10 minutest at 95oC, 
followed by 40 cycles of denaturation at 95oC for 10 secs, annealing at 60oC for 15 secs 
and extension at 72oC for 20 secs then melt curve generation 95oC for secs, 60oC for 5 
secs and 72oC for 5 secs. The threshold cycle value for each run, and the number of viral 
DNA copies and cellular DNA copies per sample were obtained using Rotor Gene 
Software series 1.7.87.  Viral load was quantified as the ratio of viral copies/cellular copies 
per reaction per sample. 
Table 6. QPCR primer list 
QPCR primers to 
target genes 
Sequence  
M78 Forward 5’ATCGAGCGTGAGGTACAGGT3’ 
M78 Reverse 5’CCTAGGGAGCCTCATCCTCT3’ 
K3 Forward 5’TCTTTGTGGGCTGCTGGGTCG3’ 
K3 Reverse  5’GGCTGTGCTGATGATAGTGATG3’ 
mtitin Forward 5’AAAACGAGCAGTGACGTGAGC3’ 
mtitin Reverse  5’TTCAGTCATGCTGCTAGCGC3’ 
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2.25 Gel electrophoresis 
Amplified PCR products or restriction digest products for diagnostics were run on 0.8-1.5% 
gel in either TAE or TBE buffer supplemented with ethidium bromide (TAEE or TBEE) for 
DNA visualisation. 
2.26 Western blot 
NIH-3T3 or RAW-C2TA cells were infected (1 PFU/cell, 24 hrs) with wild type or mutant 
MCMV or MHV-68 or recombinant OVA MCMV and MHV-68 viruses or left uninfected. For 
OVA detection, supernatants and floating dead cells were centrifuged at 4oC for 1 hr at 
11,000 x g to remove FCS. Supernatant was stored at -20oC as secreted fraction. The 
pellet was then washed once in PBS and resuspended in lysis buffer (150 mM NacI, 1% 
Triton x-100, 50 mM Tris-HCl pH 8.0) supplemented with a cocktail of protease inhibitor 
(SIGMA) or 1 mM PMSF and incubated on ice for 30 minutes. After 30 minutes, the lysate 
was either centrifuged at 11,000 x g, for 15 minutes to extract the cytoplasmic fraction or 
left without centrifugation as whole cell lysate. The cytoplasmic or whole cell lysates were 
stored at -20oC for later analysis. For virions, infected cells were ultracentrifuged at 33,000 
x g for 2 hrs at 4oC. The supernatant was discarded, and the pellet resuspended in 2% 
complete DMEM and centrifuged at 545 x g for 5 minutes. The supernatant was either 
stored at -80oC or further spun at 21,000 x g for 1 hr to pellet virions. The supernatant was 
discarded, and the pellet resuspended in 200 μL PBS and stored at -20oC.  
To detect OVA or viral proteins, secreted, cytoplasmic and whole cell fractions and virion 
were mixed in 3X Laemmli's buffer [(4% w/v SDS, 20% glycerol v/v, 10% v/v 2-
mercaptoethanol, 0.01% w/v bromophenol blue and 125 mM Tris-HCI pH 6.8)] at a ratio 
1:1. For OVA, samples were boiled at 95oC for 5 minutes while virions, cell lysate or whole 
cell lysate fractions for M78 detection were incubated at 42oC for 5 minutes.  All samples 
were resolved by 10-12.5% SDS-PAGE (3.75 mL 1.5M Tris-HCI, pH 8.8, 4.2 mL 30:1 
Acrylamide base, 2.05 mL  deionised water, 50 µL 10% APS, 5 µL TEMED and 100 µL 
10% SDS) on a 4% stacking gel (1mL 1M Tris-HCI, pH 6.8, 1 mL 30:1 Acrylamide base, 5 
mL ionised water, 5 µL TEMED and 100 µL 10% APS) using a power Pac 1000 (Bio-Rad) 
gel system in SDS-PAGE running buffer (25 mM Tris-HCI, 12 mM glycine, 0.1% w/v SDS) 
at 174V for 30 to 40 minutes. The membrane was then transferred onto 0.45 µM PVDF 
membrane (activated in methanol for 1 minute) at a constant current 250 mA for 1 hr. The 
membrane was blocked in 10% skim milk/PBST for 1 hr at RT with gentle rocking and 
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probed with a number of antibodies; rabbit anti-OVA pAb (Abcam), rabbit anti-M78, rabbit 
anti-MCMV, rabbit serum, rat anti-beta-actin and mouse anti-IE1 (chroma 101) in 5%skim 
milk/PBST overnight at 4oC followed by three times wash in PBST and detection in 
IRDye® 800CW Goat-anti-Rabbit Antibody IgG (H+L) (LI-COR) or rabbit anti-rat or goat 
anti-mouse IgG antibodies in 5%skim milk/PBST. Membrane bands were detected using 
LI-COR odyssey infrared imager.   
2.27 Generation of RAW-C2TA and BALB/c-3T3-C2TA expressing cell lines 
M78 was amplified from K181 viral DNA and from B53 plasmid that has an HA- tagged 
M78 to generate an independent M78 clone. M78 was amplified using two sets of DNA 
polymerases as follows; 3 μL of (15.89 ng/μL viral DNA) or 1 μL (1 ng or 5 ng plasmid 
DNA), 20 μL 5X Q5 buffer, 2 μL 10 mM dNTP, 5 μL 10 µM Forward and Reverse, 1 μL Q5 
DNA polymerase and water to a final volume of 50 μL. OneTaq DNA polymerase  was also 
used for amplification as follows; 20 μL 5X OneTaq buffer, 2 μL 10 µM dNTP, 2 μL 10 µM 
Forward and Reverse, 0.5 μL One Taq polymerase, 3 μL (15.89 ng/μL viral DNA) or 1 μL 
(1 ng or 5 ng) plasmid DNA and water to volume of 100 μL. The PCR reaction was 
performed as follows: 95oC 5 minutes, 35 cycles of 95oC 30 secs, 55oC 30 secs, 72oC 1 
min 45 secs and 7 minutes extension at 72oC, and indefinitely at 4oC.   
2.27.1 PCR purification 
Q5 PCR amplified products were purified as follows according to the manufactures 
instructions (MACHEREY-NAGEL); Briefly, 100 μL of PCR product was mixed in 200 μL 
NT1 by pipetting up and down and then added to a NucleoSpin column and centrifuged 
(11,000 x g, for 30 secs). The flow through was discarded and 700 μL of NT3 was added 
and centrifuged (11,000 x g, 30 secs). This was repeated, and the silica membrane was 
dried by centrifugation (11,000 x g, for 1 min). 30 μL of elution buffer was then added to 
the column, left to stand at RT for 1 minute and centrifuged (11,000 x g, for 1 min). Eluted 
DNA was quantified using nanodrop and prepared for subsequent manipulation.   
2.27.2 Restriction digest 
The purified M78 PCR products were then digested with Bg1II and then with EcoRI in a 40 
μL reaction as follows; 30 μL PCR purified templates, 4 μL Buffer 3.1, 3 μL BgIII and 3 μL 
water. The reaction was performed at 37oC on a water bath for 2 hrs, then PCR purified as 
above. 30 μL PCR purified BgIII digested product was then digested with EcoRI-HF as 
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follows; 30 μL PCR purified templates, 4 μL EcoRI Cutsmart buffer, 3 μL EcoRI-HF and 3 
μL water. The reaction was performed at 37oC in a water bath for 2 hrs. The MSCV vector 
was also digested as follows; 3 μL vector (1697.03 ng/µl), 4 μL 10X Cutsmart buffer, 2 μL 
EcoRI-HF and 2 μL BamHI-HF and 29 μL water. The reaction was performed at 37oC for 1 
hr and half. 10 μL loading dye was then added to the 40 μL digested products and run on 
a gel. Bands corresponding to 1.4kb (M78) and 7kb MSCV vector were excised and gel 
purified. Nucleic acid concentration was determined by nanodrop. Ligation was then 
performed in a 20 μL reaction as follows; 8 μL of (48.62 ng/µL) MSCV vector, 8 μL of 
(57.95 ng/uL or 61.75 ng/uL) insert or water (no insert control), 2 μL of DNA ligase buffer 
and 2 μL T4 DNA ligase and mixed by pipetting up and down and incubated overnight at 
16oC. To inactivate the enzyme, the samples were incubated at 65°C for 10 minutes. 
2.27.3 Transformation 
50 μL of competent DH5α E.coli were thawed on ice and 1 μL of 1/20 dilution (100 ng) of 
ligation added. The tubes were gently flicked to mix and left on ice for 30 min, 42oC for 90 
seconds and then on ice for 2 minutes. 900 μL of 2TY broth (no antibiotic) was added and 
incubated for 40 minutes at 37oC with shaking at 4500 rpm. The bacteria were then plated 
on 100 µg/ml ampicillin enriched agar plates overnight at 37oC. Single colonies were then 
picked and grown on agar and in 10 mL LB broth containing ampicillin. The bacteria were 
then pelleted at 908 x g for 15 minutes and plasmid DNA extracted using alkaline lysis as 
described above and DNA concentration quantified by nanodrop. 
2.27.4 To confirm ligation and transformation 
Plasmid DNA extracted above were digested with EcoRI-HF and Xhol in a 50 µL reaction 
as follows; 5 µL of 1 to 3 µg plasmid DNA, 5 µL Cutsmart buffer, 2 µL EcoRI-HF RE, 2 µL 
XhoI RE and 36 µL water to diagnose presence of M78 in the MSCV vector. The samples 
were incubated at 37oC for 2 hrs and 10 µL was run on a 1% agarose gel.  Positive 
Plasmid DNA clones were used for transfection.  
2.27.5 Transfection 
1x106 293T cells were seeded in 10 cm culture dish overnight. Transfection was 
performed according to manufacturer’s instructions (MIRUS). Briefly, transfection reagent 
consisting of 500 µL Optimum and 20 μL transfect Lipid (TransIT®-LT1) was mixed in 1.5 
mL tube by gently pipetting up and down. 2 µg of retrovirus packing plasmids PC143N and 
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PVSVG were then added. To these separate tubes, 1 µg positive DNA clones isolated 
from transformed E.coli generated from either independent M78 clone 2, M78 clone 4 or 
MSCV vector as control were then added and incubated at RT for 30 minutes. The mix 
was then added to seeded 293T cells and left to incubate at 37oC, 5% CO2 for 24, 48 and 
72 hrs for retroviral virions to form.  
2.27.6 Transduction of BALB/c-3T3-C2TA and RAW-C2TA 
1x106 BALB/c-3T3-C2TA or RAW-C2TA cells were seeded in 10 cm culture dish 
overnight. The culture media was removed and 5 mL complete medium containing 10 
µg/mL polybrene was added to the cells and 24-hr culture supernatant from retroviral 
transduced 293T cells filtered through 0.45 µM filter was then added to the cells for a final 
concentration of 5 µg/mL polybrene. This process was repeated at 48 and 72 hrs post 
retroviral transfection to maximise retroviral transduction of target cells. The cells were 
then selected in complete medium containing 10 µg/mL puromycin. Media was changed 
accordingly and selected resistant cells were frozen in 10% DMSO 90% FCS.  
2.28 Generation of clones by limiting dilution 
Continuous passage of RAW-C2TA led to loss of MHC II expression resulting in a mixture 
of MHC II high and MHC II low cells. M78 expressing RAW-C2TA were also found to 
unequally express M78. To isolate high expressing MHC II or M78 expressing clones, 200 
µL of 1/1000 dilution of 4x106 cells/mL RAW-C2TA or RAW-C2TA-M78 cells were added 
to 96 well plates. This was then diluted 10-fold, and finally 3-fold in 10% complete DMEM 
containing zeocin or puromycin, a selectable marker for MHC II and M78 expressing cells 
respectively. The cells were incubated at 37oC 5%, CO2 and monitored for growth. Media 
was changed accordingly. Individual clones were then cultured to scale in 6 well plates 
and assessed for MHC II and M78 expression using a 96 well immunofluorescence 
staining format. Briefly, cells were scrapped using a pipette and counted using a 
hemocytometer, and 2x104 cells from each individual clone was seeded in a 96 well plate 
and left to adhere for 4 hrs. The cells were then washed twice in PBS and fixed in 
1%PFA/PBS for 1 hr and permeablised in 0.1%tritonX-100/PBS for 15 minutes. To detect 
MHC II or M78, the cells were washed twice in PBS, blocked in 2% normal goat serum 
(NGS) in PBS for 1 hr and stained with rat anti-MHC II (M5/114) or rabbit anti-M78 sera for 
1 hr. The cells were then washed in PBS, stained with Alexa Fluor 594 goat anti-rat or 
Alexa Fluor 488 goat anti-rabbit in 2%NGS/PBS for 1 hr and then washed. The plates 
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were viewed under a fluorescence microscope. Clones positive for MHC II or M78 
expression were further cultured to scale and analysed for MHC II expression using flow 
cytometry or M78 using microscopy. Clones expressing 95 to 100% MHC II or M78 were 
frozen. RAW-C2TA clones were tested for their ability to secrete nitric oxide (NO2) and 
present OVA323-339 peptide to simulate CD4+ T cell hybridomas to secrete IL-2. M78 
expressing RAW-C2TA were further manipulated by microscopy to determine MHC II 
redistribution. 
2.29 NO2 test 
106 cells (RAW-C2TA clones, NSO, BALB/c-3T3, and BALB/c-3T3-3T3-C2TA) were 
seeded in 24 well plates and left to adhere. The cells were then treated with 250 μL (1 
mg/ml) LPS or left untreated and incubated overnight at 37oC, 5%CO2. NO2 release was 
detected according to manufactures (Sigma) instructions. Briefly, 80 μL of culture medium 
from each well was added to 96 well plate in duplicates. NaNO2 standard solution 100 µM 
(0.1 nmole/μL) was added as 0, 20, 40 and 80 μL in duplicates. Solution buffer was then 
added to each sample well and standards to bring the reaction volume to 100 μL. 50 μL of 
Griess reagent A was then added to the wells and left to incubate at room temperature 
(RT) for 5 minutes, then 50 μL of Griess reagent B was added and incubated for another 
10 minutes  on a horizontal shaker. Absorbance was read at 570 nm using POLARstar® 
Omega Plate Reader Spectrophotometer (BMG Labtech; ex 400 nm, em 505 nm; 37°C) 
2.30 Antigen presentation assay 
I-Ad-restricted, OVA323–339-specific DO11.10 CD4+ T cell hybridoma cells respond to 
ovalbumin by expressing the OVA323-339-specific T cell receptor (Tcr) (156). This receptor 
binds OVA323-339 peptide complex presented on MHC class II (1-Ad/1-Ab) by antigen 
presenting cells (pAPCs) (156). To test CD4+ T cell stimulation, uninfected BT3 and RAW 
C2TA cells were incubated with ten-fold serial dilution of OVA323-339 peptide in the presence 
of OVA323–339-specific DO11.10 hybridoma cells. To determine presentation of OVA323-339 
peptide in infected cells, the following procedures were employed; 
2.30.1 BALB/c-3T3-C2TA 
3×104 H2d BALB/c-3T3-C2TA cells were left uninfected or were infected MOI 0.3 with WT 
or OVA-expressing MCMV or MHV-68 recombinants in the presence of 3×104 I-Ad-
restricted, OVA323–339-specific DO.11.10 hybridoma cells. Uninfected controls were co-
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cultured in the presence of OVA323–339 peptide.  After 24 hrs, supernatants were harvested 
and assayed for IL-2 by ELISA. 
2.30.2 RAW-C2TA 
3×104 H2d RAW C2TA cells were left uninfected or were infected MOI 2 with WT or OVA-
expressing MHV-68 recombinants or with 1 P.F.U/cell WT or OVA-expressing MCMV. 
After 96 hrs, 3×104 I-Ad-restricted, OVA323–339-specific DO.11.10 hybridoma cells were 
added to each well. Uninfected controls had 10-fold serial dilutions of OVA323–339 peptide. 
After 24-48 hrs, supernatants were harvested and assayed for IL-2 by ELISA. 
2.31 Enzyme-linked immunosorbent assay (ELISA) 
2.31.1 IL-2 
96 well EIA/RIA flat bottom without lid High Binding Polystyrene non-sterile (Corning 
Incorporated, NY) plates were coated with rat anti-mouse IL-2 mAb (clone JES6–1A12, 
BD-Pharmingen) overnight at 4oC in 50 mM NaHCO3 pH 7.6 overnight at 4oC. The plates 
were then washed five times in 0.1% PBS/Tween-20 and blocked in 2%BSA/PBST (1hr, 
37oC). Captured IL-2 was detected with biotinylated mAb JES6–5H4 (BD-Pharmingen) 
(1hr, 37oC), washed five times in PBST and incubated with streptavidin-conjugated 
alkaline phosphatase (BD-Pharmingen) for 1hr at 37oC, washed five times with 
0.1%Tween-20/PBS and developed using nitro-phenyl-phosphate substrate (Sigma) (30 
minutes, RT) in the dark. Absorbance was read at 405 nm using SPECTRA MAX 190 
ELISA plate reader (Bio-strategy).  
2.31.2 Preparation of sera from mouse blood 
Blood was collected in 1.5 mL tubes from alert mice by tail bleed or from the peritoneum 
cavity during surgery. Briefly, for tail bleeds, mice were exposed to mild heat using a heat 
lamp to increase blood circulation. 5 mm of tail was then cut using a razor and blood was 
collected in 1.5 mL test tubes. During surgery, blood was collected from the peritoneum 
cavity following excision of the main blood vessel that supplies the abdominal organs. The 
blood was allowed to clot at RT for 2 to 4 hrs. After clotting, the blood was centrifuged at 
high speed (11,000 x g for 1 minute). Top layer sera were transferred to a new tube and 
stored at -20oC for later analysis. 
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2.31.3 IgM and IgG 
96 well EIA/RIA flat bottom without lid High Binding Polystyrene non-sterile (Corning 
Incorporated, NY) plates were either coated with MHV-68 or MCMV lysate or OVA 
(Abcam) overnight at 4oC in 50 µL 50 mM NaHCO3 pH 7.6 overnight at 4oC. The plates 
were then washed five times in 0.1% PBS/Tween-20. For MHV-68 or MCMV specific 
antibody, plates were blocked in 2%BSA/PBST (1hr, 37oC) while OVA-specific response 
plates were blocked in 10%skim milk/PBST. Sera were diluted 1/00 in PBS and then 
serially diluted 3-fold in either 2%BSA/PBST or 5%skim milk/PBST. 100 μL was then 
added to each well in each respective plate and incubated for 2 hrs at 37oC. The plates 
were then washed four times in PBST and incubated with 50 µL of either goat anti-mouse 
IgM (Southern Biotech) or IgG (SIGMA) conjugated alkaline phosphatase for 1 hr at 37oC, 
washed five times in PBST and developed using nitro-phenyl-phosphate substrate (Sigma) 
(30 minutes to 2 hrs at RT) in the dark. Absorbance was read at 405 nm using Spectramax 
190 ELISA plate reader (Bio-strategy). 
Table 7. IL-2 ELISA detection antibodies 
IL-2 detection Manufacturer 
and batch 
Reactivity/isotope Stock 
(mg/mL) 
Working 
concentration 
Anti-Mouse IL-2 
(JES6-1A12) 
BD Pharmingen 
554424 
Rat IgG2a 0.5 1:500 
Recombinant IL-2 BD Pharmingen 
550069 
Mouse 0.2 1:1000- serial 
dilution starting 
1:128 to 
1:2048 
Biotin Anti-Mouse 
IL-2 (JES6-5H4) 
BD Pharmingen 
554426 
Rat IgG2b 0.5 1:2000 
AKP streptavidin BD Pharmingen 
554065 
 1 1:2000-5000 
Antibody 
detection 
    
Ovalbumin Millipore 
AB1225 
Rabbit pAb 10 1:400 
MHV-68 lysate In house Mouse N/A 1:400 
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MCMV lysate In house Mouse  1:400 
IgM Southern 
Biotech 1021-04 
Goat  N/A 1:2000 
IgG Sigma 
051M4891 
Goat N/A 1:2000 
IgG1 Southern 
Biotech 1070-04 
Goat  N/A 1:2000 
IgG2a Southern 
Biotech 1080-04 
Goat  N/A 1:2000 
IgG2b Southern 
Biotech 1090-04 
Goat  N/A 1:2000 
 
2.32 The Enzyme-Linked Immunospot assay (ELISPOT) 
2.32.1 Coating plates 
96 well plate IP sterile white plates 0.45 µM Hydrophobic High Protein Binding Immobilon-
P PVDF membrane (Merck Millipore, Ireland) were activated in 50 μL 70% ethanol for 2 
minutes, washed four times in 200 μL PBS and coated with 50 μL rat anti-mouse IFN-γ 
mAb (clone R4-6A2; BD-Pharmingen) in PBS and left overnight at 4oC. On the day of the 
assay, the plates were washed five times in PBS and blocked in complete RPMI medium 
until target cells were prepared for incubation. 
2.32.2 Ficoll plaque gradient lymphocyte isolation 
Uninfected and infected spleens, lymph nodes, lungs or noses were harvested, 
homogenised and single cell suspensions were graded on ficoll-paque density gradient 
media and centrifuged (20 minutes at 281 x g at 20oC) to separate serum, lymphocytes, 
monocytes and blood. The lymphocyte fraction was washed once in PBS (8 minutes at 
281 x g at 20oC) and again in complete DMEM (5 minutes at 245 x g at 20oC) and 
resuspended in complete RPMI medium. 
2.32.3 CD4+ T cell enrichment using Mouse Depletion Dynabeads 
To enrich CD4+ T cells, Ficoll plaque gradient isolated lymphocytes above were 
resuspended in isolation buffer (2%FCS/PBS supplemented with 2 mM EDTA) and 
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enrichment of CD4+ T cells performed using manufactures instructions (Invitrogen). Briefly, 
500 μL-1 mL leucocytes (107-109 cells) were incubated in 100 μL heat inactivated FCS 
supplemented with 50 μL antibody mix which contains a cocktail of rat monoclonal 
antibodies against mouse CD8, CD45R (B220), CD11b (Mac1), Ter-119 and CD16/CD32 
(Life technologies). The cells were then mixed and incubated at 4oC for 20 minutes. After 
incubation, the cells were washed in isolation buffer and centrifuged (5 to 8 minutes at 500 
x g at 4oC). The cell pellet was resuspended in 1 mL isolation buffer and incubated with 
500 μL pre-washed Mouse Depletion Dynabeads (are superparamagnetic polystyrene 
beads of 4.5 µM diameter ) coated with a polyclonal sheep anti-rat IgG antibody and 
incubated for 15 minutes at RT with gentle tilting. 4 mLs isolation buffer was then added to 
the bead bound cells, resuspended by pipetting using a pipette and placed in a magnet for 
2 minutes. Supernatant containing the untouched CD4+ T cells were transferred to a new 
tube, centrifuged (5 minutes at 245 x g at 4oC), resuspend in RMPI medium and counted. 
For ovalbumin specific IFN-γ response, naïve target cells were either left untreated or 
incubated with 5 µM OVA323-339 peptide (InvivoGen) or 10 µM OVA257-264 (InvivoGen) or 
infected with MHV-68 mOVA (MOI 3) in suspension. The cells were then irradiated at 2000 
rads using a GC220 irradiator. For virus specific responses, naïve target cells were 
infected with MCMV (MOI 1) or MHV-68 (MOI 3) in suspension and irradiated as above. 
Infected target cells were left to incubate for 2 hrs at 37oC, 5% CO2. After 2 hrs, the cells 
were washed once in PBS and in complete RPMI medium. The cells were then 
resuspended in complete RPMI medium and 100 µL of 2x105 cells were then added to the 
coated and blocked 96 well plate and incubated at 37oC, 5%CO2 until effector cells were 
ready. 100 µL of 3-fold serial dilutions (1x105 to 1x104) CD4+ T cell enriched or unenriched 
effector cells from MHV-68 mOVA, MHV-68 or MCMV WT or M78- infected mice were then 
added to the seeded target cells respectively. The plates were incubated at 37oC, 5%CO2 
for 48 hrs. After 48 hrs, the wells were washed twice in deionised water for 3 to 5-minute 
intervals, three times in 0.05% Tween-20/PBS (PBST) and captured IFN-γ was detected 
with biotinylated rat anti-mouse IFN-γ mAb (clone XMG1.2; BD-Pharmingen) in 10% 
FCS/PBS at RT for 2 hrs. The wells were then washed four times in PBS/T and 
streptavidin-conjugated alkaline phosphatase (BD-Pharmingen) supplemented in 10% 
FCS/PBS was added and left to incubate at RT for 1hr. The wells were then washed four 
times in PBST and three times in PBS. Parafilm was applied to the bottom of the plate and 
the membrane bound plate firmly attached onto the parafilm to minimise background.  50 
μL of 5-bromo-4-chloro-3-indolyl phosphate/nitro-blue tetrazolium substrate (Sigma-Aldrich 
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Co. LLC) dissolved in water was then added to each well and left to develop at RT. The 
reaction was stopped by washing the wells in running water. The plates were then left to 
air dry overnight and spots were manually enumerated using a dissecting microscope. 
Background spots from uninfected wells were averaged and subtracted from spots in 
treated wells.  
Table 8. IFN-γ detection peptides and antibodies 
IFN-γ detection Manufacturer 
and batch 
Reactivity
/isotope 
Stock 
(mg/mL) 
Working 
concentration 
OVA323-339 InvivoGen vac-isq 1 1:100 
OVA257-264 InvivoGen vac-sin 1 1:100 
Anti-Mouse IFN-γ (R4-
6A2) 
BD Pharmingen 
551216 
Rat IgG1 1 1:1000 
Biotin Anti-Mouse IFN-
γ (XMG1.2) 
BD Pharmingen 
554410 
Rat IgG1 0.5 1:2000 
AKP streptavidin BD Pharmingen 
554065 
 1 1:4000 
 
2.33 Immunohistochemistry 
Organs were fixed in PLP mixture (1% formaldehyde, 10 mM sodium periodate, 75 mM L-
lysine) for 18 hrs at 4oC. The organs were then placed in 30% sucrose at 4oC for 18 hr. 
The tissue samples were then frozen in OCT embedding medium. 5 µM tissue sections of 
lungs, spleens, salivary glands or lymph nodes were cut using a cryostat (manufacturer) 
air dried overnight at RT, washed three times in phosphate-buffered saline (PBS), blocked 
in 5% NGS/0.3% Triton X-100 for 1 hr at RT, followed by a combination of primary 
monoclonal or polyclonal antibodies diluted in 2%NGS/0.3%triton X-100/PBS for 18 hrs at 
4oC. After an overnight incubation, the sections were washed three times in PBS and 
incubated for 1hr at RT with a combination of secondary antibodies and DAPI to stain 
nucleus in 2%NGS/0.3%Triton X-100/PBS. Sections were then mounted onto microscope 
coverslips in Prolong Gold and visualised using laser confocal or an epifluorescence 
microscope. Antibodies and concentrations are tabled in the appendix section. 
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2.34 Immunofluorescence 
Coverslips were sterilised in 70% ethanol and placed in 24 well plates, washed twice in 
PBS and 2x105 cells in 500 μL 10% complete DMEM were seeded and left to adhere for 4 
hrs or overnight at 37oC 5%CO2. The cells were then infected with MHV-68 BAC+ or BAC- 
WT or OVA-recombinant MHV-68 viruses or WT or recombinant MCMV OVA expressing 
viruses (MOI 0.3, 18 hrs). The culture medium was discarded, washed twice in PBS and 
fixed in 2%PFA/PBS for 1hr at RT with gentle agitation, washed twice in PBS and 
permeablised in 0.1% triton-x100/PBS for 15 minutes. Non-specific binding was blocked 
using 2%NGS/PBS for 1 hr at RT. A combination of primary antibodies diluted in 
2%NGS/PBS were added to the cells and incubated for 1 hr at RT with gentle rocking or 
overnight at 4oC. Cells were then washed twice in PBS and incubated in a combination of 
secondary antibodies and DAPI for nuclei stain in 2%NGS/PBS for 1 hr at RT. Cells were 
then washed twice with PBS and three times in water before mounting coverslips onto 
microscope slides with Prolong Gold. The slides were cured overnight, nailed polished 
around the rim. Antibodies and concentrations are tabled in the appendix section. 
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Table 9. Primary antibody list 
   Working concentration 
Primary antibodies Manufacture 
and Batch  
Stock 
(mg/mL) 
WB IHC IF FACS 
Rabbit pAb anti-
MHV-68 IgG 
In house - 1:10000 1:10000 1:10000  
Rabbit pAb anti-
ovalbumin IgG 
Millipore 
AB1225 
10 1:5000 - 1:5000 - 
Rabbit pAb anti-
ovalbumin IgG 
Abcam 
181688 
1 1:4000 1:4000 1:4000  
Rabbit pAb anti-
MCMV IgG 
In house - 1:0000 1:16000 1:16000  
Rabbit pAb anti-M78 
IgG 
In house - 1:400 - 1:8000 - 
Mouse anti-IE1 
(chroma101) IgG1 
In house - 1:5 1:10 1:10 1:5 
Rat mAb anti-α-
Tubulin (P-16) IgG2a 
Biorad 
MCA77G 
0.5 1:2000 NA NA NA 
Biotin Rat mAb anti-
CD44 (IM7) IgG1 
BD 
Pharmingen 
553132 
0.5 NA NA 1:1000 1:500 
Rat anti-MHC II 
(M5/114.15.2) IgG2b 
BD 
Pharmingen 
556999 
0.5 1:1000 1:1000 1:1000 1:1000 
Armenian hamster 
anti-CD11c (HL3) 
IgG1 
BD 
Pharmingen 
553799 
0.5  1:500   
Rat mAb anti-F4/80 
(3C137) IgG2b 
Santa Cruz 
71086 
0.1  1:100   
Rat mAb anti-CD68 
(FA-11) IgG2a 
Abcam 53444 1  1:1000   
Goat pAb anti-SPC 
(M-20) IgG 
Santa Cruz 
7706 
0.2  1:200   
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Rat mAb anti-CD206 
(MR5D3) IgG2a 
Biorad 
MCA2235 
0.25  1:250   
Chicken anti-β-gal 
IgY 
Abcam 9361 0.25 - 1:1000 1:1000 1:1000 
Rat mAb anti-CD169 
IgG2a 
Biorad 
MCA884 
0.2 - 1:200 - - 
Goat pAb anti-
podoplanin IgG 
R&D 
Systems AF 
3244 
0.2 - 1:200 - - 
Rat mAb anti-CD45R 
RA3-6B2 IgG2a 
Santa Cruz 
19597 
0.2 - 1:100 - - 
Rat anti-mouse CD4 
(L3T4- GK1.5) IgG2b 
BD 
Pharmingen 
553727 
0.5 - 1:500 - - 
Mouse anti-mouse 
DO-11.10  Clonotypic 
TCR ( KJ1-26) IgG2a 
BD 
Pharmingen 
551771 
0.5 - 1:500 - - 
Biotin conjugate 
mouse anti-mouse 
DO-11.10 TCR (KJ1-
26) IgG2a 
Thermo 
Scientific 
MA5-17661 
0.1 - 1:100 - - 
Biotin Mouse anti-
mouse H-2D (d) (34-
2-12) 
BD 
Pharmingen 
553578 
0.5 - 1:1000 1:1000 1:500 
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Table 10. Secondary antibody list 
   Working concentration 
Secondary 
antibodies 
Manufacture 
and Batch  
Stock 
(mg/mL) 
WB IHC IF 
 
FACS 
Alexa Fluor 594 
donkey anti-rat IgG 
(H+L) 
Life 
Technologies 
A21209 
2 - 1:2000 1:2000 - 
Alexa Fluor 568 goat 
anti-rat IgG (H+L) 
Abcam 
175476 
2 - 1:2000 1:2000 - 
Alexa Fluor 568 goat 
anti-rabbit IgG (H+L) 
Invitrogen 
A11011 
2   1:2000  
Alexa Fluor 594 goat 
anti-rat IgM (µ chain) 
Life 
Technologies 
A21213 
2 - 1:2000 1:2000 1:2000 
TRITC goat anti-
Armenian Hamster 
IgG (H+L) 
Abcam 5741 1 - 1:1000 - - 
Alexa Fluor 647 goat 
pAb to Armenian 
Hamster IgG  
Abcam 
173004 
2 - 1:2000 - - 
Alexa Fluor 647 goat 
anti-rat IgG (H+L) 
Life 
Technologies 
A21247 
2 - 1:2000 1:2000 1:2000 
Alexa Fluor 647 
donkey anti-rat IgG 
(H+L) 
Abcam 
150155 
2 - 1:2000 1:2000 - 
Alexa Fluor 647 goat 
anti-mouse IgG1 (γ1) 
Life 
Technologies 
A21206 
2 - 1:2000 - 1:2000 
Alexa Fluor 488 goat 
anti-rat IgG (H+L) 
Life 
Technologies 
A11006 
2 1:10000 1:2000 1:2000 - 
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Alexa Fluor 488 
donkey anti-rabbit 
IgG (H+L) 
Invitrogen 
A21206 
2 - 1:2000 1:2000 - 
Alexa Fluor 488 goat 
anti-rabbit IgG (H+L) 
Life 
Technologies 
A11008 
2 1:10000 1:2000 1:2000 - 
Alexa Fluor 488 goat 
anti-chicken IgY 
(H+L) 
Abcam 
150173 
2 - 1:2000 1:2000 1:2000 
Alexa Fluor 488 goat 
anti-mouse IgG1 (γ1) 
Life 
Technologies 
A21121 
2 - 1:2000 1:2000 1:2000 
Dylight 800 
Conjugated rabbit 
anti-rat IgG (H+L) 
Rockland  1 1:10000
-20000 
- - - 
IRDye® 680RD Goat 
pAb anti-mouse IgG 
(H + L) 
LI-COR 
C30117-01 
1 1:10000
-20000 
- - - 
IRDye® 800CW Goat 
pAb anti-mouse IgG 
(H + L) 
LI-COR 
C30409-07 
1 1:10000
-20000 
- - - 
Oregon Green 488 
goat pAb anti-mouse 
IgG (H+L) 
Life 
Technologies 
011033 
2 -  1:2000  
DAPI Life 
Technologies 
1 - 1:1000 1:1000 - 
73 
 
 
2.35 Microscopy 
2.35.1 Epi-fluorescence 
Coverslips were viewed on a Nikon fluorescence microscope using 40X or 100X (oil 
immersion) objective. The microscope is equipped with the blue (330-380 nm), green (465-
495) and red (540-580 nm) channels. 
2.35.2 Confocal laser 
For more detailed images, coverslip or tissue mounts were viewed on ZEISS LSM 710 
Confocal microscope using 40X, and oil immersion objectives 63X and 100X. The 
microscope is equipped with 405, 561 and 633 lasers that can be switched on or off using 
the ZEN2012 software. Multi-tracking was used to randomly take pictures of multiple 
sections within tissues for cell counting. 
2.36 Image analysis 
Images were processed and analysed in image J or using ZEN2012. To determine number 
of infected cells or cells expressing cell type markers of interest, images were analysed 
using the cell counter plugin. Nuclei staining was used to determine total number of cells 
per field of view. 
2.37 Flow cytometry 
2.37.1 Genotyping  
C57BL/6 MHC II knockout mice (IA-/-) were genotyped using flow cytometry. Briefly, the 
mice were exposed to mild heat using a heat lamp to increase blood follow. 5 mm of tail 
was then cut, and blood was collected in 1.5 mL test tubes containing 50 µL (400 µg/mL) 
heparin sulphate or 20 µL of 0.5 M EDTA, pH 6.8. To lyse red blood cells, 1 mL 
ammonium chloride lysis buffer was added to the tubes and incubated at 37oC for 15 to 30 
minutes or until reddish colour was observed. The cells were then centrifuged for 5 
minutes at 500 x g. The supernatant was discarded, and the cell pellet was washed twice 
in PBS and double stained for CD4+ and CD8+ T cells as described in the flow cytometry 
section for primary cells below. 
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2.37.2 Primary cells 
106 lymphocytes isolated from blood as above, or spleens and lymph nodes were washed 
twice in PBS and stained in 2% FCS/PBS containing a cocktail of antibodies in the 
presence of mouse Fc receptor block purified rat anti-mouse CD16/CD32 clone 2.4G2 for 
1 hr at 4oC. The cells were then washed twice in PBS and resuspended in 200 µL ice-cold 
PBS for analysis on BD Accurri C6 flow cytometer. Flow cytometry antibodies used are 
described in the appendix section of the thesis. 
2.37.3 Immortalised cells 
106 cells were seeded in six well plates and left uninfected or infected with MHV-68 or 
MCMV WT or number of mutants expressing different reporter genes.  
For surface staining, the cells were scrapped, washed twice in PBS, counted and stained 
with a combination of directly conjugated antibodies or unconjugated antibodies in 
2%FCS/PBS or 2%NGS/PBS for 1 hr at 4oC in the presence or absence of purified rat 
anti-mouse CD16/CD32 Fc block. Cells directly stained with fluorophore-conjugated 
antibodies were washed twice in PBS and resuspended in PBS for later analysis or 
manipulated further for intracellular staining as described in the subsequent section below. 
For unconjugated antibody labelled cells, the cells were washed twice in PBS and 
incubated with either phycoerythrin (PE) or PerCP-Cy5.5 conjugated streptavidin to detect 
biotinylated antibodies or Alexa Fluor secondary antibodies to rat or mouse in 
2%FCS/PBS or 2%NGS/PBS for 1 hr at 4oC. The cells were then washed twice in PBS 
and resuspended in 200 µL ice-cold PBS for later analysis. 
For intracellular staining, cells stained above, or unstained cells were fixed in 2%PFA/PBS 
for 30 minutes at RT, washed twice in PBS and incubated in 0.5% saponin/PBS for 15 
minutes at RT. To detect infected cells, the cells were stained in antibodies to hamster 
anti-β-gal to detect recombinant MCMV viruses expressing β-gal, or monoclonal mouse 
anti-mouse IE1 sera to detect IE1 or polyclonal rabbit anti-HA to detect HA tagged MCMV 
viruses in combination with antibodies to MHC II, CD44 or MHC I (if previously unstained) 
diluted in 2%NGS/0.5%saponon/PBS incubated for 1hr at RT. The cells were then washed 
twice in 0.5%saponin/PBS and incubated with secondary antibodies against their 
respective primary targets in 2%NGS/0.5%saponin/PBS for hr at 4oC. The cells were then 
washed once in 0.5%saponin/PBS, once in PBS and resuspended in 200 uL ice-cold PBS 
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and analysed on a multicolour flow cytometer or BD Accurri C6 flow cytometer. Propidium 
iodide (1mg/mL, batch MKBP1360V, Sigma) was used to detect and gate out dead cells 
using the PE 575/25 nm channel. GFP expressing viruses were detected directly.  
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Table 11. Flow cytometry antibodies 
 Flow cytometry 
antibodies 
Manufacture 
and Batch  
Isotype Stock 
(mg/mL) 
Working 
concentration 
FITC Rat anti-mouse 
CD4 GK1.5 
BD Pharmingen 
 
Rat  1:500 
FITC Rat Anti-Mouse 
CD4 (RM4-4) 
BD Pharmingen 
553055 
Rat IgG2b 0.5 1:500 
Alexa Fluor 488 Rat 
anti-mouse CD4 (RM4-
5) 
BD Pharmingen 
557667 
Rat IgG2a 0.2 1:200 
FITC Rat Anti-Mouse 
CD71 (C2/C2F2) 
BD Pharmingen 
561936 
Rat IgG1 0.5 1:500 
PE Rat Anti-Mouse 
CD11b (M1/70) 
BD Pharmingen 
553311 
Rat IgG2b 0.2 1:200 
PE Hamster Anti-Mouse 
CD69 (H1.2F3) 
BD Pharmingen 
553237 
Armenian 
Hamster IgG1 
0.2 1:200 
PE Rat anti-mouse 
CD62L MEL-14 
BD Pharmingen 
553151 
Rat IgG2a 0.2 1:200 
PE Rat anti-mouse 
CD8β (H35-17.2) 
BD Pharmingen 
550798 
Rat IgG2b 0.2 1:500 
PE Rat anti-mouse 
CD19 ID3 
BD Pharmingen Rat  1:500 
PE streptavidin BD Pharmingen 
554061 
N/A 0.5 1:500 
Propidium Iodide  Sigma-Aldrich 
MKBP1360V 
DNA 10 1:1000 
PerCP Cy5.5 Rat anti-
mouse I-A/I-E 
(M5/114.15.2)  
BD Pharmingen 
562363 
IgG2b 0.2 1:200 
PerCP Cy5.5 
streptavidin 
BD Pharmingen 
554061 
N/A 0.5 1:500 
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PerCP Cy5.5 Rat anti-
mouse CD8α (53-6.7) 
BD Pharmingen 
551162 
Rat IgG2a 0.2 1:200 
Alexa Fluor 647 Rat 
anti-mouse CD19 (ID3) 
BD Pharmingen 
557684 
Rat IgG2a 0.2 1:200 
Alexa Fluor 647 Rat 
anti-mouse 1-A/1-E 
M5/114.15.2 
BD Pharmingen 
562367 
Rat IgG2b 0.2 1:100 
Alexa Fluor 647 mouse 
anti-mouse DO.11.10 
clonotypic TCR KJ-126 
BD Pharmingen 
562524 
Mouse IgG2a 0.2 1:500 
Biotin Rat anti-mouse 
CD86 (GL1) 
BD Pharmingen 
553690 
Rat IgG2a 0.5 1:500 
Purified Rat anti-mouse 
Cd16/CD32 (2.4G2) 
BD Pharmingen 
553142 
Rat IgG2b 0.5 1:500 
BV241 Rat anti-mouse 
CD71 (C2/C2F2) 
BD Horizon 
562716 
Rat IgG1 0.2 1:200 
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2.38 Statistical analysis 
Data analysis was performed in GraphPad Prim 6 or excel. Unpaired 2 tailed student t-test 
was performed. For multiple analysis, Bonferroni-Dunn post-test was performed to correct 
for multiple comparisons. Statistical analysis was performed on log10 transformed data. 
Fischer exact test was also performed on counted cells or percentage data obtained from 
flow cytometry analysis.  
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CHAPTER 3: MCMV AS A LIVE-ATTENUATED PERSISTENT VACCINE VECTOR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
3.1 Results 
3.1.1 Characterisation of recombinant OVA+ MCMV viruses 
To use ovalbumin as model antigen, recombinant OVA+ MCMV viruses were 
characterised. MCMV OVA viruses, express membrane bound (mOVA) or secreted 
(sOVA) forms of ovalbumin from the viral genome. In MCMV mOVA, transferrin receptor is 
fused to the C-terminus of OVA (unpublished). This directly targets OVA to the endocytic 
pathway for efficient processing and presentation as OVA323-339 peptide to CD4+ T cells 
(160). The sOVA virus has an intact signal sequence. OVA is expressed as a soluble 
cytoplasmic protein and secreted from infected cells (160). The HCMV IE promoter drives 
OVA expression in both viruses. In vivo, MCMV mOVA or sOVA is expected to prime 
CD4+ and CD8+ T cells via MHC II epitope OVA323-339 and MHC I epitope OVA257-264 
respectively. 
3.1.2 In vitro characterisation of MCMV recombinant OVA viruses 
To confirm the presence of ovalbumin in MCMV OVA viruses, viral DNA was extracted 
from infected NIH-3T3 cells and the OVA sequence amplified using two sets of primers 
(OVA 1 and OVA 2, 900 bps) or (OVA 2 and OVA 3, 430 bps) by PCR (Table 5). Bands of 
approximately 900 and 430 bps were detected in mOVA and sOVA respectively (Fig. 
3.1a). WT was negative for either OVA bands, confirming primer specificity.  
To determine whether ovalbumin was expressed, NIH-3T3 cells were infected with MCMV 
mOVA or sOVA at MOI 1 for 48 hrs or left uninfected. Cell culture (secreted) and cell 
lysate (cytoplasmic) fractions were then denatured (95oC for 5 minutes) and resolved on a 
10-12.5% SDS-PAGE gel, transferred to methanol activated PVDF membrane and blotted 
for OVA. A single band of 43 KDa, consistent with the size of OVA was detected in the cell 
culture fraction derived from sOVA- infected cells, while mOVA was negative (Fig. 3.1b). 
Both cell lysate fractions stained positive for OVA (Fig. 3.1b) similar to purified OVA as 
positive control. MCMV mOVA had an additional slower migrating band consistent with a 
glycosylated form of OVA (indicated by the asterisk). To confirm OVA expression, MEFs 
were infected at MOI 2 with MCMV mOVA or sOVA or left uninfected. The cells were then 
fixed, permeablised and stained for OVA or MCMV lytic antigens by indirect 
immunofluorescence. In mOVA and sOVA infected MEFs, infected cells stained positive 
for lytic antigens and expressed ovalbumin (Fig. 3.1c).  
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Fig. 3. 1. In vitro characterisation of recombinant MCMV ovalbumin viruses.  
a) Viral DNA extracted from infected 3T3 cells was amplified for OVA using two sets of 
primers and the products ran on a 1% agarose gel. Bands of 0.9 Kb and 0.43 Kb were 
detected. b) 1x106 3T3 cells were left uninfected or infected (MOI 1, 18 hrs) with MCMV 
OVA expressing viruses in 24 well plates. Cell lysate and culture media supernatant were 
diluted in 3X Laemmli buffer and resolved by SDS-PAGE and were analysed by 
immunoblotting with polyclonal rabbit anti-OVA. A band of 43 KDa was detected. c) MEFs 
infected at MOI 2 overnight were fixed and stained for OVA and lytic antigens. Cell nuclei 
was stained with DAPI. All images were captured at X 63 magnification. Data are 
representative of 3 independent experiments.  
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To determine whether MCMV OVA+ infected cells would present OVA323-339 peptide to 
stimulate OVA323-339-specific CD4+ T cell hybridomas in vitro, MHC class II+ RAW-C2TA 
and BALB/c-3T3-C2TA cells were used as antigen presenting cells. Since OVA323-339-
specific CD4+ T cell hybridomas secrete IL-2 following engagement with OVA323-339 (160), 
IL-2 levels in co-cultures were used as a marker of T cell stimulation. BALB/c-3T3-C2TA 
cells were left uninfected or infected at MOI 0.3 with either OVA+ MCMVs or WT MCMV in 
the presence of CD4+ T cell hybridomas. After 24 hrs, IL-2 in culture medium was 
analysed by ELISA. CD4+ T cells in MCMV mOVA infected cells secreted more IL-2 than 
in sOVA relative to uninfected cells incubated in the presence of 1 µM OVA323-339 peptide 
(Fig. 3.2a). No IL-2 secretion was observed in uninfected or WT infected cells (Fig. 3.2a). 
The experiment was repeated using RAW-C2TA cells. MCMV mOVA again stimulated 
CD4+ T cells to secrete high levels of IL-2 compared to MCMV sOVA relative to uninfected 
cells incubated in the presence of 1 µM OVA323-339 peptide (Fig. 3.2b). This suggests that 
MCMV mOVA stimulates CD4+ T cells better than sOVA in vitro.  
 
Fig. 3. 2. MCMV OVA viruses induce IL-2 secretion.  
a) 3x104 BALB/c-3T3-C2TA cells were either left uninfected or infected (MOI 0.3, 24 hrs) 
with WT or MCMV OVA in the presence of 3x104 OVA323-339 peptide CD4+ T cell 
hybridomas. 24 hrs later, supernatants were assayed for IL-2 secretion using ELISA. b) 
3x104 RAW-C2TA cells were either left uninfected or infected (MOI 1, 96 hrs) with WT or 
MCMV OVA. 3x104 OVA323-339 peptide CD4 T cell hybridomas were then added and IL-2 
was assayed using ELISA after 24 hrs. Error bars show ± SEM from the mean of duplicate 
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cultures from 3 independent experiments. Dotted line shows limit of detection relative to 
uninfected cells. Difference in IL-2 was determined using unpaired 2-tailed t-test. 1 µM was 
used for comparison. (* p>0.05; ** p<0.01; *** p<0.001; **** p<0.0001). Dotted line shows 
limit of IL-2 detection and error bars show ± SEM (n=2-4 per group). 
3.1.3 In vivo replication kinetics of recombinant MCMV OVA virus 
Live attenuated vaccines are required to be latency deficient but should be immunogenic 
for the host to mount an immune response (143). 6-8 weeks old C57BL/6 mice were 
anesthetized and infected via the i.n route with 3x104 plaque forming units per mouse 
(p.f.u/mouse) of WT, MCMV mOVA or MCMV sOVA. Four days post infection, replication 
in the lungs and salivary glands was determined by plaque assay. Infectious virus was 
detected in the lungs of WT (mean titer 3.2) and MCMV sOVA (mean titer 2.9) infected 
mice although the latter was modestly lower (Fig. 3.3, p<0.05). In contrast, MCMV mOVA 
was severely attenuated (mean titer 1.7, p<0.001). At this early time point, no virus was 
found in the salivary glands of mice infected with either WT, MCMV mOVA or sOVA (Fig. 
3.3). Eight days post infection, virus was detected in the salivary glands and lungs of WT 
infected mice by plaque assay, but not in sOVA or mOVA infected samples (Fig. 3.3). The 
results show that, MCMV mOVA and sOVA caused lytic replication at site of inoculation 
but failed to spread to the salivary glands. This provided an excellent in vivo model for a 
live attenuated vaccine using ovalbumin as model antigen. Accordingly, the effectiveness 
of MCMV sOVA as a live attenuated vaccine against a challenge with recombinant MHV-
68 was tested in preliminary experiments.  
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Fig. 3. 3. MCMV OVA viruses are defective in SG colonisation.  
C57BL/6 mice were infected i.n under anaesthesia with 105/p.f.u WT, MCMV mOVA or 
MCMV sOVA in 30 µL DMEM. After 4 and 8 days post infection, virus replication in the 
lungs and salivary glands were determined by plaque assay on MEFs. Each symbol 
represents titres from individual mice. Difference in mean was determined using unpaired 
2 tailed t-test with Bonferroni-Dunn correction for multiple comparison with WT as control. 
ns ‘not significant’ (p>0.05). Dotted line shows limit of detection and error bars show ± 
SEM (n=3 per group).  
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3.2 MCMV sOVA as a model live attenuated vaccine vector to secreted ovalbumin 
3.2.1 Does MCMV sOVA protect against MHV-68 M3 sOVA lytic infection? 
The aim of this experiment was to determine whether vaccinating mice with MCMV sOVA 
would protect against a subsequent challenge with MHV-68 M3 sOVA. Recombinant MHV-
68 M3 sOVA expresses ovalbumin under the M3 promoter, a highly expressed lytic protein 
(160). 6-8 weeks old BALB/c mice were vaccinated with 105 p.f.u/mouse of MCMV mOVA 
or MCMV sOVA via the i.p route or left unvaccinated as control. To confirm infection, 
antibody to MCMV and OVA was determined by ELISA 14 and 21 days post i.p injection.  
3.2.2 Antibody response to MCMV and ovalbumin 
IgM and IgG2a responses to MCMV were detected in MCMV mOVA and MCMV sOVA 
infected mice but not in unvaccinated mice at both 14 and 21 days post vaccination (Fig. 
3.4a, c). MCMV sOVA infected mice had slightly lower IgM and IgG2a levels at day 21 to 
MCMV mOVA (Fig. 3.4a, b, p<0.001). Interestingly, MCMV mOVA but not sOVA-infected 
mice showed a rising OVA-specific IgG2a response (Fig. 3.4e, p<0.001). There was no 
IgG1 response to either MCMV or OVA at either day 14 or 21 post vaccination (Fig. 3.4c, 
d).  
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Fig. 3. 4. MCMV and OVA-specific primary antibody response following i.p infection.  
6-8 week old BALB/c mice were vaccinated via the i.p route with 105 p.f.u/100 µL of MCMV 
mOVA or sOVA or left unvaccinated. 14 and 21 days post vaccination, antibody levels to 
MCMV (a, b and c) and OVA (d and e) were determined by ELISA. For virus (a-c) and 
OVA (d-e) specific IgM, IgG1 and IgG. Absorbance was read at 405 nm. Error bars show ± 
SEM (n=2 per group) in duplicates. Data was analysed using unpaired student 2 tailed t-
test (ns, p>0.05; * p<0.05; ** p<0.01; *** p<0.001, **** p<0.0001). MCMV mOVA was used 
to compare differences.  
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3.2.3 Response to MHV-68 M3 sOVA in MCMV sOVA and mOVA vaccinated mice 
Thirty-three days post vaccination, BALB/c mice were challenged with MHV-68 sOVA via 
i.n infection with or without anaesthesia to model lower and upper respiratory tract 
infection. Six days later, blood, noses and lungs were harvested. Aged-matched 
unvaccinated mice had low IgM and IgG to MHV-68 and OVA consistent with a primary 
infection while MCMV mOVA and sOVA vaccinated mice had elevated levels of IgG but 
not IgM to OVA (Fig. 3.5a-b). There was no significant difference in virus titer between 
vaccinated and unvaccinated controls (Fig. 3.5c, p>0.05). Taken together, this showed 
that neither MCMV mOVA nor sOVA vaccination conferred protection or reduced lytic 
MHV-68 M3 sOVA infection.  
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Fig. 3. 5. Immune response to MHV-68 sOVA following intranasal infection.  
a, b) Adult BALB/c vaccinated with MCMV mOVA, MCMV sOVA or left unvaccinated were 
challenged with 104-105 p.f.u/mouse. 6 days post challenge MHV-68 and OVA-specific 
antibody responses in the serum were measured by ELISA. Absorbance was read at 405 
nm. The error bars show ± SEM (n=3 per group). Data was analysed using unpaired 
student 2 tailed t-test (ns, p>0.05; * p<0.05; ** p<0.01; *** p<0.001). Unvaccinated mice 
were used for comparison. c) Lungs and noses were tittered on BHK cells. Each data point 
represents virus titer per mouse error bars show ± SEM from the mean (n=3 per group). 
Difference in mean between unvaccinated and vaccinated groups was determined by 
multiple unpaired 2 tailed t-test using Bonferroni Dunn correction for multiple comparisons. 
ns ‘not significant’, p > 0.05. Dotted line shows limit of detection. 
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3.2.4 Does adoptive transfer of OVA323-339 transgenic CD4+ T cells protect BALB/c mice 
against MHV-68 infection? 
To understand how CD4+ T cells control lytic infection in the nose or lung, OVA323-339-
specific CD4+ T cells were isolated from lymph nodes and spleens of naïve DO11.10 
transgenic mice and enriched for CD4+ T cells using magnetic beads. 2x106 OVA323-339-
specific DO11.10 CD4+ T cells were then transferred to naïve BALB/c mice (“treated”) via 
intravenous injection via the lateral tail vein. These mice were then primed with MCMV 
sOVA. Control mice that did not receive DO11.10 OVA323-339-specific CD4+ T cells 
(“untreated”), were either primed with MCMV sOVA or MCMV WT. Seventeen days post 
priming, splenocytes from treated and untreated mice were stained for CD4 and KJ1-26 to 
detect DO11.10 OVA323-339-specific CD4+ T cells and activation markers CD62L and CD69 
to determine activation status of these cells. Splenocytes from treated and not untreated 
mice primed with MCMV sOVA stained positive for KJ1-26 (Fig. 3.6- red circle). This 
confirmed adoptive transfer of naïve DO11.10 OVA323-339-specific CD4+ T cells worked. 
Surprisingly, the cells expressed CD62Lhi and CD69lo, a profile of naïve CD4+ T cells.  
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Fig. 3. 6. Presence of adoptively transferred DO11.10 CD4+ T cells in treated BALB/c 
mice.  
6-8 week old naïve BALB/c mice were injected i.v with 2 x 106 naïve DO11.10 OVA323-339-
specific CD4+ T cells or left untreated and infected via the i.p route with 105 p.f.u/mouse of 
MCMV sOVA and WT. After 17 days, splenocytes were stained for CD4+ T cells (Alexa 
Fluor 488 rat anti-mouse CD4 4.4), KJ1-26 CD4+ T cells (Alexa Fluor 647 mouse anti-
mouse DO11.10 Tcr), CD62L (PE rat ant-mouse CD62L) or CD69 (PE). KJ1-26+ CD4+ T 
cells were found in mice that received DO11.10 OVA323-339-specific CD4+ T cells shown in 
red.  
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To determine whether treated mice would protect against MHV-68 infection, the remaining 
treated and untreated groups were challenged via the i.n route with MHV-68 M3 mOVA. 
Seven days post infection, organs of interest were harvested, and virus titer determined by 
plaque assay. There was no difference in lytic virus between treated and untreated groups 
in either the nose or lung (Fig. 3.7b, p>0.05). Mediastinal lymph nodes and superficial 
cervical lymph nodes and spleen titers also showed no significant differences (Fig. 3.7c).  
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Fig. 3. 7. Absence of adoptively transferred DO11.10 CD4+ T cells in treated BALB/c.  
Remaining BALB/c mice in figure 3.6 were challenged with MHV-68 mOVA via the i.n 
route with 1x105 p.f.u/mouse without anaesthesia for nose infection and 3x104 p.f.u/mouse 
under anaesthesia for lung infection. a) Seven days post challenge, splenocytes were 
again stained for CD4+ T cells (Alexa 488 CD4 4.5), KJ126 CD4+ T cells (Alexa 647 
KJ126), CD62L (PE) or CD69 (PE) and analysed by flow cytometry. b) Virus titer in lungs 
and noses of day 7 infected mice was determined by plaque assay on BHK-21 cells. c) 
Infectious center assay was performed on SCLN, MLN and spleen homogenates on BHK-
21 cells. Each data point represents virus replication per mouse and error bars show 
±SEM (n=4 per group). Difference in mean was determined using multiple unpaired 2-
tailed t-test using Bonferroni Dunn correction for multiple comparisons. Significance was 
taken as p< 0.05, ns ‘not significant’, and p > 0.05. 
Flow cytometry analysis showed absence of CD4+KJ126+ cells in treated mice that had 
previously stained positive (Fig. 3.7a). This was also observed 11 days post challenge 
(Fig. 3.8b). At this time point, there was no difference in infectious virus in the SCLN, MLN 
or spleen between treated and untreated groups (Fig. 3.8c). This suggests that secreted 
OVA was not efficiently processed or presented to stimulate and expand DO11.10 OVA323-
339-specific CD4+ T cells. To exclude absence of MHC II epitope within the MCMV mOVA 
sequence, MCMV mOVA and sOVA viral DNA were amplified for OVA using primer set 
(OVA 2 and OVA 3). The 430 bp fragment (Fig. 3.1a) was gel purified and sequenced. 
Sequence results showed MHC I (SIINFEKL-red) and MHC II (ISQAVHAAHAEINEAGR-
green) epitope sequences were present in both MCMV mOVA and sOVA viral DNA (Fig. 
3.9).  
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Fig. 3. 8. MCMV sOVA priming does not stimulate OVA-specific DO11.10 CD4+ T 
cells.  
BALB/c mice challenged as in figure 3.7 were sacrificed after 11 days. a, b) splenocytes 
were stained for CD4+ T cells (Alexa 488 CD4 4.5), KJ126 CD4+ T cells (Alexa 647 
KJ126), CD62L (PE) or CD69 (PE) and analysed by flow cytometry. c) Infectious center 
assay was performed on SCLN, MLN and spleen homogenates on BHK-21 cells. Each 
data point represents virus titer per mouse (n=4 per group) and error bars show ±SEM. 
Difference in mean was determined using multiple unpaired 2-tailed t-test with Bonferroni 
Dunn correction for multiple comparisons. ns ‘not significant’ p > 0.05. 
 
 
Fig. 3. 9. MHC I and MHC II epitopes in MCMV mOVA and sOVA.  
MCMV mOVA and sOVA viral DNA extracted from infected 3T3 cells was amplified for 
OVA using primers spanning the MHC I and MHC II epitopes. The 430bp bands were 
excised, and sequenced. Red shows MHC I epitope and green MHC II.  
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3.3 MCMV mOVA, a model live attenuated vaccine vector to induce CD4+ T cell 
immunity. 
The failure of MCMV sOVA to expand adoptively transferred DO11.10 OVA323-339-specific 
CD4+ T cells in BALB/c mice, suggested that sOVA was perhaps not efficiently presented. 
To directly test a CD4+ T cell vaccine against MHV-68, MCMV mOVA was used. This virus 
stimulated OVA323-339-specific CD4+ T cell hybridomas in vitro (Fig. 3.2a, b). In vivo, it is 
expected to induce OVA323-339 CD4+ T cell responses as well as OVA257-264-specific CD8+ T 
cell responses. Thus, to study how CD4+ T cells control MHV-68 mOVA infection, C57BL/6 
and BLAB/c mice were vaccinated in parallel with MCMV WT or MCMV mOVA virus. 
C57BL/6 vaccination was to control for OVA-specific CD8+ T cell response as OVA priming 
stimulates robust OVA257-264 specific memory CD8+ T cells. Fifty-one days post priming, 
mice were tail bled to measure antibody response to OVA then challenged with MHV-68 
mOVA. MHV-68 mOVA has a transferrin receptor linked to the C-terminus of OVA that 
directs OVA to the endocytic pathway for efficient processing and presentation of OVA323-
339 peptide in infected myeloid cells or B cells. MHV-68 M3 promoter drives ovalbumin 
expression predominately during lytic infection (160).  
3.3.1 BALB/c vaccination restricts lytic mucosal infection but not lymphoproliferative 
disease 
Antibody response to OVA in MCMV mOVA and MCMV WT primed mice showed 
predominately IgG response to OVA in the former confirming ovalbumin vaccination status 
(Fig. 3.10a). Lytic replication of MHV-68 mOVA in the nose (N) and lung (L) of MCMV 
mOVA vaccinated mice was reduced compared to MCMV WT (Fig. 3.10b, p<0.001). 
Expansion of B cells in the lymph nodes (lymphoproliferation) was significantly enhanced 
particularly in the superficial lymph node (CLN) of MCMV mOVA vaccinated mice 
compared to WT (Fig. 3.10d, p<0.05). In the mediastinal lymph node (MLN) and the 
spleen (SP), where B cell expansion causes lymphoproliferation and splenomegaly was no 
different between MCMV mOVA and WT vaccinated mice respectively (Fig. 3.10d, 
p>0.05). Antibody confirmed MHV-68 and OVA-specific IgG response in MCMV mOVA 
and MCMV WT vaccinated mice (Fig. 3.10e-f). The latter had lower IgG to OVA and higher 
IgM to MHV-68 mOVA suggesting primary response compared to MCMV mOVA 
vaccinated group (Fig. 3. 10f). 
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Fig. 3. 10. MCMV mOVA vaccination primes OVA-specific CD4+ T cells.  
Adult BALB/c mice were vaccinated via i.p injection with 106 p.f.u/mouse with MCMV 
mOVA or WT virus. After 51 days, IgM and IgG antibody response to OVA was determined 
by ELISA. The error bars show ± SEM (n=5 per group). The mice in a were then 
challenged with MHV-68 mOVA via the i.n route with 1x105 p.f.u/mouse without 
anaesthesia for nose infection and 3x104 p.f.u/mouse under anaesthesia for lung infection. 
b) Plaque assay was performed on noses and lungs after 7 days and infectious center 
assay (c, d) on SCLN, MLN and spleen after 7 and 13 days post challenge on permissive 
BHK-21 cells. Each data point represents virus titer per mouse (n=5 per group) and error 
bars show ±SEM. Mean difference was determined using multiple unpaired 2-tailed t-test 
using Bonferroni Dunn correction for multiple comparisons. ns ‘not significant’, p > 0.05. e, 
f) MHV-68 and OVA-specific antibody responses at day 13 post challenge was measured 
by ELISA. The error bars show ± SEM (n=5 per group). Data are representative of 2 
independent experiments. 
3.3.2 How do CD4+ T cells restrict MHV-68 mOVA lytic infection in BALB/c? 
3.3.2.1 IFN-γ response to OVA 
IFN-γ has been shown to be the major cytokine secreted by CD4+ T cells in response to 
MHV-68 infection (121). To measure IFN-γ response to OVA, BALB/c mice vaccinated 
with MCMV mOVA were challenged with MHV-68 mOVA. Seven days p.i, mice were 
depleted or not of CD4+ and/ or CD8+ T cell lymphocytes. Naïve target splenocytes were 
then infected with MHV-68 mOVA or incubated with 5 µM OVA323-339 or 10 µM OVA257-264 
peptide or left untreated as control. Effector cells from undepleted, CD4+ T cell depleted, 
CD8+ T cell depleted, or CD4+ and CD8+ depleted mice were then co-cultured with the 
treated and untreated feeder cells and IFN-γ secretion measured. Only effector cells from 
undepleted and CD8 depleted mice secreted IFN-γ upon re-stimulation with MHV-68 
mOVA and OVA323-339 peptide (Fig. 3.11). IFN-γ to MHV-68 mOVA was highly variable 
between mice. The IFN-γ response was specific, since the OVA257-264 peptide provided 
little stimulation to undepleted or CD4+ T cell depleted effector cells (Fig. 3.11). Taken 
together, these results suggest that IFN-γ response to OVA or MHV-68 in BALB/c mice 
was predominately CD4+ T cell dependent. Differences between mice in the level of MHV-
68 mOVA infection could account for the variability of the IFN-γ response.  
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Fig. 3. 11. Frequency of IFN-γ producing T lymphocytes.  
Adult BALB/c mice vaccinated by i.p injection with MCMV mOVA as in fig. 3.10 were 
depleted of T lymphocytes or left undepleted and then challenged via the i.n route with 
MHV-68 mOVA. Seven days post challenge, the frequency of IFN-γ producing T cells in 
splenocytes of undepleted, CD4+ T cell depleted, CD8+ T cell depleted and CD4+ and 
CD8+ depleted mice upon stimulation with MHV-68 mOVA, OVA323-339 or OVA257-264 or 
uninfected target cells was determined by ELISPOT. Each symbol represents the number 
of spots per 1x105 effector cells from which the mean number of spots of uninfected target 
cells were subtracted. The error bars show difference in spots between mice in 
quadruplicates (n=2 per group). Data was analysed using multiple t-test (ns, p>0.05; * 
p<0.05; *** p<0.001). Undepleted (Cont) IFN-γ spots was used to compare response 
between CD4+, CD8+ and CD4/8+ depleted effector T lymphocytes.  
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3.3.2.2 Adoptive transfer of CD4+ T cell OVA323-339 
To better characterise the contribution of CD4+ T cells in limiting lytic infection, DO11.10 
OVA323-339-specific CD4+ T cells were adoptively transferred to naïve BALB/c mice as 
previously described. Subsequently, mice were primed with MCMV mOVA by i.p injection. 
After 14 days, the mice were challenged with MHV-68 mOVA or MHV-68 WT. Seven days 
post challenge organs of interest were harvested. First, splenocytes were processed and 
stained KJI-26 as before to determine whether DO11.10 OVA323-339-sepcific CD4+ T cells 
expanded. These cells were undetectable by flow cytometry (results not shown). Infectious 
virus was then determined by plaque assay. MHV-68 mOVA lung and nose titers were 
significantly reduced compared to MHV-68 WT (Fig. 3.12a). Lytic antigen staining showed 
infection in MHV-68 mOVA infected lungs was localised compared to WT infected lung 
where infection was dispersed throughout the tissue (Fig. 3.12b-c). Infected cells in both 
groups expressed podoplanin and were negative for CD68 suggesting type 1 alveolar 
epithelial cells. CD4+ T cells are seen proximal to infected cells (Fig. 3.12c). 
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Fig. 3. 12. OVA primed CD4+ and CD8+ T cells control lytic infection.  
Adult BALB/c mice were adoptively transferred naïve 2x106 OVA323-339-specific CD4+ T 
cells from DO11.10 transgenic mice by i.v injection and primed with 1x105 p.f.u/200µL 
MCMV mOVA via the i.p route. After 14 days, the mice were then infected via the i.n route 
with MHV-68 WT or MHV-68 mOVA. a) Virus titer in the lungs was determined by plaque 
assay 7 days post infection. Each data point represents virus titer per mouse (n=3 per 
group) and error bars show ± SEM. Difference in mean was determined using multiple 
unpaired 2 tailed t-test using Bonferroni Dunn correction for multiple comparisons. ns ‘not 
significant’, p > 0.05. b, c) MHV-68 WT and MHV-68 mOVA lungs were stained for MHV-
68 lytic antigens and for podoplanin, CD68 and CD4. Arrows show podoplanin and CD4+ T 
cells. CD4+ T cells are seen proximal to infected cells. All images were taken at X63 
magnification.  
3.3.3 DO11.10 transgenic mice are heterogeneous  
To understand why OVA323-339-specific KJ1-26+CD4+ T cells were undetectable, DO11.10 
transgenic mice were genotyped. The mice were found to be heterogeneous for the 
clonotypic marker KJ1-26 that recognises OVA323-339 Tcr (Fig. 3.13a). As expected BALB/c 
splenocytes were negative for KJ1-26 (Fig. 3.13b). This implies the reduction in lytic 
replication and restriction of infected cells by CD4+ T cells observed in MHV-68 mOVA 
infected mice is the result of the action of endogenously primed CD4+ T cell clones. 
Previous reports have shown that, BALB/c (H-2d) mice primed with OVA generated distinct 
clones of CD4+ T cells in response OVA323-339 peptide stimulation compared to DO11.10 
transgenic mice. It was then postulated that in BALB/c mice, OVA323-339 could be 
presented in three different forms, potentially generating three distinct T cell epitopes 
(167). 
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Fig. 3. 13. OVA323-339-specific DO11.10 transgenic mice are heterogeneous.  
Splenocytes from DO11.10 transgenic mice and BALB/c were harvested, homogenised 
and single cell suspensions stained. DO11.10 splenocytes were stained with rat anti-
mouse CD19 BV421, CD4+ T cells using rat anti-mouse CD4 clone RM4-4 fluorescein or 
double stained with CD4+ and KJ1-26 647. CD19 was used to gate out B cells. DO11.10 
transgenic mice (a) had KJ1-26 high and low cells while BALB/c mice (b) stained negative 
for KJ1-26 cells.    
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3.3.4 C57BL/6 vaccination confers protection against mucosal infection and short-term 
lymphoproliferative disease   
Ovalbumin priming of C57BL/6 mice stimulates memory OVA257-264 specific CD8+ T cells. 
Thus, to control for CD8+ T cell response and determine how CD4+ T cells reduced MHV-
68 mOVA infection in BALB/c mice, MCMV mOVA and MCMV WT primed C57BL/6 were 
tail bled fifty-one days post priming and challenged with MHV-68 mOVA. Antibody 
response to OVA in MCMV mOVA and MCMV WT primed mice showed predominately 
IgG response to OVA in the former confirming ovalbumin vaccination (Fig. 3.14a). During 
lytic infection, MHV-68 mOVA nose and lung infection was controlled in MCMV mOVA 
vaccinated mice compared to MCMV WT (Fig. 3.14b). Lymphoproliferation and 
splenomegaly which occurs 13 to 18 days post infection was controlled at day 13 in MCMV 
mOVA vaccinated mice but not MCMV WT (Fig. 3.14d). During persist infection which 
occurs from 21 days, MCMV mOVA vaccination failed to control long term persistent 
infection of B cells in the lymph node and spleen (Fig. 3.14e) despite elevated levels of 
IgG to OVA (Fig. 3.14g-h). 
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Fig. 3. 14. MCMV mOVA primes OVA-specific CD8+ T cells.  
Adult C57BL/6 mice were vaccinated via the i.p route with 106 p.f.u/mouse with MCMV 
mOVA or WT. After 51 days, IgM and IgG response to OVA were determined by ELISA. a) 
Absorbance was read at 405 nm. The error bars show ± SEM (n=5 per group). The mice in 
a were then challenged with MHV-68 mOVA via the i.n route with 1x105 p.f.u/mouse 
without anaesthesia for nose infection and 3x104 p.f.u/mouse under anaesthesia for lung 
infection. b) 7 days post challenge, virus titer in the nose and lung was determined by 
plaque assay and by infectious centre assay on SCLN, MLN and spleen after 7 (c), 13 (d) 
and 22 (e) days. Each data point represents virus titer per mouse (n=5 per group) and 
error bars ±SEM of the mean. Difference in mean was determined using multiple unpaired 
2 tailed test using Bonferroni Dunn correction for multiple comparisons. ns ‘not significant’, 
p > 0.05. f, g and h) MHV-68 and OVA-specific antibody response in the serum at day 13 
and 21 post challenge was measured by ELISA. The error bars show ± SEM (n=5 per 
group). Data are representative of 2 independent experiments. 
3.3.5 To understand T cell mediated immune control of MHV-68 mOVA using F1 mice 
The vaccination response to MHV-68 mOVA in BALB/c and C57BL/6 mice showed neither 
CD4+ nor CD8+ T cells alone were effective at controlling infection. To understand how 
CD4+ and CD8+ T cells coordinate the control MHV-68 infection, BALB/c mice were 
crossed with C57BL/6 mice. Adult F1 offspring were then vaccinated with MCMV mOVA or 
MCMV WT. One-month post vaccination, the mice were tail bled to measure antibody to 
MCMV and OVA and the challenged via the i.n route with MHV-68 mOVA. Antibody to 
MCMV was predominately IgG in MCMV WT and MCMV mOVA vaccinated mice 
suggesting persistent infection meanwhile while antibody to OVA was predominately IgG 
in the former and not the latter, confirming ovalbumin vaccination status (Fig. 3.15a). After 
7 days post challenge, lytic infection in the nose and lung of MCMV mOVA vaccinated 
mice was reduced compared to MCMV WT (Fig. 3.15b, p<0.01). To understand how lytic 
infection was reduced, MCMV mOVA vaccinated F1 mice were depleted of T cell 
lymphocytes or not and challenged with MHV-68 mOVA. Seven days post challenge, lytic 
infection in the nose and lung of undepleted, CD4+ and CD4 and/ or CD8+ depleted mice 
was determined by plaque assay. T lymphocyte depletion was confirmed by flow cytometry 
(Fig. 3.15d). The results show that neither CD4+ nor CD8+ T cells alone were sufficient to 
control infection at the lungs and the nose (Fig. 3.15c). However, depleting both CD4+ and 
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CD8+ T cells increased virus infection (Fig. 3.15c, p<0.01). This suggests that primed 
CD4+ and CD8+ T cells are both necessary to restrict lytic replication. 
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Fig. 3. 15. Lytically primed OVA-specific CD4+ T cells restrict lytic infection.  
a) Adult F1 mice were vaccinated i.p with 106 p.f.u/mouse with MCMV mOVA or WT. After 
31 days, IgM and IgG antibody response to MCMV and OVA were determined by ELISA. 
Error bars show ± SEM (n=5 per group). b) The mice in a were then challenged with MHV-
68 mOVA via the i.n route with 1x105 p.f.u/mouse without anaesthesia for nose infection 
and 3x104 p.f.u/mouse under anaesthesia for lung infection. Plaque assay was performed 
on noses and lungs after 7 days. d) T cell lymphocytes were depleted in MCMV mOVA 
vaccinated mice in a at 96 hrs, 48 hrs and at time of infection with MHV-68 mOVA via i.n 
with 3x104-1x105 p.f.u/mouse and every 48 hrs until termination at day 7. Virus titer was 
then determined by plaque assay in c. T lymphocyte depletion in d was determined by 
staining lymphocytes from SCLN, MLN and spleen for CD4+ and CD8+ T cells and CD19 to 
gate out B cells. Each data point in b and c represents virus replication per mouse (n=5-6 
per group) and error bars show ± SEM. Data was determined using multiple t-test with 
Bonferroni Dunn correction for multiple comparisons. ns ‘not significant’, p > 0.05.  
3.3.6 F1 mice fail to control latent infection 
To determine whether CD4+ T cells would rescue persistent infection observed in C75BL/6 
mice, F1 mice were vaccinated as above, and infection was monitored over a course of 
100 days. Seven days post infection, virus was detected in the MLN of MCMV WT but 
MCMV mOVA vaccinated mice (Fig. 3.16a). At day 13, a period of acute 
lymphoproliferation, lymph node virus titers measured by infectious centre assay in MCMV 
mOVA vaccinated mice was reduced while in the spleen it was controlled compared to 
MCMV WT (Fig. 3.16b). At day 18 and day 22 post infection, a period of extensive B cell 
expansion (splenomegaly), the level of virus in the lymph node and spleen was 
comparable between MCMV mOVA and MCMV WT vaccinated mice (Fig. 3.16c-d, 
p>0.05). This was also observed by qPCR at day 30, day 72 and day 100 in the spleen 
(Fig. 3.16e-g).  
110 
 
 
Fig. 3. 16. Lytically primed OVA-specific CD4+ T cells restrict acute but not long-term 
infection 
Adult F1 mice vaccinated and challenged as in Fig. 3.15 were monitored over a course of 
100 days. Infectious virus in a, b, c and d was determined by infectious center assay. Viral 
load in e, f and g was determined by QPCR. Each data point represents the ratio of K3 
viral copies normalised to mtitin cellular copies per mouse tissue (n=5-6 per group). Error 
bars show ± SEM. Multiple unpaired 2 tailed t-test with Bonferroni Dunn post-test 
correction was used to analyse difference in means. ns ‘not significant’, p > 0.05. 
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Viral DNA was also detected in the bone marrow of mice at day 72 and day 100 (Fig. 
3.16f-g) and in the nose and lung at the latter time point. There was no difference between 
MCMV mOVA and WT groups (Fig. 3.16d-g, p>0.05). This suggests that MHV-68 evades 
host immune response and recirculates in latently infected cells between peripheral and 
non-periphery sites to establish persistent infection in the host. Antibody to OVA was 
abundantly produced throughout infection but was ineffective at neutralising MHV-68 
mOVA (Fig. 3.17a). Thus, cytotoxic T cell lymphocyte response to infected cells that 
present OVA is probably more effective, than neutralisation in C57BL/6 or F1 mice.  
 
Fig. 3. 17. F1 mice retain elevated levels of OVA-specific antibody IgG. 
Adult F1 mice vaccinated and challenged as in Fig. 3.16 were analysed for IgM and IgG 
antibody response to MHV-68 and OVA after 13, 30 and 100 days post infection by ELISA. 
Absorbance was read at 405 nm. Error bars show ± SEM (n=5 per group). 
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3.3.7 Primed lytic CD4+ T cells restrict splenomegaly in MHV-68 IiOVA infected mice 
CD4+ T cells have been shown to be important during latency. To determine whether 
primed CD4+ T cells can limit B cell proliferation in the spleen (splenomegaly), BALB/c 
mice were vaccinated with MCMV mOVA and MCMV WT. The mice were then challenged 
with MHV-68 IiOVA. MHV-68 IiOVA expresses OVA323-339 in tandem with IRES 
downstream of ORF73 to translate the epitope when the promoter is active (160). During 
latency, OVA323-339 is then presented in the context of 1-Ad/1-Ab by infected antigen 
presenting cells (160).  During lytic infection, there was no difference in virus titer in the 
nose, lungs or lymphoid organs between MCMV mOVA and MCMV WT vaccinated mice 
(Fig. 3.18a). The presence of relatively high titer virus in the lymph nodes and spleen at 
day 7 (Fig. 3.18b) suggests virus replication was unrestricted at mucosal sites. By day 13, 
a period of lymphoproliferation and onset of splenomegaly, MCMV mOVA vaccinated mice 
had reduced infectious virus in the spleen suggesting reduced splenomegaly compared to 
MCMV WT (Fig. 3.18c). In the lymph nodes, there was no difference in virus titer between 
MCMV mOVA and WT mice (Fig. 3.18c) suggesting lymphoproliferation was comparable. 
Thus, the results suggest that, lytically primed CD4+ T cells can reduce splenomegaly 
when the OVA323-339 epitope is expressed during latency.  
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Fig. 3. 18. Lytically primed OVA-specific CD4+ T cells restrict splenomegaly. 
Adult BALB/c mice were vaccinated via the i.p route with 106 p.f.u/mouse with MCMV 
mOVA or WT. After 51 days, the mice were challenged with MHV-68 IiOVA via the i.n 
route with 1x105 p.f.u/mouse without anaesthesia for nose infection and 3x104 p.f.u/mouse 
under anaesthesia for lung infection. Virus titer in the nose and lung in a was determined 
by plaque assay after 7 days and infectious center assay on SCLN, MLN and spleen in b 
and c after 7 and 13 days post challenge. Each data point represents virus titer per mouse 
(n=5 per group) and error bars show SEM from the mean. Difference in mean was 
determined using multiple unpaired 2 tailed t-test using Bonferroni Dunn post-test. ns ‘not 
significant’, p > 0.05. 
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3.4 Can pre-existing antibody restrict mucosal infection? 
To address whether antibody was required to control MHV-68 infection, BALB/c were 
vaccinated with vaccinia virus expressing MHV-68 glycoprotein gH/gL and an irrelevant 
non MHV-68 glycoprotein for a month. To confirm antibody response to gH/gL, sera from 
vac control and gH/gL vaccinated BALB/c was assayed on CHO expressing gH/gL (CHO 
gH/gL) or CHO cells and analysed by flow cytometry.  
3.4.1 gH/gL antibody in BALB/c mice controls MHV-68 infection 
Flow cytometry results showed BALB/c vaccinated with vac gH/gL, shown as dotted line, 
bound to gH/gL expressing CHO cells, while vac control did not bind to gH/gL expressing 
CHO cells (Fig. 3.19b). Vac gH/gL vaccination restricted MHV-68 lytic infection in the nose 
but not the lung (Fig. 3.19c). Lymphoproliferation in the lymph nodes and splenomegaly in 
the spleens was also controlled in vac gH/gL vaccinated mice compared to vac control 
(Fig. 3.19d-e, p<0.001) 
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Fig. 3. 19. Pre-existing gH/gL controls acute lytic infection and B cell 
lymphoproliferation. 
a, b) Adult BALB/c mice were vaccinated i.p with 106 p.f.u/mouse recombinant vaccinia 
virus expressing gH/gL or irrelevant protein. After a month, the mice were tail bled and 
antibody to gH/gL was determined by immunofluorescence using CHO cells expressing 
gH/gL or irrelevant protein. Bound antibody was detected using goat anti-mouse Alexa 
Fluor 488 IgG (H+L) and analysed by flow cytometry. c-e) The mice were then challenged 
i.n with MHV-68 via the i.n route with 1x105 p.f.u/mouse without anaesthesia for nose 
infection and 3x104 p.f.u/mouse under anaesthesia for lung infection. Virus titer in the nose 
and lung in c was determined by plaque assay and reactivating virus in d and e was 
determined by infectious center assay. Each data point represents reactivating virus per 
mouse organ (n=5-6 per group) and error bars show ± SEM. Multiple unpaired 2 tailed t-
test with Bonferroni Dunn correction post-test was used to analyse difference in means. ns 
‘not significant’, p > 0.05. 
3.4.2 gH/gL antibody in C57BL/6 mice fails to control MHV-68 infection 
To determine whether antibody was also required to control MHV-68 infection in C57BL/6 
mice, the mice were vaccinated with vaccinia virus expressing MHV-68 glycoprotein gH/gL 
and an irrelevant non MHV-68 glycoprotein for a month. To confirm antibody response to 
gH/gL, sera was analysed on CHO cells expressing gH/gL or not by flow cytometry. Vac 
gH/gL vaccinated C57BL/6 sera bound gH/gL expressing CHO cells while vac control sera 
did not (fig. 3.20b). However, there was considerable variability between mice. The mice 
were then infected i.n with MHV-68 WT.  After seven days post infection, vac gH/gL 
vaccinated mice failed to restrict MHV-68 nose and lung infection (fig. 3.20c, p>0.05). 
Lymphoproliferation in the lymph node of vac gH/gL vaccinated mice was controlled by 
day 13 (fig. 3.20d-e). Splenomegaly in the spleen of vac gH/gL vaccinated mice was 
increased compared to vac control at day 7 and reduced by day 13 (fig. 3.20d-e). In 
summary, pre-existing antibody to gH/gL is more effective in BALB/c mice than in C57BL/6 
mice. 
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Fig. 3. 20. Pre-existing gH/gL fails to control lytic infection and B cell 
lymphoproliferation. 
a, b) Adult C57BL/6 mice were vaccinated i.p with 106 p.f.u/mouse recombinant vaccinia 
virus expressing MHV-68 glycoproteins gH/gL or an irrelevant protein. After a month, the 
mice were tail bled and antibody to gH/gL was determined by immunofluorescence using 
CHO cells expressing gH/gL or irrelevant protein. Bound antibody was then detected using 
goat anti-mouse Alexa Fluor 488 IgG (H+L) and analysed by BD Accurri C6 flow 
cytometer. c-e) The mice were then challenged i.n with MHV-68 via the i.n route with 
1x105 p.f.u/mouse without anaesthesia for nose infection and 3x104 p.f.u/mouse under 
anaesthesia for lung infection. Virus titer in the nose and lung in c was determined by 
plaque assay and reactivating virus in d and e was determined by infectious center assay. 
Each data point represents reactivating virus per mouse organ (n=5-6 per group) and error 
bars show ± SEM. Data analysis was performed using multiple unpaired 2 tailed t-test with 
Bonferroni Dunn post-test for multiple comparisons. ns ‘not significant’, p > 0.05. 
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3.5 Discussion 
Vaccination with MCMV mOVA showed OVA-specific CD4+ T cells reduced lytic infection 
in the nose and lungs of BALB/c mice but failed to control lymphoproliferation or 
splenomegaly during latency. Lytic infection was restricted by IFN-γ through OVA-specific 
T lymphocytes responding to the OVA323-339 peptide, and not OVA257-264, a CD8+ T cell 
epitope. This is consistent with the described role of CD4+ T cells in controlling MHV-68 
infection in the lung via IFN-γ in B-cell deficient mice (121, 168). This was confirmed in 
DO11.10 transgenic mice in which OVA323-339 specific CD4+ T cells were found to restrict 
lytic infection and reduced latency but failed to prevent latency when MHV-68 mOVA was 
given i.p (159). These results show that, CD4+ T cells play a role early during infection but 
are limited as infection progresses. Moreover, CD4+ T cells are also known to drive 
proliferation of latently infected B cells in lymph nodes and spleen (116, 129, 169). MCMV 
mOVA primed mice had elevated virus titers compared to control mice suggesting CD4+ T 
cell help. Whether primed OVA323-339 CD4+ T cells are the same subset of memory CD4+ T 
cells driving B cell proliferation and splenomegaly remains to be determined.  
The effective control of MHV-68 mOVA lytic and acute lymphoproliferation in C57BL/6 
replicated previous observations using OT1/B6 and OT1/RAG systems (170) despite 
MHV-68 interference with MHC I antigen presentation (171, 172). This showed the 
SIINFEKL epitope in MCMV mOVA was presented to and recognised by cytotoxic CD8+ T 
cells inducing a robust cytotoxic response. This robust response failed to prevent 
persistent infection consistent with previous results. Interestingly, OT-1 specific CD8+ T 
cells was found to decrease in number 22 days post infection, a time which coincided with 
re-emergence of virus replication (170). This decline in CD8+ T cells was attributed to lack 
of CD4+ T cell help but could also reflect the role of CD4+ T cells long term (122, 170). Re-
emergence of infectious virus was observed 22 days after challenge in our vaccine model 
despite the presence of CD4+ T cells in primed C57BL/6 immunocompetent mouse. Why 
this occurs is unknown. It is possible that MHV-68 evades primed CD4+ T cells by 
transcriptional regulation of viral antigen expression in latently infected B cells. This was 
somewhat the case when primed MCMV mOVA mice were challenged with MHV-68 IiOVA 
that expressed OVA323-339 peptide in tandem with ORF73. Lytically primed CD4+ T cells 
reduced splenomegaly. This showed that OFR73 could be modulating expression of viral 
antigens on latently infected germinal center B cells (150, 173). What CD4+ T cells see as 
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antigen during lytic infection is perhaps transcriptionally silent in latency or in latently 
infected B cells and only when reactivation occurs, are these cells effective. This selective 
viral gene expression in B cells is perhaps a strategy to sacrifice myeloid cells as targets 
since they have less stable forms of latency and are prone to reactivate (150).  
The contribution of CD4+ and CD8+ T cells in controlling MHV-68 infection is well 
characterised (122, 174-176). This was tested in F1 mice, which in theory should generate 
proportionate CD4+ and CD8+ T cell responses to OVA. MCMV mOVA vaccinated F1 mice 
restricted lytic MHV-68 mOVA infection in the nose and lung. Virus clearance was 
dependent on primed CD4+ and CD8+ T cells as depleting both led to elevated virus titers 
in these mice (175). Antibody in this setting provided no protection, probably because OVA 
is not a viral protein, and neutralisation is thus ineffective. The underlining challenge in 
vaccine design against EBV is limiting persistent infection as demonstrated by reduced 
infectious mononucleosis. MHV-68 viral DNA was still detectable by real time PCR in the 
bone marrow and spleen at day 72 and in the nose, lung and in lymphoid tissue after 100 
days. MHV-68 infection of the bone marrow occurs around 12 to 15 days post i.n or i.p 
infection and persists long term (116, 120, 177). EBV and KSHV have been detected in 
the bone marrow of AIDS patients and in transplant patients of the latter (178, 179). The 
bone marrow is thought to function as a site for haematopoiesis and activation of naïve or 
memory immune cells (120). Thus, access to the bone marrow through either trafficking of 
virions or by circulating mature B cells or reactivating cells or directly via the blood 
suggests an important strategy to replenish peripheral sites by infected immature B cells 
that seed to the spleen to undergo maturation (120). Therefore, early intervention at site of 
entry could limit bone marrow colonisation which in turn could limit persistence. 
Antibody is important in preventing or reducing primary infection. The role of immune sera 
and monoclonal antibodies in reducing MHV-68 infection has previously been explored 
and found to reduce lytic infection via IgG Fc receptor engagement (133). However 
antibody coated virions were also found to be taken up via FcR mediated endocytosis by 
FcR+ myeloid cells which was gp150 dependent (180). In the absence of gp150, post 
exposure to polyclonal gH/gL elicited by vaccinia virus vaccination blocked FcR- mediated 
infection (181). This protective result was replicated in BALB/c but not in C57BL/6 mice 
when given vac gH/gL i.p and challenged with MHV-68 i.n. The mechanism of action of 
gH/gL neutralising antibody occurs by inhibiting endocytosis or membrane fusion in 
fibroblasts or epithelial cells (182-184). Monoclonal gH/gL can to some extent enhance 
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FcR+ myeloid cell infection (180, 184). The fact that BALB/c mice revealed protection 
implies less epithelial /fibroblast infection and more myeloid infection where MHV-68 is 
less lytic. Although this is plausible, it is limited by the assay performed in this thesis. 
Perhaps, identifying infected cells by histology to determine the ratio of epithelial/fibroblast 
to myeloid cells would provide a better insight into the molecular mechanism of protection 
as Rosa and colleagues showed to some extent that gH/gL monoclonal antibody shifts 
MHV-68 infection from epithelial or fibroblasts to FcR+ myeloid cells were infection is latent 
(180). Whether this is strain dependent remains to be determined.  
MHV-68 is not known to inhibit NK cell antibody dependent cellular cytotoxicity. However, 
Alder and colleagues showed that MHV-68 can escape NK cell mediated immune 
surveillance by upregulating CEACAMI expression on lung alveolar epithelial cells (185). 
CAECAMI is an inhibitory receptor expressed by several cells including NK cells (185). 
MHV-68 infection of CAECAMI knockout mice showed faster clearance than in wild type 
mice. Depletion of NK cells in CAECAMI knockout mice showed much higher lung titers 
than undepleted CAECAMI knock out mice confirming that expression of CAECAMI either 
inhibits or initiates NK-cell killing. It is possible, that in C57BL/6 mice, infected cells are 
more resistant to NK-cell killing via induction of CAECAMI expression on infected epithelial 
cells. Whether this mechanism restricts antibody mediated cellular cytotoxicity remains to 
be investigated. 
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CHAPTER 4: MURINE CYTOMEGALOVIRUS DEGRADES MHC CLASS II TO 
COLONIZE THE SALIVARY GLANDS 
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Abstract 
Cytomegaloviruses (CMVs) establish persistent, systemic myeloid cell infections in 
immunocompetent hosts. Persistence implies immune evasion, and CMVs evade CD8+ T 
cells by inhibiting MHC class I-restricted antigen presentation. The myeloid cells that 
CMVs colonize can also interact with CD4+ T cells via MHC class II (MHC II). Human CMV 
(HCMV) attacks the MHC II presentation pathway in vitro. What role this evasion might 
play in host colonization is unknown. We show that Murine CMV (MCMV) down-regulates 
MHC II via M78, a multi-membrane spanning viral protein that captured MHC II from the 
cell surface for pH-dependent degradation in lysosomes. M78-deficient MCMV down-
regulated MHC I but not MHC II. After intranasal inoculation, it showed a severe defect in 
salivary gland (SG) colonization that was associated with MHC II expression on infected 
cells and was significantly rescued by CD4+ T cell loss. Therefore, MCMV requires CD4+ T 
cell evasion by M78 to colonize the SG, its main site of long-term shedding. 
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Author summary 
Human cytomegalovirus is the commonest infectious cause of harm to unborn children. 
Vaccines have not stopped it establishing chronic, systemic infections. Murine 
cytomegalovirus (MCMV) provides an accessible model to understand why. We show that 
MCMV evades CD4+ T cells via its M78 protein, and that this helps infection to spread 
despite the immune response. Thus, while CD4+ T cells are important for host defence, 
viral evasion limits their capacity to act alone in controlling infection. 
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Introduction 
 Herpesviruses pre-date adaptive immunity, and in response to its evolution have 
acquired counter-balancing mechanisms of evasion. Persistent, productive infections 
result, with high prevalence in most populations and consequently significant disease 
burdens. Congenital infection by HCMV is a serious public health problem that motivates 
vaccine development. Vaccines to date have blunted acute infection but have not 
prevented viral persistence or transmission. 
 CMVs have extensive arsenals of immune evasion genes. To improve infection 
control we must understand what limits these set on immune function. This requires animal 
models. The most accessible is MCMV. Like HCMV, MCMV attacks MHC class I to evade 
CD8+ T cells. This promotes SG infection [1]; similar evasion by Rhesus CMV helps to re-
infect immune hosts [2]. HCMV also attacks MHC II, reducing interferon-γ (IFNγ)-
dependent induction [3] and triggering MHC II degradation via US2 [4], US3 [5] and pp65 
[6]. The rationale for evading CD4+ T cells through attack on MHC II is less clear than for 
CD8+ T cells and MHC I: MHC II can present cell-endogenous antigens after autophagy [7] 
but presents mainly exogenous antigens so presenting cells need not be infected; and 
while CD4+ T cells can induce target cell apoptosis [8], they are much less effective killers 
than CD8+ T cells. To understand the importance of MHC II attack by CMVs we must 
measure its impact in vivo. 
 Analysis of how MCMV might evade CD4+ T cells has focussed on cytokines: low 
MHC II expression on infected cells is attributed to IFNγ inhibition [9] and IL-10 induction 
[10] reducing MHC II transcription. The viral genes responsible have not been identified. 
M27 reduces IFNγ signalling through STAT-2, but from day (d) 7 of infection M27- MCMV 
is no less attenuated in IFNγ receptor-deficient than in wild-type mice [11], arguing against 
significant CD4+ T cell evasion. We show that MCMV, like HCMV, degrades MHC II in 
infected cells. For MCMV this required M78, a multi-membrane spanning viral protein with 
homology to chemokine receptors but without canonical signalling motifs. M78- MCMV 
propagates poorly in cultured macrophages and poorly colonizes the SG [12-14]. Cells 
infected by M78- but not wild-type (WT) MCMV retained MHC II in vivo, and CD4+ T cell 
loss significantly reversed the M78-dependent defect in SG colonization. Therefore CD4+ T 
cell evasion is an important M78 function that is necessary for MCMV to colonize its main 
site of long-term shedding. 
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Results 
MCMV degrades MHC II in infected cells. 
 Most myeloid cells express MHC II inducibly rather than constitutively. IFNγ induces 
MHC II expression but also inhibits MCMV replication [15, 16]. To track viral effects on 
MHC II without this complication, we induced MHC II in RAW-264 monocytes (normally 
MHC II-) by expressing the MHC II transactivator (C2TA), which acts down-stream of IFNγ 
[17]. RAW-C2TA cells were constitutively MHC II+. When they were exposed to MCMV-
GFP, GFP+ cells lost MHC II but not CD44 or CD71 (Fig.1a). Immunostaining cells 
exposed to β-galactosidase (βgal)+ MCMV (Fig.1b) similarly showed normal or increased 
MHC II expression in βgal- (uninfected) cells and MHC II loss in strongly βgal+ cells. In 
weakly βgal+ cells MHC II was clumped and internalized, suggesting that this was an 
intermediate stage in down-regulation. 
 Antibody IBL5/22, which recognizes a conformation-independent MHC II epitope, 
gave equivalent results to antibody M5/114 (Fig.1c), so MCMV caused MHC II degradation 
rather than just denaturation. MCMV also reduced MHC II on thioglycollate-induced 
peritoneal macrophages of BALB/c and C57BL/6 mice (Fig.1d). Thus, the degradation did 
not depend on constitutive C2TA expression, and applied across at least 2 MHC II 
haplotypes. 
127 
 
 
Figure 1. MCMV degrades MHC II. 
a. RAW-C2TA cells infected with MCMV-GFP (0.5 p.f.u. / cell, 48h) were analysed for 
surface MHC II by flow cytometry. Mean fluorescence intensity was >10-fold lower on 
GFP+ cells than on GFP-. CD44 and CD71 mean fluorescence intensity of GFP+ cells was 
reduced <2-fold. Numbers show % cells in each quadrant. Each data set represents at 
least 3 experiments. 
b. RAW-C2TA cells were uninfected or infected with MCMV-βgal (1 p.f.u. / cell, 72h), then 
fixed, permeabilized and stained for βgal and MHC II. White arrows show example MHC II- 
infected cells; dark grey arrows show MHC II+ uninfected cells in the same cultures; light 
grey arrows show weakly βgal+ cells with MHC II in internal vesicles. Significantly fewer 
MCMV+ cells (<10%, n>200) than MCMV- cells (>90%, n>200) were MHC II+ (p<10-4 by 
Fisher's exact test). >100 weakly βgal+ cells showed MHC II redistribution. 
c. RAW-C2TA cells were infected as in b. MHC II+ cells were identified with conformation-
dependent (M5/114) and -independent (IBL5/22) antibodies. Arrows show example 
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infected cells. Significantly fewer GFP+ (<15%, n>100) than GFP- cells (>90%, n>100) 
were M5/114+ and IBL5/22+ (p<10-4 by Fisher's exact test). 
d. Peritoneal macrophages were recovered from BALB/c or C57BL/6 mice 72h after i.p. 
thioglycollate. Non-adherent cells were discarded. The remaining cells were infected or not 
with MCMV-GFP (1 p.f.u. / cell, based on total cell numbers before adherence). 48h later 
surface MHC II and CD44 were analysed by flow cytometry. Numbers show % total cells in 
each quadrant, collecting >5000 cells. In uninfected cultures, macrophages were 22% 
(BALB/c) and 26% (C57BL/6) MHC II+. In infected cultures, GFP- macrophages were 27% 
(BALB/c) and 24% (C57BL/6) MHC II+, while GFP+ macrophages were 0.3% (BALB/c) and 
0.2% (C57BL/6) MHC II+ (p<10-4 by X2 test). 
 
MCMV removes MHC II from the cell surface and degrades it in acidic endosomes 
 Unlike RAW-C2TA cells, MCMV-infected fibroblasts expressing C2TA preserved 
MHC II (Fig.2a). This result suggested that MHC II degradation might require macrophage-
specific, acidic endosomes. To test the need for low pH, we exposed infected RAW-C2TA 
cells to ammonium chloride or bafilomycin, which inhibit endosomal acidification. Both 
treatments significantly rescued MHC II expression (Fig.2b-c). By contrast the proteasome 
inhibitor MG-132 had no effect (Fig.2d-e). 
 Complete MHC II loss from infected cells suggested that in addition to any effect on 
nascent protein, MCMV removed mature MHC II from the plasma membrane. To test this 
idea, we incubated RAW-C2TA cells with an MHC II-specific antibody (1h, 4oC), using 
excess antibody to minimize cross-linking and using rat antibodies to avoid binding by 
MCMV Fc receptors. We then washed off unbound antibody, infected the cells or not 
overnight (18h, 37oC), then added a fluorescently labelled secondary antibody (1h, 4oC) 
and assayed its binding by flow cytometry (Fig.2f). Thus, we assayed MHC II that was on 
the plasma membrane before infection (for primary antibody binding) then retained there 
(for secondary antibody binding). We also stained MHC II on uninfected cells without a 
37oC incubation (1h, 4oC) (t=0h). The surface MHC II of uninfected RAW-C2TA cells was 
similar at t=0h and t=18h, indicating that its turnover is normally slow. By contrast MCMV-
infected (GFP+) cells showed a marked loss of surface-tagged MHC II over 18h. 
Therefore, MCMV removed MHC II from the plasma membrane of infected cells. As RAW-
C2TA cells maintained surface MHC II for at least 18h, reduced synthesis - for example 
through transcriptional suppression - could not explain the down-regulation. Minimal MHC 
II down-regulation by MCMV in BALB/c-3T3-C2TA cells (Fig.2a) and rescue by bafilomycin 
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(Fig.2b-e) also argued against transcriptional suppression making a significant 
contribution.  
 
 
Figure 2. Viral MHC II degradation occurs in low pH endosomes. 
a. RAW-C2TA and BALB/c-3T3-C2TA cells were infected or not with MCMV-GFP (3 p.f.u. 
/ cell and 0.5 p.f.u. / cell respectively, as MCMV more efficiently infects fibroblasts than 
RAW-264 cells). 18h later surface MHC II was assayed by flow cytometry. Unlike RAW-
C2TA macrophages, infected 3T3-C2TA fibroblasts retained MHC II expression. 
b. RAW-C2TA cells infected or not with MCMV-GFP (1 p.f.u. / cell, 24h) were exposed 
(18h) to 100mM ammonium chloride, 20nM bafilomycin or medium alone (control), then 
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fixed, permeabilized and stained for MHC II. Viral GFP was visualized directly. Nuclei were 
stained with DAPI. Arrows show cells with rescued MHC II. The table quantitates MHC II 
expression for GFP+ cells. 
c. RAW-C2TA cells were infected with MCMV-GFP (3 p.f.u. / cell, 2h). Then bafilomycin 
(20nM) was added or not (control), and the cells cultured for a further 6h or 24h. They 
were then stained for MHC II with Alexa647-conjugated mAb M5/114 and analysed by flow 
cytometry. Virus-expressed GFP was assayed directly. Numbers show the % of total cells 
in each quadrant. 
d. RAW-C2TA cells were infected with MCMV-GFP (1 p.f.u. / cell, 72h), treated with 
bafilomycin (20nM) or the proteasome inhibitor MG-132 (50µM), and 18h later stained for 
MHC II. Arrows show example infected cells. The MHC II rescued by bafilomycin had an 
endosomal distribution. MG-132 gave no rescue. The graph in e shows total cell counts 
across at least 10 fields of view (>200 cells per bar). Statistical comparison was by 
Fisher’s exact test. 
f. RAW-C2TA cells were incubated (1h, 37oC) with M5/114 or IBL5/22 rat mAbs to MHC II, 
washed to remove unbound antibody, infected (MCMV, 18h) or not (UI, 18h) with MCMV-
GFP (2 p.f.u. / cell), cultured overnight (18h, 37oC), stained at 4oC with anti-rat IgG pAb 
and analysed by flow cytometry. Control untreated cells (UI, 0h) were stained in parallel for 
surface MHC II using M5/114 and anti-rat IgG pAb without overnight culture. 
 
MHC II degradation by MCMV requires M78 
 MHC II loss from the cell surface, and the intracellular distribution of the MHC II 
rescued by ammonium chloride or bafilomycin (Fig.2), argued that MCMV initiates MHC II 
degradation by relocalizing it to endosomes. The MCMV M78 is highly endocytic [13], so 
we tested its contribution, infecting RAW-C2TA cells with WT or M78- MCMV (Fig.3). M78- 
MCMV is reported to grow normally in fibroblasts and poorly in macrophages [12, 14]. We 
found impaired infectious virus production in RAW-264 cells after low multiplicity of 
infection, with less defect after higher multiplicity infection (Fig.3a). There was no 
difference between MHC II+ and MHC II- RAW-264 cells. There was no obvious defect in 
RAW-264 cell infection as measured by viral β-gal expression (Fig.3b), or by flow 
cytometry of viral GFP expression (S1a Figure), and RAW-C2TA cells infected by WT or 
M78- MCMV showed no obvious difference in viral or MHC II transcription (S1b-c Figure). 
 Flow cytometry of WT MCMV-infected cells showed a marked loss of both surface 
(non-permeabilized), and total (permeabilized) MHC II (Fig.3b). M78- MCMV infection little 
affected either. MHC II loss from peritoneal macrophages also required M78 (Fig.3c). 
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Identifying infected cells by immunofluorescent staining with a polyclonal anti-MCMV 
antibody (Fig.3d) or with an IE1-specific antibody (Fig.3e) confirmed that MHC II loss was 
M78-dependent. We also tested bone marrow-derived macrophages (Fig.3f). When 
uninfected, approximately 30% of these were MHC II+; when infected with WT or M78+ 
REV MCMV, expression decreased to <5%; and when infected with M78- MCMV there 
was no decrease. 
 Flow cytometry of cells infected with an independent M78- mutant (Fig.3g) 
confirmed that MHC II loss was M78-dependent. MHC I loss was contrastingly M78-
independent. In H2d cells this depends primarily on m06, which degrades MHC I in 
lysosomes [18]. Therefore, M78 was not required for all MCMV-driven, lysosome-
dependent protein degradation. As M78+ MCMV down-regulated neither CD71 (Fig.1a), 
which cycles through early endosomes, nor CD44, neither did M78 generally promote 
glycoprotein endocytosis and loss. 
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Figure 3. MHC II degradation by MCMV requires M78. 
a. RAW-264 and RAW-C2TA cells were infected at low multiplicity  (0.01 p.f.u. / cell, 1h) 
and washed x3 in PBS. RAW-C2TA cells were also infected at high multiplicity (3 p.f.u. / 
cell) by centrifuging virus onto the cells (536 x g, 30min), then washed x 3 in PBS. The 
cells were cultured in complete medium, and at each time point, triplicate cultures were 
plaque-assayed for infectious virus. Symbols show mean ± SEM. Time=0 shows the 
calculated virus input. M78- MCMV had similar growth defects in MHC II+ and MHC II- 
cells. 
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b. RAW-C2TA cells were infected with WT or M78- gal+ MCMV (1 p.f.u. / cell, 72h), or left 
uninfected (UI), then stained for surface MHC II (non-permeabilized) before fixation, 
permeabilization and staining for gal; or fixed, permeabilized then stained for MHC class 
II plus gal (permeabilized). MHC II either just at the cell surface (non-permeabilized) or 
also in the cell (permeabilized) was assayed by flow cytometry. Numbers show % total 
cells in each gated region. This was significantly less for M78- than for WT MCMV (p<10-4 
by X2 test.) Total gal+ cell numbers were comparable. 
c. Peritoneal macrophages from thioglycollate-treated BALB/c mice were infected with WT 
or M78- βgal+ MCMV (1 p.f.u. / cell, 48h), then fixed, permeabilized, stained with antibodies 
to MHC II and βgal, and analysed by flow cytometry. Numbers show % total cells in each 
quadrant. Significantly more GFP+ cells were MHC II+ with M78- than with WT MCMV 
(p<10-4 by X2 test). 
d. RAW-C2TA cells infected as in b were fixed, permeabilized, stained for MHC II and for 
MCMV antigens with polyclonal immune serum, then imaged by confocal microscopy. For 
WT MCMV, white arrows show infected cells and the grey arrow an uninfected cell. For 
M78- MCMV, arrows show infected cells. M78- but not WT infected cells showed MHC 
II+MCMV+ vesicles just below the plasma membrane. Significantly fewer MCMV+ cells 
were MHC II+ for WT (4/59 cells) than for M78- infection (62/69 cells) (p<10-4 by Fisher's 
exact test). 
e. RAW-C2TA cells were infected with WT, M78- or revertant (REV) viruses (1 p.f.u. / cell, 
72h), or left uninfected (UI). They were then fixed, permeabilized and stained for MHC II 
plus MCMV IE1. White arrows show infected cells that have lost MHC II expression; grey 
arrows show cells that retain it. Where WT and REV-infected cells retained some MHC II, 
corresponding presumably to an earlier stage of infection, it showed an altered, endosomal 
distribution. The table gives total counts for >30 fields of view per sample. 
f. Macrophages grown from bone marrow cells were infected with WT, REV or M78- 
MCMV (2 p.f.u. / cell, 24h), then fixed and stained for MHC II. Symbols show counts for 
individual fields of view. Bars show means. WT and REV infections caused significant 
MHC II+ cell loss; M78- infection did not. 
g. RAW-C2TA cells were infected with WT or M78- (deletion mutant) MCMV-GFP (1 p.f.u. / 
cell, 72h), then analysed by flow cytometry for surface glycoproteins. % total cells in each 
quadrant is shown. M78 disruption significantly reduced loss of MHC II (p<10-4 by X2 test) 
and not MHC I. CD44 was maintained. 
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M78 relocalizes MHC II to endosomes 
 RAW-C2TA cells expressing M78 via retroviral transduction showed some MHC II 
loss but much less than that of infected cells (Fig.4a). Both MCMV-infected RAW-C2TA 
cells (Fig.4b) and RAW-C2TA cells transduced with an M78+ retrovirus (Fig.4c, 4d) 
expressed M78 in internal vesicles - previous studies have identified it in early endosomes 
[13]. In transduced cells, CD44 remained on the plasma membrane whereas MHC II 
relocalized to M78+ vesicles. MCMV-infected bone marrow-derived macrophages (Fig.4e) 
and RAW-C2TA cells transiently transfected with an M78 expression plasmid (Fig.4f) 
similarly showed MHC II / M78 co-localization in vesicles. 
 Surprisingly, despite M78-transduced cells being readily obtained and despite 
retroviral transduction generally giving uniformly strong recombinant gene expression [19], 
M78-transduced RAW-C2TA cells showed variable M78 expression (Fig.4d), as did RAW-
C2TA-M78 cell clones and an independently-derived RAW-C2TA-M78 line (Fig.4g). Cells 
with strong M78 expression redistributed MHC II, but puromycin-resistant cells that 
expressed less M78 had less effect on MHC II. To understand why, we tracked M78 from 
the cell surface. We infected RAW-C2TA cells with MCMV expressing HA-tagged M78 (4h, 
37oC), labelled them with HA-specific rabbit IgG and MHC II-specific rat IgG (1h, 4oC), 
washed off excess antibody, then incubated the cells at 37oC for different times before 
fixation, permeabilization and staining with anti-rabbit IgG and anti-rat IgG labelled 
secondary antibodies. M78 tagged by antibody at the infected cell surface was rapidly 
endocytosed (Fig.4h). It co-localized with MHC II in internal vesicles, then became 
undetectable, as did surface-tagged MHC II (Fig.4i). Transfected HA-M78 was also lost 
rapidly, whereas transfected HA-CCR5 was preserved (Fig.4j). Therefore, rapid M78 and 
MHC II endocytosis appeared to be accompanied by M78 degradation, and in infected 
cells also by MHC II degradation. 
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Figure 4. M78 relocalizes MHC II. 
a. Cloned RAW-C2TA cells were transduced with vector alone or with M78 (line 1 and line 
2), or infected with MCMV-GFP (+ MCMV, 1 p.f.u. / cell, 72h), then stained for MHC II 
(dashed lines). Solid lines show uninfected, untransduced RAW-C2TA cells. The biphasic 
population with MCMV corresponds to GFP+ (MHC II-) and GFP- (MHC II+) cells. M78 
transfection had much less effect than MCMV infection on cell surface MHC II expression. 
b. MCMV-GFP-infected RAW-C2TA cells were stained for M78. GFP was visualized 
directly. Nuclei were stained with DAPI. Arrows show example of infected cells with M78 in 
vesicles. 
c. Untransduced (control) and M78-transduced RAW-C2TA cells were stained for M78 and 
CD44. Arrows show M78 staining, which did not co-localize with CD44. 
d. M78-transduced RAW-C2TA cells were stained for M78 and MHC II. M78 occupied 
intracellular vesicles, as did MHC class II in M78+ cells. White arrows show examples of 
co-localization. Grey arrows show M78- cells with MHC II on the plasma membrane. 
136 
 
e. Macrophages grown from bone marrow were infected with WT MCMV (1 p.f.u. / cell, 
24h), then fixed and stained for M78 and MHC II. The white arrow shows a typical 
uninfected MHC II+ cell. The yellow arrow shows a typical infected cell with MHC II in 
vesicles. >80% of vesicles were M78+MHC II+, <20% were M78+MHC II- and <1% were 
M78-MHC II+ (n>300). Thus, there was significant endosomal M78 / MHC II co-localization 
(p<10-4 by Fisher's exact test). 
f. RAW-C2TA cells were transfected with a plasmid expressing HA-tagged M78. 3d later 
they were fixed, permeabilized and stained for M78 and MHC II. Nuclei were stained with 
DAPI. Arrows show examples of M78 and MHC II co-localizing in internal vesicles. 
g. Cloned RAW-C2TA-M78 cells were stained for MHC II and M78. White arrows show 
M78+ cells with MHC II in vesicles; grey arrows show cells with diffuse M78 staining and 
MHC II not relocalized. M78/MHC II co-localization was observed in >30% of transduced 
cells (n>500) and not in untransduced controls. 
h. RAW-C2TA cells were infected with HA-M78+ MCMV (4h, 37oC), incubated with rabbit 
anti-HA and rat anti-MHC II IgG (1h, 4oC), then washed and incubated at 37oC for the 
times indicated before fixation, permeabilization and staining with anti-rat (red) and anti-
rabbit (green) antibodies. Nuclei were stained with DAPI. Stainings show the change in 
distribution of surface-labelled M78 from 0 to 30min, and at 30min M78 co-localization with 
internalized MHC II (yellow, arrows). 
i. Summary of staining results from h shows similar kinetics of surface-labelled M78 and 
MHC II loss. Cells were scored as stained or not regardless of internalization. Each point 
shows mean ± SEM of 5 fields of view and >100 cells counted. 
j. RAW-C2TA cells were transfected with plasmid expressing HA-tagged M78, or HA-
tagged CCR5 as a control. 3d later they were incubated with rabbit anti-HA IgG (1h, 4oC), 
then washed and either fixed and permeabilized at once (0 min) or first incubated at 37oC 
(60 min). All cells were then stained with for rabbit IgG (green). Nuclei were stained with 
DAPI. HA-CCR5 detection was maintained over 60min, whereas HA-M78 detection was 
lost. 
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CD4+ T cell loss significantly rescues in vivo infection by M78- MCMV 
 As M78 was necessary for MCMV-driven degradation of MHC II, M78- MCMV 
provided an opportunity to understand what CD4+ T cell evasion contributes to host 
colonization in vivo. We gave mice intranasal (i.n.) WT or M78- MCMV (Fig.5). After 1-3d 
few WT-infected lung cells expressed MHC II, whereas many of those infected by M78- 
MCMV did so (Fig.5a, 5b). Therefore, M78 also down-regulated MHC II in vivo. 
 M78 has been studied as an MCMV gene of unknown function: M78- MCMV given 
intraperitoneally (i.p.) shows reduced liver, spleen and SG infections [12]; given i.n. it 
shows reduced lung and SG infections [14]. Rat CMV lacking its M78 homolog (R78) is 
also attenuated in vivo [20]. Plaque assays of infectious virus and QPCR of viral DNA 
showed normal acute lung infection. This reflected presumably that macrophages are not 
a major source of acute virus production in the lungs [26]. However, M78- MCMV was 
cleared faster from the lungs, and showed a marked defect in SG infection (Fig.5c). 
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Figure 5. M78- MCMV replication in vivo. 
a. BALB/c mice were given i.n. WT or M78- MCMV (3x104 p.f.u.). 3d later lung sections 
were stained for MCMV IE1 and MHC II. Nuclei were stained with DAPI. Arrows show 
infected cells.  
b. Quantitation of staining as in a, for sections from 3 mice. Few WT infected cells were 
MHC II+. At d1 and d3, significantly more M78--infected cells were MHC II+. 
c. Mice were infected as in a. Lungs and salivary glands were plaque-assayed for 
infectious virus, and QPCR-assayed for viral genomes relative to cellular (βactin) 
genomes. Bars show means, other symbols show individual mice. Dashed lines show 
assay sensitivity limits. Significant differences are indicated. 
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 Antibody responses to M78- MCMV were significantly lower than those to WT 
infection (Fig.6a), consistent with M78- viral loads being lower. ELIspot assays (Fig.6b-c) 
showed no obvious difference in CD4+ T cell response between M78- and WT MCMV. We 
assessed the functional contribution of CD4+ T cells to M78- MCMV attenuation by 
infecting BALB/c mice depleted of T cell subsets (Fig.6d). CD8+ T cell depletion increased 
M78- MCMV titers in the lungs at d10. However, it increased WT titers by a similar amount 
(p>0.5). It did not significantly affect SG infection. Therefore M78- MCMV attenuation was 
not due to better control by CD8+ T cells. 
 CD4+ T cell depletion did not alter lung infection. However, it increased SG infection 
by M78- MCMV. Some M78-dependent defect remained relative to WT, but unlike with 
CD8+ T cell depletion there was a significant relative increase in M78- virus titers (p<0.04). 
CD4+ T cell depletion also increased M78- viral genome loads relative to WT (Fig.6e). 
Therefore CD4+ T cell evasion appeared to be an important in vivo M78 function. 
 To confirm this result, we infected MHC II-deficient C57BL/6 mice (IA-/-) with WT, 
M78- mutant or M78+ revertant (REV) viruses (Fig.6f-g). At d10, virus titers in the lungs 
and SG of immunocompetent mice (IA+/-) were significantly lower for M78- MCMV than for 
WT or REV. IA-/- lungs showed higher M78- plaque titers, and the increase in M78- titer 
with CD4+ T cell loss (IA-/- mice) was significantly greater than for WT or REV MCMV 
(p<0.05). CD4+ T cell loss also increased M78- titers in SG, relative to both WT and REV 
(p<0.004), as well as M78- viral DNA loads (p<0.01). To exclude a generally greater effect 
of CD4+ T cell depletion on low level SG colonization, we compared our untagged M78 
deletion mutant (M78-I) with M131- MCMV [21], which also poorly colonizes SG (Fig.6h). 
Again M78- titers in SG showed a greater defect relative to WT in IA+/- than in IA-/- mice 
(p<0.01), indicating significant rescue by CD4+ T cell loss. By contrast M131- titers in SG 
showed a greater defect relative to WT in IA-/- mice. Nor did CD4+ T cell depletion rescue 
SG infection by i.n. M33- MCMV (Fig.6i). Therefore CD4+ T cell loss specifically rescued 
SG infection by M78- MCMV. 
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Figure 6. Significant M78- MCMV rescue by CD4+ T cell loss. 
a. C57BL/6 mice were given WT or M78- MCMV i.n. (3x104 p.f.u.). 56d later sera were 
assayed for MCMV-specific IgG and IgM by ELISA. Naive = age-matched, uninfected 
controls. Each point shows the mean of results for 7 mice. M78- MCMV elicited 
significantly less IgG response than WT (p<0.01). 
b. C57BL/6 mice were given WT or M78- MCMV, or as a control MuHV-4 i.n. (3x104 p.f.u.). 
56d after MCMV infection or 10d after MuHV-4 infection, CD4+ T cells were purified from 
splenocytes, pooled from 2 mice per group, by depleting other cells with magnetic beads 
(Untouched mouse CD4 cell kit, Thermofisher). IFNγ production in response to MCMV-
exposed or MuHV-4-exposed naive syngeneic spleen cells (1 p.f.u. / cell) was measured 
by ELIspot assay. Symbols show replicate wells, bars show means. 
c. C57BL/6 mice were given WT or M78- MCMV i.n. (3x104 p.f.u.). 56d later IFNγ 
production by splenocytes exposed to uninfected or MCMV-exposed naive syngeneic 
spleen cells was measured by ELIspot assay. Symbols show individual mice, bars show 
means. CD4+ T cell responses to WT and M78- MCMV were not significantly different. 
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d. BALB/c mice were depleted of CD4+ or CD8+ T cells (αCD4, αCD8) or left undepleted 
(cont), then given i.n. WT or M78- MCMV (3x104 p.f.u.). 10d later lungs and SG were 
plaque assayed for infectious virus. Symbols show individuals, bars show means. In lungs, 
immune depletions did not significantly change the ratio of WT to M78- titers. In SG, CD4+ 
T cell depletion significantly reduced this ratio. 
e. Viral DNA loads of SG in d were determined by QPCR. Again CD4+ T cell depletion 
significantly reduced the ratio of WT to M78- infection, that is significantly reversed the 
M78- infection defect. 
f. Immunocompetent (IA+/-) and MHC II- (IA-/-) C57BL/6 mice were given WT, M78- or 
revertant (REV) MCMV i.n. (3x104 p.f.u.). At d10 lungs and SG were plaque-assayed for 
infectious virus. Symbols show individual mice, bars show means. For both lungs (p<0.05) 
and SG (p<0.01), CD4+ T cell loss (IA-/- mice) significantly increased M78- plaque titers 
relative to WT or REV. 
g. For the mice in f, CD4+ T cell loss significantly increased M78- viral DNA loads in SG 
relative to WT or REV (p<0.05). 
h. IA-/- and IA+/- mice were given i.n. WT, M131- or M78 deletion mutant (M78-I) MCMV. At 
d10 lungs and SG were plaque assayed for infectious virus. Symbols show individuals, 
bars show means. The ratio of M78-I/WT salivary gland titers was significantly higher in IA-
/- than IA+/- mice (p<0.01), while the ratio of M131-/WT salivary gland titers was reduced. 
i. BALB/c mice were depleted of CD4+ T cells as in d, then given WT or M33- MCMV i.n.. 
After 10d SG were plaque assayed for infectious virus. Symbols show individuals, bars 
show means. CD4+ T cell depletion increased WT MCMV SG infection but failed to rescue 
SG infection by M33- MCMV. 
j. BALB/c mice were depleted of CD4+ T cells and given WT or M78- MCMV i.n. as in d. At 
d10 salivary gland sections were stained for MHC II and MCMV IE1. UI = uninfected 
control. Arrows show example infected cells (speckled nuclear IE1 staining). These cells 
were all MHC II- with WT MCMV and MHC II+ with M78- MCMV. Images are representative 
of 6 mice per group. 
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SG cells infected by M78- but not WT MCMV are MHC II+ 
 SG contain MHC II+ interstitial cells, but acinar cells are MHC II- [22] (Fig.6j, 
uninfected). Therefore, MHC II degradation should not promote acinar cell infection 
directly. However myeloid cells disseminate MCMV, and for at least 2 weeks after i.n. 
MCMV >80% of infected cells in the SG are CD11c+ (myeloid) rather than Aquaporin V+ 
(acinar). At d10 after WT infection of CD4+ T cell-depleted mice, all infected cells (n>100, 
counting samples from 6 mice) were MHC II- (Fig.6j, WT), but those infected by M78- 
MCMV were MHC II+ (Fig.6j, M78-). Without CD4+ T cell depletion, no M78- infected cells 
were seen. Therefore, M78 promoted SG colonization by guarding disseminating infected 
myeloid cells against CD4+ T cell engagement. 
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Discussion 
 M33 of MCMV [23], and UL33 and US28 of HCMV [24] encode chemokine receptor 
homologs that signal constitutively. M78 and its equivalents in HCMV (U78) and rat CMV 
(R78) have not been shown to signal, nor to bind chemokines, implying that they have 
other functions. M78 relocalized MHC II to endosomes and was required for MCMV-driven 
MHC II degradation. M78- MCMV also produced less infectious virus than did WT MCMV 
from MHC II+ and MHC II- RAW-264 cells, so MHC II degradation is unlikely to be the only 
M78 function. However, CD4+ T cell loss significantly rescued poor SG infection by M78- 
MCMV. Therefore M78-dependent CD4+ T cell evasion made a demonstrably important 
contribution to host colonization. 
 MCMV reaches the SG via infected, migratory dendritic cells [25-27]. With WT 
MCMV, these cells lacked detectable MHC II. With M78- MCMV, infected cells were not 
seen in SG of immunocompetent mice. However, CD4+ T cell loss led to the appearance 
of MHC II+ infected cells. Thus, M78 promoted SG infection by acting in infected myeloid 
cells, presumably protecting them against CD4+ T cell engagement. Impaired virus 
production by M78- infected myeloid cells might also impair infection transfer to SG acinar 
cells, but the primary defect seemed to be in infected myeloid cells reaching the SG. While 
infected myeloid cells spread i.n. MCMV from the lungs to new sites, type 2 alveolar 
epithelial cells appear to be the main source of infectious virus in the lungs [28]. Thus, 
normal acute lung infection by M78- MCMV was consistent with a myeloid cell-focussed 
defect. M78 could be considered a myeloid cell-specific infection module, which couples 
CD4+ T cell evasion to virus production in myeloid cells and so increases systemic 
infection spread. 
 Despite MHC II degradation by CMVs, CD4+ T cells play an important role in 
infection control [29, 30]. Effective antigen presentation by MCMV-infected dendritic cells 
may be possible even when MHC II is undetectable by immunostaining. Alternatively, 
protective CD4+ T cells could act indirectly, responding to antigen on uninfected presenting 
cells. Such a scheme is suggested by MHC II presenting mainly  cell-exogenous rather 
than cell-endogenous antigens, and by MCMV disrupting a range of presenting functions 
in infected cells [31, 32]. The failure of M78 disruption to increase MCMV-specific CD4+ T 
cell responses was consistent with uninfected presenting cells driving most CD4+ T cell 
priming. It follows that primed, protective CD4+ T cells may not directly recognize CMV-
infected cells, but rather recruit and activate other anti-viral effectors with independent 
modes of recognition, for example NK cells. 
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 What then does MHC II degradation in infected cells achieve? Because MCMV 
exploits normal dendritic cell migration to spread [26], infected cells are likely to encounter 
CD4+ T cells in lymph nodes. CD4+ T cell recognition of MHC II plus antigen on infected 
dendritic cells would not necessarily lead to killing, as CD4+ T cells primarily activate rather 
than kill engaged presenting cells. CD8+ T cell evasion is more important for infected cell 
survival. However, CD4+ T cell-derived cytokines have anti-viral effects [16], and CD4+ T 
cell engagement would reduce the migration of infected myeloid cells and so would reduce 
infection spread. Increased CD4+ T cell engagement would also promote local antibody 
responses and innate effector recruitment. Thus, MHC II expression on infected myeloid 
cells, even if presenting mainly non-viral antigens, would open up a new front of host 
defence, with more precise targeting of recruited effectors to infected cells. By removing 
MHC II from the surface of infected myeloid cells, M78 isolated them from any CD4+ T cell 
engagement, promoting systemic infection spread and making MCMV-infected cells harder 
for CD4+ T cell-dependent defences to find. 
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Materials and Methods 
Mice.  BALB/c, C57BL/6 and IA-/- mice [33] were infected i.n. at 6-12 weeks old (3x104 
p.f.u. in 30µL, under anaesthesia). We depleted CD4+ / CD8+ T cells with mAbs GK1.5 / 
2.43 (Bio X Cell, 200g/mouse/48h, from 96h pre-infection). Flow cytometry of spleen cells 
showed that the depletions were >95% complete (S2 Figure). Embryonic fibroblasts were 
obtained from 15–17d old embryos harvested from pregnant out-bred CD1 mice.  
 
Ethics statement.  Experiments were approved by the University of Queensland Animal 
Ethics Committee (projects 301/13, 391/15 and 479/15) in accordance with the Australian 
code for the care and use of animals for scientific purposes, from the Australian National 
Health and Medical Research Council. 
 
Plasmids.  M78 was amplified from K181 MCMV with Q5 polymerase (New England 
Biolabs), adding MfeI and SalI sites to its 5' and 3' ends, ligated into pMSCV-IRES-PURO 
[34] and verified by DNA sequencing. Expression plasmids for HA epitope-tagged-M78 
and CCR5 are described [13]. Each HA tag was N-terminal and so extracellular when the 
protein spanned the plasma membrane. 
 
Cells.  Peritoneal macrophages were obtained by peritoneal lavage 48h after i.p. 3% 
Brewer's thioglycollate. B cells were removed by adherence to plastic and washing with 
PBS. Recovered cells were >90% F4/80+CD19-. Macrophages were grown from bone 
marrow by culture with M-CSF-1 (10ng/ml, Peprotech). These cells, mouse embryo-
derived fibroblasts, NIH-3T3 (American Type Culture Collection (ATCC) CRL-1658), 293T 
(ATCC CRL-3216), RAW-264 cells (ATCC TIB-71), RAW-264 cells transduced with the 
human MHC II transactivator to induce MHC II (RAW-C2TA) [35], BALB/c-3T3 and 
BALB/c-3T3 cells transduced with C2TA, were grown in Dulbecco’s modified Eagle’s 
medium with 2mM glutamine, 100IU/ml penicillin, 100g/ml streptomycin and 10% fetal 
calf serum (complete medium). Retroviral transduction was by transfecting 293T cells with 
pMSCV-M78-PURO and a packaging plasmid [34], adding supernatants to cells with 
hexadimethrine bromide (10µg/ml), then selecting with puromycin (10µg/ml). RAW-C2TA 
cells were transfected by electroporation. 
 
Viruses.  We used MCMV strain K181. Variants expressing GFP from the M131 intron 
(MCMV-GFP) [28] or βgal from the M33 intron (MCMV-βgal) [36]; with a premature stop 
codon in M131 (M131-) [21]; with a βgal cassette replacing M33 (M33-) [37]; with a βgal 
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expression cassette at genomic coordinate 111681 (Genbank GU305914) disrupting M78 
(M78-); and a revertant with an N-terminal HA epitope tag on M78 (REV) [13] are 
described. An independent M78 mutant (M78-I) was made by homologous recombination, 
deleting the ORF (coordinates 111084-112499). This mutation was also recombined into 
MCMV-GFP. Viruses were grown in NIH-3T3 cells. Viruses were plaque assayed on 
embryonic fibroblasts [28]. Statistical comparison was by Student's 2-tailed unpaired t test 
unless otherwise stated. 
 
Immunostaining.  Organs were fixed in 1% formaldehyde-10mM sodium periodate-
75mM L-lysine (24h, 4oC), equilibrated in 30% sucrose (18h 4oC), then frozen.  6M 
sections were blocked with 0.3% Triton X-100 / 5% normal goat serum, then incubated 
(18h, 4oC) with mAbs to MHC II (rat, M5/114) and MCMV IE1 (mouse IgG1, CROMA101) 
[38]. Sections were washed x3 in PBS, incubated (1h, 23oC) with Alexa 488-goat anti-
mouse IgG1 and Alexa 568-goat anti-rat IgG pAb plus DAPI (1µg/ml), then washed x3 in 
PBS, and mounted in ProLong Gold (Life Technologies). Cultured cells were adhered to 
coverslips, then fixed (2% formaldehyde, 30min), blocked in PBS / 0.1% Triton-X100 / 1% 
bovine serum albumin, then stained with antibodies to MHC II (M5/114 or IBL5/22), CD44 
(rat mAb IM7, MCMV IE1 (CROMA101), βgal (chicken pAb, AbCam), MCMV (rabbit pAb), 
and M78 (rabbit pAb) [13]. Cells were washed x3 in PBS / 0.1% Tween-20, incubated with 
combinations of Alexa488-goat anti-chicken IgG pAb, Alexa488-goat anti-mouse IgG1, 
Alexa488- or Alex568-goat anti-rabbit pAb and Alexa568-goat anti-rat IgG pAb, plus DAPI 
(1µg/ml), then washed x3 in PBS / 0.01% Tween-20, x2 in PBS and mounted ProLong 
Gold. GFP fluorescence was visualized directly. Images were acquired with a Zeiss 
LSM510 microscope and analyzed with ImageJ. 
 
Flow cytometry.  Cells were detached from plates, blocked with 1% BSA / 1µg/ml anti-
CD16/32 (2.4G2), incubated (1h, 4oC) with antibodies to MHC II (APC-mAb M5/114), 
CD44 (biotin-IM7), MHC class I (biotin-34-5-8S), CD71 (biotin-C2, BD Biosciences), 
washed x2 in PBS, then incubated with fluorescein-streptavidin, washed x2 in PBS and 
analysed on an Accuri flow cytometer. GFP fluorescence was measured directly. To detect 
βgal, cells were fixed in 2% PFA after surface staining, then permeabilized in 70% ethanol, 
washed x2 and incubated with chicken anti-βgal followed by Alexa488-goat anti-chicken 
IgG pAb (AbCam). To test CD4+ and CD8+ T cell depletions, spleen cells were stained with 
antibodies to CD4 (fluorescein-RM4-4), and CD8β (phycoerythrin-H35-17.2) (BD 
Biosciences). 
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Quantitative PCR.  DNA was extracted from organs or blood (Wizard Genomic DNA 
Purification, Promega).  MCMV coordinates 111218-111461 were amplified (LightCycler 
480 SYBR green, Roche Diagnostics) and converted to genome copies by comparison 
with plasmid DNA amplified in parallel.  Cellular DNA was quantified in the same samples 
by amplification of a -actin gene segment.  Viral DNA loads were normalized by cellular 
DNA loads. 
 
RT-PCR. RNA was extracted from cells (Ambion) and reverse-transcribed with an 
oligo-dT primer (New England Biolabs). MHC II, β2M cellular cDNAs and IE1 and M33 
viral cDNAs were then amplified by PCR. To distinguish cDNA from genomic DNA, each 
primer pair spanned an intron. The primers were (5' to 3'): MHC II - 
GATGCCGCTCAACATCTTGCTC and CATCCACACAGCTTATTAGGAATG; β2M - 
TAGACCAAAGATGAGTAACTGCATC and GAGACTGATACATACGCCTGCAG; IE1 - 
AACCGTCCGCTGTGACCTGAC and CGATGCGCTCGAAGATATCATTG; M33 - 
TCAGGATGATCACCGTGTTGATG and GAAACTTCTTAACCTTTCCAACGG. PCR 
products were separated by electrophoresis on 2% agarose gels and visualized by 
staining with ethidium bromide. 
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Supporting figure 1. Normal M78- MCMV infection of RAW-C2TA cells. 
a. BHK-21, NIH-3T3 cells and RAW-C2TA cells were infected with GFP+ WT or GFP+ M78- 
MCMV at different multiplicities. GFP expression was then quantified by flow cytometry, 
after 18h for BHK-21 and NIH-3T3 cells, and after 24, 48 and 72 hrs for RAW-C2TA cells. 
No significant difference in infection was observed between WT and M78- MCMV. 
b. RAW-C2TA cells were infected with WT or M78- MCMV (3 p.f.u. / cell, 72h). RNA was 
then harvested, reverse transcribed with an oligo-dT primer and used to amplify MHC II, 
β2-microglobulin (β2M), the MCMV IE1 or the MCMV M33. Each primer set spanned an 
intron. The filled arrow shows the predicted size of the product amplified from spliced 
cDNA, and the open arrow that amplified from unspliced cDNA or genomic DNA. For MHC 
II and β2M, unspliced product was not seen as it would be very large. -RT = control 
samples without reverse transcription. UI = uninfected. No difference was observed in IE1 
or M33 transcription, or in MHC II induction. 
c. RAW-C2TA cells were infected with GFP+ WT or GFP+ M78- MCMV (3 p.f.u. / cell, 72h) 
then flow cytometrically sorted into GFP+ and GFP- fractions. RNA was extracted, reverse-
transcribed and amplified by PCR as in b, using primers for MHC II and 2M. nil = no 
template control. MHC II band intensity is shown, normalised by 2M band intensity for the 
same sample (mean ± SEM of triplicate samples). MHC II induction was evident in the 
GFP- cells of infected cultures. GFP+ cells showed no MHC II transcriptional shut-down. 
 
 
Supporting Figure 2. T cell depletion. 
Mice were given i.p. every 48h 200µg protein G-purified anti-CD8α (2.43) or anti-CD4 
(GK1.5) mAb, starting 96h before infection. Control = no antibody. Spleens taken at 10 
days post-infection were analysed for CD4+ and CD8+ T cells by flow cytometry with 
antibodies to CD4 (RMA4-4 and CD8β (mAb H35-17.2). Numbers show mean ± SEM of 
FSC/SSC-gated lymphocytes for 5 mice. 
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4.1 Unpublished supporting research data. 
4.1.1 Characterising BALB/c-3T3-C2TA and RAW-C2TA cells 
BALB/c-3T3 and RAW 264.7, which are normally MHC class II negative, were transduced 
with the C2TA transactivator using a retrovirus. MHC I and MHC II were constitutively 
expressed in these cells (Fig. 4.1a-b) and were able to present OVA323-339 peptide to 
stimulate DO11.10 hybridoma CD4+ T cells to secrete IL-2 (Fig. 4.1c). Parent cell lines 
BALB/c-3T3 and RAW 264.7 were deficient in presenting OVA323-339 peptide as expected.  
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Fig. 4. 1. BALB/c-3T3-C2TA and RAW-C2TA constitutively express MHC II.  
Untransduced and MHC II transduced BALB/c-3T3 and RAW 264.7 cells were fixed, 
permeablised and blocked in 2%NGS/PBS (RT, 1 hr). MHC II was stained using rat anti-
MHC II- M5/114 (4oC,18 hrs) and detected using Alexa Fluor goat anti-rat 594 and DAPI 
stained nucleus (RT, 1 hr). The cells were visualised on an epifluorescence microscope at 
63X magnification. b) Cells in a were incubated in rat anti-mouse CD16/CD32 Fc block in 
combination with Alexa Fluor 647 rat anti-MHC II (M5/114) (4oC, 1 hr). MHC I was stained 
using biotinylated mouse anti-MHC I (H-2D (d) (34-2-12) (4oC, 1 hr) and detected using 
streptavidin PerCP Cy5.5 (4oC, 1 hr). MHC II and MHC I expression was analysed on BD 
Accurri C6 flow cytometer. Data was visualised on weasel as in b. Arrows show 
expression profiles of expression. Dotted line shows unstained cells, dashed line; 
untransduced BALB/c-3T3 and RAW 264.7 cells and solid line; transduced BALB/c-3T3-
C2TA and RAW-C2TA. Cells in a were co-cultured with CD4+ T cell hybridoma cells 
specific for OVA323-339 peptide in the presence of 1 µM OVA323-339 peptide or medium. After 
24 hrs, IL-2 in culture was detected using ELISA. Data represents log IL-2 (pg/ml) of 
duplicate cultures. Error bars difference in mean. Data are representative of 3 independent 
experiments.  
4.1.2 Generation of uniform MHC II expressing clones 
Continuous culture of RAW-C2TA cells, led to MHC II high and MHC II low populations 
(data not shown). To generate high expressing MHC II clones, RAW-C2TA cells was 
serially diluted to generate individual clones that were maintained in zeocin, a selection 
marker for MHC II expressing cells. Individual clones were then screened for MHC II 
expression by immunostaining using a 96 well format. Positive clones were further 
expanded and analysed by flow cytometry. The results showed RAW-C2TA clones 2 and 7 
had 64-75% MHC II expression while clones 6, 9 11 and 12 had 91-98% expression (Fig. 
4.2a). Parent RAW-C2TA line (mixed) had 14.7% and the untransduced RAW 264.7, had 
no MHC II expression (Fig. 4.2a). Similarly, BALB/c-3T3-C2TA had 99% MHC II 
expression compared to 12% in BALB/c-3T3. To determine whether the RAW-C2TA 
clones would stimulate I-Ad-restricted OVA323–339-specific DO11.10 hybridoma cells to 
secrete IL-2, BALB/c-3T3, BALB/c-3T3-C2TA, NSO and RAW-C2TA clones 7, 9 and 11 
were co-cultured with OVA323-339-specific DO11.10 hybridoma cells in the presence of 1 µM 
OVA323-339 peptide or medium. BALB/c-3T3-C2TA and RAW-C2TA clones stimulated 
OVA323-339 specific DO11.10 hybridoma cells to secrete IL-2 compared to BALB/c-3T3 and 
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NSO cells respectively (Fig. 4.2b). To confirm the RAW-C2TA clones were macrophages, 
clones 7, 9 and 11 were stimulated with or without LPS for 4 hrs and analysed for NO2 
secretion 24 hrs later. All RAW-C2TA clones secreted NO2 except fibroblast cell lines 
BALB/c-3T3-C2TA and BHK-21 cells and NSO cells (Fig. 4.2c). RAW-C2TA clone 9 was 
used throughout this thesis as RAW-C2TA. 
 
 
Fig. 4. 2. RAW-C2TA clones uniformly express MHC II  and stimulate CD4+ T cells. 
a) Untransduced and MHC II transduced fibroblasts and macrophages were directly 
stained for MHC II using rat anti-MHC II- M5/114 (4oC, 1 hr). MHC II was detected BD 
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Accurri C6 flow cytometerrri6 flow cytometer. Data was visualised and analysed on 
weasel. Bar graph represents percentage means of three independent experiments. Error 
bars show difference in means. Positive clones (>95%) were used for further analysis. b) 
RAW-C2TA positive clones in a and fibroblast cell lines BALB/c-3T3 and BALB/c-3T3-
C2TA and NSO Cells were co-cultured with CD4+ T cell hybridoma cells specific for 
OVA323-339 peptide in the presence of 1 µM OVA323-339 peptide or medium. After 24 hrs, IL-
2 in culture was detected using ELISA. Data represents log IL-2 (pg/ml) of duplicate 
cultures. Error bars difference in mean. c) Cells in b were stimulated with LPS (10 µg/ml) 
or medium for 4 hrs, then washed and supplemented with fresh 10% complete medium. 
After 24 hrs, NO2 in culture medium was detected using NO2 kit. Absorbance was read at 
570 nm using POLARstar® Omega Plate Reader Spectrophotometer. Data represents 
NO2/µM of duplicate cultures. Error bars show difference in mean. Data are representative 
of 3 independent experiments.  
4.1.3 MCMV restricted CD4+ T cell stimulation in vitro 
MCMV was previously shown to interfere with CD4+ T cell stimulation in vitro by interfering 
with MHC II expression. Thus, RAW-C2TA cells were infected with WT or recombinant 
MCMV or MHV-68 expressing transferrin linked OVA (mOVA) from the viral genome or left 
uninfected. The cells were then co-cultured with DO11.10 CD4+ T cell hybridomas and IL-2 
was measured after an overnight incubation. CD4+ T cell hybridomas in mOVA- 
recombinant MCMV infected wells secreted less IL-2 (1.32 ± 0.55) compared to in mOVA-
recombinant MHV-68 infected wells (2.90 ± 0.122), a 1.58 ± 0.56 log difference (Fig. 4.3b, 
p<0.001). To determine whether this was macrophage specific, BALB/c-3T3-C2TA cells 
were infected overnight as above in the presence of DO.11.10 hybridoma cells and 
secreted IL-2 measured. Interestingly, OVA323-339-specific CD4+ cells in mOVA- 
recombinant MCMV infected wells secreted 1.38 ± 0.18 log IL-2 compared to 1.20 ± 0.25 
in mOVA-recombinant MHV-68 infected wells, a -0.08 ± 0.31 log difference (Fig. 4.3a, 
p>0.05). The results suggested, the difference in IL-2 secretion could be macrophage 
specific and probably due to CD4+ T cell restriction by MCMV. To test this hypothesis, 
BALB/c-3T3-C2TA cells were infected with recombinant MHV-68 expressing EF1a eGFP 
or MCMV GFP. There was no significant change in MHC II expression in MHV-68 EF1a 
eGFP or MCMV GFP infected cells (Fig. 4.4a). MHC I expression was slighted altered in 
MHV-68 EF1a eGFP infected cells compared to MCMV GFP where MHC I downregulation 
was more evident (Fig. 4.4b). The results demonstrate that, neither MHV-68 nor MCMV 
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affect MHC II expression in fibroblasts, which could explain the unaltered IL-2 response 
observed. In RAW-C2TA cells, GFP+ MHV-68 Δ73 sOVA or gM eGFP infected RAW-
C2TA cells expressed MHC II while MCMV GFP+ cells downregulated MHC II (Fig. 4.4c). 
Both viruses downregulated MHC I but retained CD44 expression (Fig. 4.4d-e).  Thus, 
direct infection rather than soluble factor contributed to downregulation of MHC II 
expression and was specific to MCMV. 
 
 
Fig. 4. 3. MCMV restricts CD4+ T cell stimulation in RAW-C2TA cells. 
3x104 BALB/c-3T3-C2TA in a or RAW-C2TA cells in b were either left uninfected or 
infected with recombinant or WT MCMV or MHV-68. BALB/c-3T3-C2TA cells were infected 
at MOI 0.3 for 18 hrs in the presence of 3x104 CD4+ T cell hybridoma cells. RAW-C2TA 
cells were infected at MOI 2 MHV-68 or 1 MCMV for 96 hrs, then 3x104 CD4+ T cell 
hybridomas were added to the cells. Uninfected cells were incubated in OVA323-339 peptide 
or medium. After 24 hrs post co-culture, culture medium of BALB/c-3T3-C2TA and RAW-
C2TA was assayed for IL-2 using ELISA respectively. Error bars show mean difference of 
duplicate samples. Data was analysed using unpaired student 2 tailed t-test (ns, p>0.05; * 
p<0.05; *** p<0.001). Data are representative of 3 independent experiments.  
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Fig. 4. 4. BALB/c-3T3-C2TA retain MHC II expression. 
a, b) BALB/c-3T3-C2TA cells were left uninfected or infected with MCMV GFP or MHV-68 
EF1a eGFP (MOI 0.3, 18 hrs). The cells were incubated in rat anti-mouse CD16/CD32 Fc 
block in combination with Alexa Fluor 647 rat anti-MHC II (M5/114) (4oC, 1 hr). MHC I was 
stained using biotinylated mouse anti-MHC I (H-2D (d) (34-2-12) (4oC, 1 hr) and detected 
using streptavidin PerCP Cy5.5 (4oC, 1 hr). MHC II and MHC I expression was detected 
using BD Accurri C6 flow cytometer. Data was visualised on weasel and plotted on 
histogram. Dark firm line; uninfected, dotted line; MCMV and dashed line; MHV-68. c) 
RAW-C2TA cells were left uninfected or infected with MCMV GFP or MHV-68 gM eGFP or 
BAC+ Δ73 sOVA GFP (MOI 1, 48 hrs) by centrifugation (536 x g for 30 minutes). The cells 
were incubated in rat anti-mouse CD16/CD32 Fc block in combination with Alexa Fluor 
647 rat anti-MHC II (M5/114) (4oC, 1 hr). MHC I and CD44 was stained using biotinylated 
mouse anti-MHC I (H-2D (d) (34-2-12) and biotin anti-CD44 (IM7) (4oC, 1 hr) and detected 
using streptavidin PerCP Cy5.5 (4oC, 1 hr). MHC II (c), MHC I (d) and CD44 (e) 
expression was detected using BD Accurri C6 flow cytometer. Data was visualised and 
analysed on weasel. Data is representative of 3 independent experiments.  
4.1.4 Confirmation of M78 expression in WT and absence in M78- virus 
To determine whether M78 was implicated in MHC II downregulation, absence of M78 
expression in M78- virus was determined by immunostaining and western blot. M78 was 
only detected in WT but not in M78- viruses by microscopy (Fig. 4.5a). Both viruses 
expressed similar patterns of IE1 and MCMV lytic antigens on western blot (Fig. 4.5b).  
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Fig. 4. 5. M78 deficient virus does not express M78. 
RAW-C2TA cells were infected with WT or MCMV GFP (MOI 1, 48 hrs). The cells were 
fixed, permeablised and blocked in 2%NGS/PBS (RT, 1 hr) and stained with rabbit anti-
M78 antibody (4oC, 1 hr) and detected with Alexa Fluor goat anti-rabbit 488. DAPI stained 
nucleus. b) 1x106 RAW-C2TA were infected with WT or M78- virus (MOI 1, 72 hrs). The 
cells were washed, lysed in 1% TritonX-100 lysis detergent and cytoplasmic fraction 
resolved in 10-12.5% SDS-PAGE on a 6% sacking gel, then transferred onto PVDF 
membrane and blocked with 10% skim milk/PBST (RT, 1hr) and blotted with anti-IE1, anti-
M78 and anti-MCMV in 5% skim milk/PBST (4oC, 18 hrs). The membrane was then 
washed and incubated in 5%skim milk/PBST containing IRDye® 800CW goat-anti-rabbit 
or rabbit anti-rat or IRDye® 680 CW goat anti-mouse (4oC, 1 hr). Membrane bands were 
detected using LI-COR odyssey infrared imager. 75-90 kDa bands were observed with 
anti-IE1 for both viruses, 50-90 KDa bands in WT with anti-M78 and 40-160 kDa for both 
viruses with anti-MCMV. Data are representative of 2 independent experiments.  
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4.1.5 Kinetics of MHC II downregulation and degradation 
To determine when MHC II downregulation occurred, RAW-C2TA cells were left 
uninfected or infected with MCMV WT MOI 1 or 10. MHC II expression was then monitored 
over a course of 24 hrs.  Anti-MCMV sera was used to detect infected cells. MHC II 
expression was found to be altered as early as 6 hrs post infection particularly at MOI 10 in 
which MHC II clustered in the form of vesicles compared to uninfected cells (Fig. 4.6a). 
This was gradually lost as infection progressed. By 24 hrs, most infected cells completely 
lost MHC II expression regardless of MOI used compared to uninfected cells (Fig. 4.6a). 
To understand how MCMV downregulated MHC II, RAW-C2TA cells were incubated with 
MHC II- M5/114 and a monoclonal rat anti-mouse MHC II- IBL-5/22 to label surface MHC 
II. The cells were then infected with WT or M78- GFP by centrifugation. After 2 hrs, 
unbound virions and excess labelling antibody were washed in PBS. The cells were then 
incubated for a further 18 hrs before surface labelled MHC II was detected using a rat 
monoclonal secondary antibody Alexa Fluor 647. The results show that surface labelled 
WT GFP+ but not M78- infected cells lost MHC II expression (Fig. 4.6b). However, this 
difference was not significant (Fig. 4.6d, p>0.05).  
4.1.6 Bafilomycin prevents MHC II endocytosis. 
To determine whether inhibiting lysosomal acidification early during infection affects MHC 
II downregulation, RAW C2TA cells were infected with WT or M78- GFP by centrifugation. 
After 2 hrs, unbound virions were washed and fresh medium bafilomycin was added. 
Controls had normal medium. After 6 or 24 hrs, surface MHC II was analysed. MHC II was 
unaltered at 6 hrs post infection (Fig. 4.6c). However, after 24 hrs, WT but not M78- 
downregulated surface MHC II (Fig. 4.6c). This was inhibited in the presence of 
bafilomycin.  
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Fig. 4. 6. MHC II downregulation is dose dependent and occurs as early as 6 hours 
p.i. 
a) RAW-C2TA cells were left uninfected or infected with MCMV WT (MOI 1 or 10, for 6, 12 
or 24 hrs). The cells were then fixed, permeablised and blocked in 2%NGS/PBS (RT, 1 
hr). MHC II was stained using rat anti-MHC II- M5/114 and lytic antigens using rabbit anti-
MCMV (4oC,18 hr) and detected using Alexa Fluor goat anti-rat 594, Alexa Fluor goat anti-
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rabbit 488 and DAPI to stain the nucleus (RT, 1 hr). The cells were visualised on confocal 
microscope at 40X magnification. Arrows show MHC II in vesicles or complete lost from 
the surface of infected cells. b) RAW-C2TA cells as in A were saturated with 10 µg/ml or 3 
µg/ml MHC II M5/114 or IBL-5/22 antibody. Control cells were left untreated. The cells 
were then infected with WT or M78- GFP by centrifugation (536 x g for 30 minutes). 
Infection was left to proceed for 2 hrs at 37oC and unbound virions and unlabelled antibody 
washed. After 18 hrs, surface labelled MHC II was directly detected with Alexa Fluor goat 
anti-rat 647 in 2%FCS/PBS (4oC, 1 hr). WT but not M78 GFP+ cells lost surface labelled 
MHC II and was independent of MHC II antibody used but not to significant levels. c) 
RAW-C2TA cells were infected with WT and M78- GFP by centrifugation (536 x g for 30 
minutes). Infection was left to proceed at 37oC for 2 hrs. Fresh medium supplemented with 
or without 20 nM bafilomycin added. After 6 or 24 hrs, MHC II was directly detected with 
Alexa Fluor 647 rat anti-MHC II (M5/114) (4oC, 1hr). At 6 hrs, MHC II expression was 
unaltered. By 24 hrs, WT but not M78 GFP+ cells downregulated MHC II and this was 
inhibited by bafilomycin. Data are representative of 2 independent experiments.  
 
4.1.7 Characterising thioglycollate stimulated peritoneal macrophage cells 
BALB/c or C57BL/6 mice were injected i.p with thioglycollate and after 96 hrs, mice were 
sacrificed and cells from the peritoneum cavity harvested and left to adhere at 37oC 
5%CO2 for 4 hrs. The cells were then characterised by flow cytometry analysis. A tight 
gate was drawn on macrophage cells based on their FSC-A vs SSC-A profile (Fig. 4.7a).   
Adherent (enriched) and non-adherent (unenriched) cells were F4/80+CD11b+CD19- and 
expressed MHC IIhigh/low. 
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Fig. 4. 7. Characterising thioglycollate stimulated peritoneal macrophages.  
C57BL/6 IA (+/-) mice were injected i.p with thioglycollate. After 96 hrs, peritoneal cells 
were harvested, left to adhere and characterised by flow cytometry. The cells were 
incubated in 2%FCS/PBS (4oC, 1 hr), with PE rat anti-mouse CD11b (M1/70) and Alexa 
Fluor 647 rat anti-mouse CD19 (ID3) and single stain with rat anti-MHC II (M5//14) and rat 
anti-F4/80 (3C137) (4oC, 1 hr). The cells were then stained with Alexa Fluor 647 goat anti-
rat (4oC, 1 hr). Expression markers were detected on BD Accurri C6 flow cytometer. Data 
was analysed on weasel. Quadrants show percentages. Data is representative of 2 
independent experiments.  
4.1.8 M78 c-terminal domain is dispensable for MHC II degradation 
The C-terminus of M78 was critical for rapid constitutive endocytosis of M78 and CCR5 
(162, 186). To determine whether the C-terminus was required for MHC II downregulation, 
the C-terminal mutant lacking 155 amino acids from the C-terminus with an HA tag to the 
N-terminus of M78 (HAM78 cΔ155) was tested. Hemagglutinin expression was confirmed 
by western blot and immunostaining (Fig. 4.8a, b). This virus downregulated MHC II just 
like HAM78, a WT MCMV with an HA tag to the N-terminus of M78 by microscopy (Fig. 
4.8c). IE1+ cells either lost or re-localised MHC II in vesicles. This was also associated with 
strong or weak IE1 expression as previously observed. Flow cytometry analysis further 
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showed the C-terminal mutant downregulated and degraded MHC II as WT based on 
surface (non-permeablised) and total MHC II (permeablised) expression while M78 
retained expression (Fig. 4.8d). This showed a region upstream of M78 was required to 
downregulate and degrade MHC II.  
 
 
Fig. 4. 8. M78 C-terminus is dispensable for downregulation of MHC II. 
a) RAW-C2TA cells were uninfected or infected with WT, HAM78 and HAM78 cΔ155 (MOI 
1, 48 hrs). The cells were then fixed, permeablised and blocked in 2%NGS/PBS (RT, 1hr). 
HA was detected using rabbit anti-HA (4oC, 1 hr) and visualised with Alexa Fluor goat anti-
rabbit 488 and DAPI (RT, 1 hr). The cells were imaged at 63X objective on a laser 
confocal microscope. Arrows show HA expressing cells. Images are representative of 2 
169 
 
independent experiments. b) RAW-C2TA cells infected as in a were left for 72 hrs. Cell 
lysate were diluted in 3X Laemmli buffer and resolved by SDS-PAGE and were analysed 
by immunoblotting with anti-HA or anti-tubulin and detected with IRDye® 800CW goat-anti-
rabbit or rabbit anti-rat. With anti-HA, 37-75 kDa bands were observed in HAM78 cΔ155 
and a 50 KDa bands for HAM78, none for WT or UNI controls. Western blots are 
representative of 3 independent experiments. c) RAW-C2TA cells infected were uninfected 
or infected with HAM78, HAM78 cΔ155 and M78- virus by centrifugation (MOI 1, 48 hrs). 
The cells were fixed, permeablised and blocked in 2%NGS/PBS (RT, 1hr). MHC II was 
detected using rat anti-MHC II M5/114 in combination with mouse anti-IE1 using 
CHROMA101 (4oC, 18 hrs), then with Alexa Fluor goat anti-rat 594, Alexa Fluor goat anti-
mouse 488 and DAPI (RT, 1 hr). The cells were imaged at 63X on a laser confocal 
microscope. Arrows show IE1+ cells positive for MHC II in M78- cells but not HAM78 or 
HAM78 cΔ155. d) Cells infected as in c were stained for surface (non-permeablised) or 
total (permeablised) MHC II using rat anti-MHC II-M5/114 Alexa Fluor 647. Infected cells 
were detected by intracellular staining for IE1 and detected with Alexa Fluor goat anti-
mouse 488. Cells were then analysed on BD accuri6 flow cytometer and 30,000 events 
collected on gated live cells. Data was analysed on weasel and percentages shown in 
quadrants. IE1+ cells on the lower right quadrants show MHC II was downregulated or 
degraded in HAM78, HAM78 cΔ155 but not M78- virus infected cells. Data are 
representative of 2 independent experiments.  
4.1.9 Generating M78 expressing BALB/c-3T3-C2TA and RAW-C2TA cells 
M78 full protein but not the C-terminal mutant was found to be critical for downregulation of 
MHC II. To determine whether the full-length protein alone was sufficient, two independent 
M78 clones were generated. One was amplified from MCMV K181 viral DNA and the other 
from B53 HAM78 expressing plasmid. The primers were flanked by restriction enzymes 
EcoRI (sense strand) and BgIII (anti-sense) for cloning. M78 was amplified using Q5 and 
Taq DNA polymerase and 1.4kb bands were detected on a 1% agarose gel (Fig. 4.9a). 
The Q5 amplified PCR products were digested with BgIII, PCR purified and then digested 
with EcoRI. The retrovirus expression vector was digested with EcoRI-HF and BamHI-HF. 
Competent DH5α E.coli cells were then transformed using heat shock, left to recover at 
37oC and grown in ampicillin-enriched media. Four independent clones were then cultured 
and miniprep DNA extracted. M78 insertion was confirmed in all clones amplified from 
170 
 
plasmid DNA and two from K181 viral DNA based on EcoRI and XhoI digest (Fig. 4.9c). All 
clones had the 1.2 kb M78 band.  
 
Fig. 4. 9. Amplification of M78 from K181 viral DNA and HAM78 plasmid. 
a) M78 was amplified using Q5 and Taq DNA polymerases from MCMV K181 viral DNA or 
B53 HAM78 plasmid. Arrow show 1.4kb band on a 1% agarose gel. b) Insertion of M78 
into the puromycin-expressing vector was confirmed by EcoRI and XhoI double digest of 
miniprep plasmid DNA extracted from four individual colonies in c. All colonies from 
plasmid M78 1-4 showed 1.2kb band while clone 3 and 4 from K181 viral DNA were 
positive. Arrow in c shows positive clones used to generate M78 expressing cell lines. 
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To generate stable M78 expressing BALB/c-3T3-C2TA and RAW-C2TA cells, 293T cells 
were transfected using Optimum-transfect lipid with retroviral packing plasmids PVSVG 
and PC143N and M78 clone 4 (M78 1), or independent M78 clone 2 (M78 2) or an empty 
vector as control. After 48 hrs, supernatants from transfected 293T cells were filtered 
through a 0.45 µM filter and diluted in medium containing 10 µg/ml polypyrene to enhance 
virion attachment. This process was repeated at 72 hrs post transfection. The cells were 
then selected in medium containing puromycin. Resistant cells were fixed, permeablised 
and stained for M78 using anti-M78 sera. M78 1 and independent M78 2 expressed M78. 
M78 expression in RAW-C2TA and its redistribution of surface MHC II is described in the 
publication. In BALB/c-3T3-C2TA, M78 expression had no effect on surface MHC II by flow 
cytometry (Fig. 4.10). Immunostaining, showed M78 and MHC II co-localised in vesicles 
similar to infected cells (Fig. 4.10b). As previously observed in RAW-C2TA cells, M78 
staining in BALB/c-3T3-C2TA was also variable despite puromycin resistance (Fig. 4.10b). 
The colocalisation of MHC II with M78 shows that M78 might interact with newly 
synthesised MHC II in fibroblasts before surface localisation while in macrophages M78 
redistributes surface MHC II in vesicles. 
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Fig. 4. 10. M78 localises with MHC II in the cytoplasm of BALB/c-3T3-C2TA. 
a) Untransduced and transduced BALB/c-3T3-C2TA with vector only, M78 1 or M78 2 
were directly stained for MHC II using Alexa Fluor 647 rat anti-MHC II (M5/114) (4oC, 1hr) 
in combination with rat anti-mouse CD16/CD32 Fc block. The cells were analysed on BD 
Accurr6 flow cytometry and histogram generated on weasel. Solid green line shows 
transduced cells with vector only and dark dashed line M78 2 and dark dotted line M78 2. 
Data are representative of 3 independent experiments. b) Cells in a were fixed, 
permeablised, blocked in 2%NGS/PBS (RT, 1hr) and stained for MHC II (rat anti-MHC II- 
M5/114) and M78 (rabbit anti- M78) (4oC, 1 hr) and detected using Alexa Fluor goat anti-
rat 594 and Alexa Fluor goat anti-rabbit 488 (4oC, 1hr). DAPI stained nucleus. WT Infected 
BALB/c-3T3 (MOI 0.3, 18 hrs) was used as control. The cells were visualised on confocal 
microscope at 63X magnification. Arrows show MHC II in M78 positive cells. Images are 
representative of 3 independent experiments.  
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4.1.10 Can complementing M78- virus downregulate MHC II? 
M78 expressing RAW-C2TA and untransduced RAW-C2TA cells were infected with WT 
and M78- GFP. Flow cytometry analysis showed GFP+ WT infected cells downregulated 
MHC II while M78- retained expression in untransduced RAW-C2TA (Fig. 4.11b) and in 
M78 transduced RAW-C2TA (Fig. 4.11d). This was also observed by microscopy (Fig. 
4.11a-c). As expected both viruses downregulated MHC I but not CD44 in both cell lines 
(Fig. 4.11b-d).   
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Fig. 4. 11. M78 expressing RAW-C2TA fail to complement M78- virus. 
RAW-C2TA cells were infected with WT or M78- GFP by centrifugation (MOI 1, 48 hrs). The cells 
were fixed, permeablised and stained for MHC II (rat anti-MHC II) and M78 (rabbit anti-M78) and 
detected using Alexa Fluor goat anti-rat 647 and Alexa Fluor goat anti-rabbit 594. DAPI stained 
nucleus. Arrows show GFP+ cells in WT and M78- infected cells. M78 is expressed in WT but not 
M78- infected cells except in M78 expressing cells. MHC II is lost in GFP+ WT but not M78- virus in 
both cell lines. b) RAW-C2TA cells infected as in a were incubated in Fc block in combination with 
Alexa Fluor 647 rat anti-MHC II (M5/114) (4oC, 1 hr). MHC I and CD44 was stained using biotin 
mouse anti-MHC I (H-2D (d) (34-2-12) and biotin anti-CD44 (IM7) (4oC, 1 hr) and detected with 
streptavidin PerCP Cy5.5 (4oC, 1 hr). Expression was detected using BD Accurri C6 flow cytometer 
on 30,000 events gated on live cells. Data was visualised and analysed on weasel. Quadrants 
show percentages. GFP+ cells on the lower right quadrant show loss of surface MHC II in WT but 
not M78-. MHC I and CD44 expression were comparable between viruses. Data are representative 
of 3 independent experiments.  
4.1.11 Other candidate genes involved in MHC II downregulation 
Having shown that M78 alone was not sufficient for MHC II downregulation in transduced 
cell lines, other candidates were tested; gL-, gO-, M131- and M33-. All mutants analysed 
downregulated MHC II but not CD44 (Fig. 4.12a, b). gO- and gL- infected cells showed 
complete loss of MHC II expression. M78 expression and localisation was relatively similar 
between mutants and WT, that is, localised intracellular and in perinuclear regions in 
vesicles (186) (Fig. 4.12c). This showed that, absence of gL, gO or M131 had no effect on 
the localisation of M78 at least by microscopy. In summary, M78 requires an unknown 
gene to degrade MHC II.  
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Fig. 4. 12. MCMV glycoprotein mutants downregulate MHC II. 
RAW-C2TA cells were infected (MOI 1, 48 hrs) with β-gal expressing WT, M131-, M33-, 
gO- and gL- by centrifugation (536 x g for 30 minutes). The cells were fixed, permeablised 
and stained for MHC II (rat anti-MHC II-M5/114), CD44 (rat antii-CD44 IM7) and β-gal 
(chicken anti-β-gal) and detected using Alexa Fluor goat anti-rat 594 and Alexa Fluor goat 
anti-chicken 488. DAPI stained nucleus. The cells were visualised on confocal microscope 
at 63X magnification. Arrows show β-gal+ cells expressing MHC II or CD44. b) Percentage 
of β-gal+ cells expressing MHC II or CD44. Uninfected cells were used as controls. c) 
RAW-C2TA cells infected in as a were stained with rat anti-MHC II-M5/114 and rabbit anti-
M78 and detected using Alexa Fluor goat anti-mouse 594 and Alexa Fluor goat anti-rabbit 
488. DAPI stained nucleus. Cells were visualised as a. Arrows show M78 in perinuclear or 
intracellular areas, comparable in all infected cells. Images are representative of 2 
independent experiments.  
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4.2 In vivo 
4.2.1 M78 infects primary lung cells as WT and retains MHC II expression 
To determine whether M78- was impaired in infecting primary cells in vivo, 
immunocompetent BALB/c mice were infected via the i.n route with WT and M78-. 
CHROMA101 staining for IE1 or anti-MCMV for lytic antigens detected infection and cell 
markers for resident macrophage, dendritic cells and type II alveolar epithelial cells, cell 
tropism. At day 1, 3 and 5, WT and M78- infected similar cell types based on IE1+ cells 
(Fig. 4.13 a-c). 
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Fig. 4. 13. M78- and WT infect similar cell types in BALB/c lung. 
BALB/c were given WT or M78- (3x104 p.f.u/30µL) i.n under anaesthesia. After 1 (a), 3 (b), 
and 5 (c) days p.i, lungs were stained with mouse anti-IE1 to identify infected cells and 
MHC II, macrophage cells (CD206, CD68, CD169), dendritic cells (CD11c) and type II 
alveolar epithelial cells (SPC). Nuclei were stained with DAPI. Ear bar graph represents 
percentage of IE1+ cells per field of view at 40X.  
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4.2.2 M78 targets MHC II expression in CD11c+ cells  
In the lungs, MHC II is expressed constitutively by type II alveolar epithelial cells (187-
189). Naïve BALB/c lung stained for MHC II in combination with markers for CD11c and 
SPC showed MHC II in predominately SPC cells and a proportion of CD11c cells (Fig. 
4.11a-b). Lytic antigen staining of day 3 lung revealed WT but not M78- infected CD11c 
lost MHC II expression (Fig. 4.14c-d).  
 
 
Fig. 4. 14. MCMV targets CD11c+ cells in the lung. 
Naïve BALB/c lungs were stained for MHC II in combination with CD11c in a or SPC in b. 
Arrows show MHC II expressing CD11c+ and SPC+ cells. c) Day 3 BALB/c lungs in Fig. 
4.13 were stained with anti-MCMV sera to lytic antigens in combination with CD11c and 
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MHC II. Arrows show MHC II-CD11c+ lytic antigen+ cells in WT but not M78- infected lung 
shown in d. 
4.2.3 Inhibiting IFN-γ partially rescues M78- salivary gland defect 
IFN-γ is known to restrict MCMV salivary gland infection. To determine whether anti-IFN-γ 
would rescue M78- salivary gland defect, BALB/c were either left untreated or depleted of 
CD4+ T cells as previously described or by i.p injection with anti-IFN-γ at the time of 
infection via the intranasal route with WT and M78-  and every 48 hrs after infection until 
the experiment was terminated at day 15. In the lungs, M78- virus titer was significantly 
lower than WT in CD4+ depleted and anti-IFN-γ treated mice (Fig. 4.15a). CD4+ T loss or 
anti-IFN-γ treatment had no effect on WT or M78- lung infection suggesting lung infection 
control is independent of CD4+ T cell and IFN-γ (Fig. 4.15a). In the salivary glands, M78- 
salivary gland defect in undepleted control mice was significantly greater than CD4+ 
depleted and anti-IFN-γ treated mice (Fig. 4.15a). This was also observed by QPCR (Fig. 
4.15b). However, M78- salivary gland replication failed to reach WT levels (Fig. 4.15a,b). 
Thus, the results show that MCMV can evade CD4+ T cells and IFN-γ response to colonise 
the salivary gland which is partially rescued by M78 deletion. 
 
 
Fig. 4. 15. Anti-IFN-γ treatment partially rescues M78- salivary gland defect. 
a, b) BALB/c mice were depleted of CD4+ T cells or treated with anti-IFN-γ or left untreated 
and infected i.n with 3x104 p.f.u/30µL WT or M78- under anaesthesia. After 15 days, 
infectious virus in the lungs and salivary glands was determined. Symbols show individual 
180 
 
titers per mice and error bars show difference in mean values (n=5 per group). b)  Viral 
load in the salivary of untreated, anti-IFN-γ treated and CD4+ T cell depleted mice was 
determined by QPCR. Symbols represent viral genome copies for individual mice 
normalised to cellular copy number for each sample. Error bars show difference in mean 
values (n=5 per group). Data were analysed by unpaired 2-tailed student t-test with 
Bonferroni-Dunn post-test. CD4+ T cell depletion and anti-IFN-γ treatment rescued M78- 
salivary gland defect but had no effect on the lungs. 
4.2.4 M78- virus dissemination is restricted by CD4+ T cells after i.p infection 
M78- given i.p showed reduced liver, spleen and salivary gland infection (190) 
demonstrating that, events downstream of salivary glands could restrict salivary gland 
colonisation. To test this hypothesis, WT and M78- was given i.p to immunocompetent 
(IA+/-) and immunodeficient MHC II- (IA-/-) mice that lack classic CD4+ T cells (Fig. 4.16a). 
M78- salivary gland defect in IA+/- mice was significantly rescued in IA-/- but not to WT 
levels (Fig. 4.16b). Interestingly, WT salivary gland titers in IA-/- was significantly greater 
than in IA+/- mice (Fig. 4.16b). This suggests that CD4+ T cells restrict salivary gland 
infection in an organ upstream of the salivary glands. Surprisingly, both WT and M78- were 
undetectable in the liver and spleen of IA+/- and -/- mice by plaque assay (data not shown), 
suggesting infection was cleared.  
4.2.5 M78 C-terminus is critical for virus dissemination 
M78 C-terminus was previously shown to be necessary for MCMV dissemination in 
immunocompetent C57BL/6 mice (162). To determine whether the C-terminal mutant of 
M78 would be rescued by CD4+ T cell loss, IA+/- and IA-/- mice were infected via the i.n 
route with WT, M78- and the C-terminal mutant (M78 ∆ c155). M78 ∆c155 was 
undetectable in the lungs or salivary glands of IA+/- and IA-/- mice compared to WT (Fig. 
4.16c). Again, M78- salivary defect in IA+/- was significantly rescued in IA-/- (Fig. 4.16c). WT 
salivary gland titer was no different between IA+/- and IA-/- mice, again confirming that M78 
was necessary for this effect. In the lung, M78- titers were slightly higher in IA-/- than IA+/- 
mice but not to significant levels compared to WT (Fig. 4.16c). This result confirms that, 
M78 is not only required for infection and virus dissemination to the salivary gland as 
previously described (162) but also for evading CD4+ T cells.  
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Fig. 4. 16. M78 C-terminus is critical for virus dissemination. 
a) C57BL/6 (IA+/-) and MHC II- (IA-/-) mice were tail bled and lymphocytes were directly 
stained for CD4 using FITC rat anti-mouse CD4 clone GK1.5 and PE rat anti-mouse CD8β 
in the presence of mouse Fc receptor block rat anti-mouse CD16/CD32 clone 2.4G2 
(4oC,1 hr). The cells were washed and analysed on BD Accurri C6 flow cytometer. b) 
C57BL/6 (IA+/-) and MHC II- (IA-/-) mice infected i.p with 3x104 p.f.u/100µL WT or M78- b or 
i.n c with 3x104 p.f.u/30µL WT, M78- or M78 cΔ155 under anaesthesia. After 10 days, 
infectious virus in the lungs and salivary glands was determined. Symbols show individual 
titers per mice and error bars show difference in mean values (n=5 per group). Data were 
analysed using unpaired 2-tailed student t-test. M78- salivary gland defect in IA+/- was 
significantly rescued in IA-/- mice. M78 C-terminal mutant M78 cΔ155 failed to replicate in 
the lungs and spread to the salivary glands in IA+/- or IA-/- mice.  
 
182 
 
4.3 Discussion 
In vitro, M78- replicated slightly less than WT at low MOI in MHC II+/+ and MHC II-/- RAW 
264.7 macrophage cells. This was restored at high MOI, suggesting M78 is required for 
efficient infection of macrophage cells upon entry. This was shown in a single step 
replication kinetics, when centrifugation improved virion attachment to the cell membrane 
and enhanced M78- virus infection. It would be interesting to determine whether 
centrifugation makes a significant difference to initial infection, as it is somewhat artificial. 
As previously shown, M78- virus  had no replication defect in fibroblasts cells but replicated 
slightly less than WT in epithelial cells (162). This suggests M78 could have an epithelial 
infection defect. In vivo, the first target cells in the lungs are resident macrophage, 
infiltrating dendritic cells (166) which are less lytic and type II alveolar epithelial cells that 
support lytic virus replication (191). M78- virus readily infected these cells as WT at day 1, 
3 and 5 by IE1 staining. The virus also replicated to WT levels by plaque assay and by 
QPCR at day 3, 5 and 7. This suggests epithelial infection, as macrophages are less lytic 
and not productive. Thus, M78- replication defect in epithelial cells in vitro should be 
interpreted with caution as both WT and M78- infected less SPC cells in the lung and 
replicated to similar levels.  
MCMV degradation of MHC II was not strain specific and the C-terminus of M78 was 
dispensable. M78 expressed alone in MHC II expressing cell lines relocalised MHC II to 
endosomes but was not sufficient for its degradation, implying a co-factor or another viral 
gene. In vitro, direct antigen presentation using ovalbumin as model antigen restricted but 
did not impair CD4+ T cell response. A lack of recombinant M78- virus to directly quantity 
how MHC II degradation impairs CD4+ T cell response in the context of endogenous 
presentation limits the scope of interpretation.  
Anti-IFN-γ partially rescued M78- salivary gland defect. This suggests that anti-IFN-γ 
function could be independent of M78 CD4+ T cell function and may restrict M78- virus 
trafficking or spread. Where and how IFN-γ restricts M78- infected cells to spread is 
unknown. Nevertheless, M78 appears to be a multi-functional protein that targets different 
aspects of the host immune response to evade surveillance and disseminate virus. 
Unlocking the M78 regions contributing to these different functions could be key to 
developing an anti-viral therapy. 
 
183 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5: USING ORF73-DEFICIENT, OVALBUMIN+ MHV-68, TO TRACK 
ANTIGEN-SPECIFIC CD4+ T CELLS IN AN ESTABLISHED PROTECTION MODEL 
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5.1 Introduction 
Gamma-herpesviruses establish latency, predominately in B cells (150, 192-194). 
However, epithelial, dendritic and macrophage cells can also harbour the virus (118, 119, 
195, 196). During latency when no preformed infectious virus is detected, gamma-
herpesviruses maintain their genome as circularised, extrachromosomal 
episomes/plasmids (197-200). This unresponsive or dormant state is critical for immune 
evasion, as gene expression is regulated during replication, persistence and reactivation 
from latency (149, 153). EBV, encodes two proteins crucial to maintaining latency; latent 
origin of replication oriP, a cis acting protein and EBV nuclear antigen 1 (EBNA-1) a trans-
acting gene. The dyad domains of oirP bind and interact with the host cell mitotic 
chromosomes and chromatin (201, 202). This allows EBV DNA to replicate as an 
extrachromosomal plasmid and segregate in infected cells during cell division (203, 204). 
A similar mechanism was shown for bovine papilloma virus proteins E1 and E2 (205). 
Kaposi’s sarcoma herpesvirus virus (KSHV), herpesvirus saimiri (HVS) and MHV-68, 
members of the gamma-2-hepesvirus subfamily encode a conserved ORF73, a latency 
associated nuclear antigen (LANA) with similar function but limited sequence similarity to 
EBNA-1 (206-208).  
KSHV LANA, is a 1162 amino acid protein that has been extensively studied. Like EBNA-
1, it interacts with virus origin of replication (209) and terminal repeats in the viral genome 
via its C-terminal domain (210, 211). The N-terminal domain is thought to facilitate docking 
onto mitotic chromosomes by binding nucleosomes through histones H2A and H2B (212). 
This is hypothesised to enable KSHV replication and episome maintenance by tethering 
the KHSV DNA to host chromosomes (213). Thus, during cell division the viral genome is 
equally partitioned to each daughter cell in dividing latently infected cells (213). MHV-68 
ORF73, a 368 amino acid protein also functions similarly to LANA (213), a common 
strategy utilised by all gamma-herpesviruses to persist in infected mammalian cells (214). 
How the latency associated viral proteins encoded by gamma-herpesviruses affect CD4+ T 
cell responses is not clear.  
In KSHV, LANA interferes with CD4+ T cell responses by hindering MHC II expression in 
infected cells, via multiple mechanisms, to restrict antigen presentation. MHC II expression 
is controlled by the key regulator of MHC II transcription, the class II transactivator (C2TA) 
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(215). C2TA interacts with cell type specific promoters to drive MHC II expression in a cell 
type specific manner. Promoters I (PI) is active in macrophage and dendritic cells, PIII acts 
on B cells and PIV is inducible by IFN-γ (215, 216). In vitro assays demonstrate that LANA 
can interact with IRF-4 to suppress MHC II in primary effusion lymphoma (PEL) cells by 
binding to PIII and PIV C2TA promoters (217, 218). LANA can also bind to the MHC II 
enhanceosome that consists of cyclic AMP response element-binding protein (CREB) and 
nuclear factor Y (NF-Y) complex and regulatory factor X (RFX) complex proteins to restrict 
C2TA recruitment to the MHC II promoters (219, 220). As a result, infected cells are 
unable to present viral antigens to CD4+ T cells, making them invisible to target. This is 
hypothesised to allow virus escape from immune surveillance and colonise the host. 
Whether this happens in vivo is unknown.   
Unlike KSHV, MHV-68 does not interfere with MHC II expression in antigen presenting 
cells. Instead, ORF73 mediates the transcription of genes associated with the lytic and 
latent cycles during infection. ORF73 is transcribed as an immediate early transcript (221) 
and also during latency (151). This suggests ORF73 can regulate viral gene expression 
early to evade immune response, or prevent expression of certain latent proteins or host 
cell stress response elements (148). In vitro, ORF73 mutants show replication defects in 
fibroblasts (NHI 3T3 and MEFs), albeit at later times during replication (148, 222). In vivo, 
ORF73 mutants show lytic replication defect in the lung following intranasal infection and 
severe attenuation in the spleen (149, 152). How ORF73 modulates CD4+ T cell response 
during infection is not well characterised. Adoptive transfer of gp150 specific CD4+ T cells 
showed expansion and contraction of CD4+ T cells as infection progressed from lytic to 
latent. This occurred independent of lytic (ORF73 mutants) or persistent (wild type) 
infection (223). However, the assay was limited by measuring cell numbers and frequency 
of proliferation rather than virus load to determine whether absence of ORF73 affected 
CD4+ T cell response.  
In a study by Smith et al., 2006, cytoplasmic ovalbumin expressed in tandem with ORF73 
failed to stimulate CD4+ T cells specific for OVA323-339 peptide in BALB/c mice (160). 
Improving presentation of the OVA323-339 had no effect on latency either in BALB/c or 
C57BL/6 mice. The authors found that secreted cytoplasmic OVA expressed under the 
control of ORF73 stimulated CD8+ T cells in C57BL/6 mice but not CD4+ T cells in BALB/c 
mice (160). The authors reasoned that latent antigen specific CD4+ T cells in BALB/c mice 
were either unable to recognise infected cells or lacked the effector functions required for 
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control, despite killing of MHC II+ cells pulsed with OVA323-339 peptide in vitro. It is possible 
that OVA323-339 peptide expression driven by ORF73 during infection is below the threshold 
of detection by CD4+ T cells. Thus, the small subset of primed CD4+ T cells have no 
cytolytic activity against latently infected B cells or myeloid cells.  
To study how a latency defect affects CD4+ T cell response, a trackable animal model 
using MHV-68 that lacks functional ORF73 expressing soluble cytoplasmic ovalbumin was 
constructed. Ovalbumin expression was driven by the lytic M3 promoter. The rational was 
to track CD4+ T cell responses to MHV-68 during lytic infection and analyse the activation 
and proliferation profile of OVA323-339-specific CD4+ T cells. It was hypothesised that, in the 
absence of ORF73, CD4+ T cells will be sensitised to recognise lytically infected cells and 
control lytic and latent infection.  
Aim 
The aim of this thesis chapter is to describe the process of making an ORF73 deletion 
mutant expressing cytoplasmic ovalbumin. The overall aim is to use this ORF73-deficient, 
ovalbumin+ MHV-68, to track antigen-specific CD4+ T cells in an established protection 
model. 
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5.2 Results 
5.2.1 Diagnosing the presence of ovalbumin in the psk pA sOVA M3 shuttle vector 
To determine the presence of ovalbumin in the psk pA sOVA M3 shuttle vector previously 
used to generate MHV-68 recombinant OVA+ viruses (160, 173), competent DH5α E.coli 
cells were transformed with the shuttle vector and cultured in agar and LB broth containing 
Kan and Cam. To check for sucrose sensitivity, transformed bacteria were plated on 
sucrose agar. No colonies were observed on either Cam or sucrose agar plates (data not 
shown) confirming the absence of Cam gene and the presence of SacB, a marker for 
negative selection in the shuttle vector. Plasmid DNA extracted from the 6 clones grown 
on Kan enriched LB broth was digested with EcoRI and a 1.6Kb band was detected on a 
1% agarose gel (Fig. 5.1a), consistent with previous observations. 
5.2.2 Transformation of BAC+ Δ73 mutant DH10B E.coli 
Competent BAC+ Δ73 mutant DH10B E.coli (149) was transformed with plasmid DNA 
(clone 5) and cultured in CamR and KanR agar at 30oC to allow homologous 
recombination. Positive clones were plated onto Kan or Cam and Kan agar plates and 
incubated at 42oC to select for BAC co-integrate. The colonies were then replated on Cam 
agar and incubated at 37oC to allow for the segregation of co-integrate colonies into either 
wild type (no ovalbumin) or recombinant. To select for co-integrates, the bacteria were 
plated onto sucrose supplemented with Cam and incubated at 30oC. 24 single colonies 
were then plated onto Cam and Kan agar and Cam LB broth. DNA was extracted from 12 
randomly selected individual colonies and screened for the presence of ovalbumin and 
ORF73 deletion mutation by restriction digest.  
5.2.3 Confirmation of BAC+ Δ73 sOVA by restriction digest 
EcoRI digest showed a 7.4Kb band (Fig. 5.1b-white arrow) present in all clones. This is a 
BAC cassette that encodes the eGFP marker (positive selection) and the two loxP sites 
(Fig. 5.1b- white arrow) as previously described (155). Incorporation of psk pA sOVA M3 
into the BAC during homologous recombination introduced a new EcoRI site which led to a 
loss of 15.7kb band (Fig. 5.1b-yellow arrow) and a gain of 12.9kb band (Fig. 5.1b-red 
arrow) in BAC+ Δ73 mutants’ clones 6, 13 and 24 and in WT clones 2, 11, 21 or 23 (Fig. 
5.1b). The 18kb band observed in clones 7 and 20 is the result of fusion of the terminal 
repeats during replication in the BAC+ Δ73 DH10B E.coli (Fig. 5.1b). An end repair during 
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BAC+ Δ73 generation led to a loss of a BstEII site at position 11101. This led to a loss of 
4.3kb bands (Fig. 5.1c-red arrow) and a gain of 10.2kb (Fig. 5.1c-yellow arrow) in Δ73 
mutants’ clones 6, 6.4, 6.5, 13, 14 and 24 compared to pHA3 plasmid, which contains 
MHV-68 genome as a BAC. Homologous recombination in the BAC Δ73 DH10B E.coli 
also generated BAC MHV-68 WT clones 2 and 21 that lost the 10.2kb band as pHA3 (Fig. 
5.1c, yellow arrow). Insertion of the 1.6kb psk pA sOVA M3 into the BAC derived Δ73 
mutant led to a gain of 13.8kb (Fig. 5.1c- purple arrow) in clones 6, 6.4, 6.5, and 13, 14 
and 24 except clones 2 and 21. Based on restriction digest analyses clones 6, 6.4 and 6.5, 
13 and 24 were identified as BAC+ Δ73 sOVA mutants. BAC+ Δ73 sOVA clones 6, 13, 14, 
21 and 24 and WT clones 2 and 21 were used for further manipulation.  
 
Fig. 5. 1. Analysis of shuttle vector and diagnosis of BAC+ Δ73 sOVA plasmid DNA.  
a) Plasmid DNA extracted from cultured colonies of psk pA sOVA M3 shuttle vector 
digested with EcoRI. b, c) Plasmid DNA extracted from cultured colonies of BAC+ Δ73 
sOVA were digested with restriction enzymes EcoRI and BstEII and resolved on 1% 
agarose gel. Arrows represent bands in a 1.6kb band represented by white arrow, b) 
EcoRI bands; 7.4kb shown as white arrow represents the BAC cassette, red- 12.9kb band 
in mutants’ clone 6, 13 and 24 and yellow- 15.7kb in wild type clones’ 2, 11, 12, 20, 21, 22 
and 23 due to introduction of new EcoRI site. c) BstEII bands; purple- 13.8kb insertion of 
OVA in clones 6.4, 6.5, 13, 14 and 24; yellow- 12.7kb band in BAC+ Δ73 mutants with 
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OVA insertion, white; 10.2kb in BAC+ Δ73 mutants, red; 5kb and 7.4kb bands internal 
repeat regions.  
5.2.4 Reconstitution of BHK-21 cells 
To reconstitute the BAC, BHK-21 cells were transfected with BAC+ Δ73 sOVA DNA 
extracted from wild type like clones 2 and 21 and mutant clones 6, 13, 14, 21 and 24. The 
cells were then monitored for GFP expression. GFP was found to be expressed in cells 
transfected with clones’ 13, 14 and 24 (data not shown).  Virus stocks were prepared from 
reconstituted BAC+ Δ73 sOVA clones 13 and 14. The presence of the BAC cassette has 
been shown to interfere with virus replication in vivo (157). To remove the BAC cassette, 
NIH-3T3 cells expressing Cre were infected with BAC+ Δ73 sOVA clone 13 and 14. The 
cells were monitored for loss of GFP expression and virus stocks prepared. To validate the 
absence of the BAC, MEFs were infected with BAC+ and BAC- WT and the recombinant 
BAC+ and BAC- Δ73 sOVA clone 13. BAC+ Δ73 sOVA clone 13 infected MEFs expressed 
GFP as wild type while BAC- Δ73 sOVA infected cells did not express GFP similar to BAC- 
WT (Fig. 5.2 a, b). To confirm infection, the BAC+ and BAC- Δ73 sOVA and WT infected 
cells were stained for lytic antigens and visualised by fluorescence. BAC+ viruses were 
GFP as expected and lytic antigen positive while BAC- viruses were GFP negative and 
lytic antigen positive (Fig. 5.2a, b). This confirmed Cre recombinase cleaved one of the 
flanking loxP sites that encodes the eGFP cassette.  
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Fig. 5. 2. Confirmation of BAC cassette cleavage by Cre recombinase. 
a, b) MEFs were infected (MOI 1, 18 hrs) with BAC+ or BAC- WT and Δ73 sOVA mutant. 
The cells were then fixed, permeablised and blocked in 2%NDS/PBS. Lytic antigens were 
stained with rabbit anti-MHV-68 in 2%NDS/PBS and detected with Alexa Fluor 594 donkey 
anti-rabbit IgG (H+L). DAPI was used to stain cell nuclei. Images were acquired using 
Nikon immunofluorescence microscope at 100X objective. Images are representative of 2 
independent experiments. 
5.2.5 Expression of ovalbumin in MHV-68 Δ73 sOVA constructs. 
To confirm OVA expression, MEFs were infected with either BAC+ or BAC- WT or Δ73 
sOVA and other MHV-68 recombinant OVA viruses that lack the BAC cassette as controls. 
Indirect detection for lytic antigens showed positive for lytic antigens in BAC+ and BAC- 
viruses (Fig. 5.3 a, b). Ovalbumin expression was detected in BAC+ and BAC- Δ73 sOVA, 
MHV-68 m3 mOVA and MHV-68 m3 sOVA but not in WT or MHV-68 IiOVA infected cells. 
To validate the IF results, NIH-3T3 cells were infected with BAC- MHV-68 recombinant 
viruses and Δ73 sOVA and analysed for OVA expression using western blot. Ovalbumin 
was detected in both culture medium and cell lysate of cells infected with MHV-68 sOVA 
and Δ73 sOVA but only in the latter in all infected cells except for IiOVA (Fig. 5.3c). This 
suggests that OVA is expressed and retained in the cytoplasm of MHV-68 mOVA infected 
cells and only secreted into the medium in MHV-68 sOVA viruses that retain their signal 
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peptide. The absence of IiOVA OVA detection suggest the antibody is not effective at 
detecting OVA323-339 peptide. 
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Fig. 5. 3. Detection of ovalbumin in Δ73 sOVA. 
a, b) MEFs were infected (MOI 1, 18 hrs) with BAC+ or BAC- WT, MHV-68 OVA 
recombinants and Δ73 sOVA. The cells were fixed, permeablised and blocked in 
2%NDS/PBS and stained with rabbit anti-OVA or rabbit anti-MHV-68. Lytic antigens and 
ovalbumin was detected using Alexa Fluor 594 donkey anti-rabbit and DAPI to stain cell 
nuclei. Images were acquired using Nikon immunofluorescence microscope at 100X 
objective. Images are representative of 3 independent experiments. c) 1x106 3T3 cells 
were left uninfected or infected (MOI 1, 18 hrs) with MHV-68 OVA expressing viruses in 24 
well plates. Cell lysate and culture media were diluted in 3X Laemmli buffer (1:1 ratio), 
boiled for 5 minutes at 95oC and resolved on 10-12% SDS-PAGE gel. The proteins were 
transferred onto methanol activated PDVF membrane, blocked in 10% skim milk/PBST (1 
hr, RT) and blotted using polyclonal rabbit anti-OVA in 5% skim milk/PBST (4oC,18 hrs), 
then washed in 0.1%PBST and detected with IRDye 800CW goat anti-rabbit IgG (H+L) in 
5% skim milk/PBST. A band of 43 KDa was detected. Data are representative of 3 
independent experiments. 
5.2.6 Characterising OVA expression and presentation using a defined CD4+ T cell 
assay. 
I-Ad-restricted, OVA323–339-specific DO11.10 hybridoma cells respond to ovalbumin by 
expressing the OVA323-339-specific T cell receptor (Tcr). This receptor binds OVA323-339 
peptide complex presented on MHC class II (1-Ad/1-Ab) by professional antigen presenting 
cells (pAPCs) (167). To test CD4+ T cell stimulation in the presence of infection and 
confirm presentation of OVA323-339, BALB/c-3T3-C2TA and RAW-C2TA cells were either 
infected with WT or OVA-recombinant MHV-68 or left uninfected in the presence of 
OVA323–339-specific DO11.10 hybridoma cells. Uninfected cells were incubated with ten-
fold serial dilution of OVA323-339 peptide.  
In BALB/c-3T3-C2TA cells, MHV-68 mOVA provided sub-optimal stimulation to CD4+ T 
cells that was significantly lower than 1 µM peptide control (Fig. 5.4a, p<0.05). MHV-68 
sOVA, IiOVA and Δ73 sOVA provided no IL-2 stimulation (Fig. 5.4a). This suggests that in 
fibroblasts, sOVA and IiOVA infected cells are not efficient at processing and presenting 
OVA323-339 to CD4+ T cells to secrete IL-2.  
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The same experiment was repeated in RAW-C2TA. MHV-68 mOVA infected cells, 
provided comparable stimulation to CD4+ T cells as 1 µM peptide control (Fig. 5.4b, 
p>0.05). IiOVA and Δ73 sOVA infected cells provided better stimulation to CD4+ T cells 
than MHV-68 sOVA but were still significantly lower than 1 µM OVA323-339 (Fig. 5.4b, 
p<0.0001). The assay however demonstrated the ability of BALB/c-3T3-C2TA and RAW-
C2TA to present OVA323-339 peptide to I-Ad-restricted, OVA323–339-specific DO11.10 CD4+ T 
cell hybridoma cells. In the context of priming, MHV-68 mOVA and IiOVA viruses provided 
the best stimulation than sOVA viruses in RAW-C2TA. This provides an excellent 
diagnostic tool in combination with immunoblotting or immunofluorescence to confirm 
expression of ovalbumin.  
 
Fig. 5. 4. MHV-68 OVA viruses induce IL-2 secretion. 
a) 3x104 BALB/c-3T3-C2TA cells were either left uninfected or infected (MOI 0.3, 18 hrs) 
with WT or MHV-68 OVA in the presence of 3x104 OVA323-339 peptide CD4+ T cell 
hybridomas. 18 hrs later, supernatants were assayed for IL-2 secretion using ELISA. b) 
3x104 RAW-C2TA cells were either left uninfected or infected (MOI 2, 72 hrs) with WT or 
MHV-68 OVA. 3x104 OVA323-339 peptide CD4+ T cell hybridomas were then added. 
Uninfected cells were incubated in the presence of 10-fold serially diluted OVA323-339. 18 
hrs later, supernatants were assayed for IL-2 secretion using ELISA. Error bars show ± 
SEM from the mean of duplicate cultures from 3 independent experiments. Data was 
analysed using unpaired student 2 tailed t-test (ns, p>0.05; * p<0.05; *** p<0.001, **** 
p<0.0001). 
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5.2.7 Δ73 sOVA is dispensable for replication in vitro 
To determine the growth kinetics of Δ73 sOVA virus, BHK-21 and RAW-C2TA cells were 
infected in suspension with WT or Δ73 sOVA at low MOI 0.01. The production of infectious 
virus was monitored over a course of seven days. At different times post infection, cells 
and supernatants were harvested and stored at -80oC. Virus titer was determined by 
plaque assay on BHK-21 cells. Δ73 sOVA replicated to wild type levels in both cell lines 
(Fig. 5.5a, b). 
 
Fig. 5. 5. In vitro characterization of BAC- Δ73 sOVA. 
a, b) RAW-C2TA and BHK-21 cells were infected with BAC- WT and BAC- Δ73 sOVA at 
MOI 0.01. Cells and supernatants were harvested at different times p.i and virus titer 
determined by plaque assay on BHK-21 cells. Titers at 0 h represent input virus. Results 
are presented as log titer/ml, error bars show difference in mean between duplicate 
infections. Symbols represent virus per time point. Data are representative of 2 
independent experiments. 
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5.2.8 Δ73 sOVA is severely attenuated in lymphoid organs 
To determine whether there was any defect in vivo, 6-8 weeks old BALB/c mice were 
infected via the i.n route with WT or Δ73 sOVA under anaesthesia to determine virus 
replication in the lower respiratory tract. Infectious virus in the lungs was determined by 
plaque assay at seven days post infection. Δ73 sOVA replicated significantly less than wild 
type with a mean titer of 2.22 compared to 4.04 which was statistically significant (Fig. 
5.6a, p<0.001). To determine whether this was consistent across different mice strains, 
adult C57BL/6 mice were then infected via the i.n route with or without anaesthesia with 
the aim of determining replication in the upper and lower respiratory tract respectively.   
In the lower respiratory tract (lungs), Δ73 sOVA also replicated less than wild type with a 
mean titer of 2.38 compared to 4.15 of wild type which was significantly different (Fig. 5.6b, 
p<0.001). This was similar to BALB/c mice. In mediastinal lymph nodes, which drain the 
lungs, no preformed infectious virus was recovered from Δ73 sOVA infected mice 6 days 
p.i compared to WT. This was also observed at day 14 in not only the mediastinal lymph 
node but also the spleen of Δ73 sOVA infected mice (Fig. 5.6b).  
In the upper respiratory tract (nose), Δ73 sOVA also replicated a log less than WT with a 
mean titer of 1.94 to 2.92 (Fig. 5.6c, p<0.05). In superficial cervical lymph nodes, which 
drain the nose, no preformed infectious virus was recovered from Δ73 sOVA infected mice 
7 days p.i compared to WT (Fig. 5.6c, p<0.001). This was also observed at day 18, a 
period of lymphoproliferation in not only the superficial cervical lymph nodes but also the 
spleen of Δ73 sOVA infected mice (Fig. 5.6c, p<0.001). The observed lytic and latency 
replication defect of Δ73 sOVA in the lung and nose of C57BL/6 mice is consistent with 
published results for ORF73 mutation (149, 152). However an OFR73 null virus was found 
to cause latency in the spleen following i.p injection (153). This was in sharp contrast to 
Fowler’s result that showed ORF73 frameshift and ORF73 deletion mutants were both 
impaired in inducing latency in the spleen 14 days post i.p injection. 
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Fig. 5. 6. In vivo characterisation of Δ73 sOVA. 
BALB/c in a and C57BL/6 in b and c mice were infected i.n with 3x104 p.f.u/30µL PBS. At 
different times post infection, infectious virus in the nose and lung was determined by 
plaque assay on BHK-21 cells following a freeze and thaw cycle. Virus in MLN, SCLN and 
SP were detected by infectious centre assay. Each data point represents the mean of six 
animals and error bars show difference in titer between mice. Data was analysed using 
multiple student 2 tail test using Bonferroni-Dunn post-test for multiple comparisons. 
Horizontal dashed line denotes limit of detection. Data are representative of 2 independent 
experiments.  
5.2.9 Δ73 sOVA virus stimulates B and CD4+ T cells in BALB/c mice 
5.2.9.1 Antibody responses 
To determine immune responses to Δ73 sOVA, adult BALB/c mice were infected via the 
i.n route and sera analysed 13 days later by ELISA for MHV-68 and OVA-specific 
antibodies. Mice infected with Δ73 sOVA had predominately IgG responses to MHV-68, 
although it was significantly lower compared to IiOVA, MHV-68 mOVA and sOVA infected 
mice (Fig. 5.7a, p<0.001). IgM was still present at low levels in all infected mice except in 
Δ73 sOVA but not to significant levels (Fig. 5.7a, p>0.05). OVA-specific responses were 
also predominately IgG except in Δ73 sOVA where IgG levels were significantly lower 
compared to sera from mOVA and sOVA infected mice (Fig. 5.7b, p<0.001). IgM to OVA 
was only detected in MHV-68 mOVA infected mice but not to significant levels (Fig. 5.7b, 
p>0.05). Interestingly, no IgM or IgG to OVA was detected in IiOVA infected mice (Fig. 
5.7b). This suggest that, OVA323-339 does not provide a robust antibody response. 
5.2.9.2 CD4+ T IFN-γ responses 
CD4+ T cells isolated from the lungs, cervical lymph nodes and the spleen of MHV-68 
mOVA and IiOVA, mounted robust OVA323-339-specific CD4+ T cell IFN-γ response 13 days 
post infection (Fig. 5.7c). However, CD4+ T cells in sOVA and Δ73 sOVA infected mice 
were unable to secrete IFN-γ upon re-stimulation. This suggests that MHV-68 mOVA and 
IiOVA stimulate strong endogenous OVA323-339 CD4+ T cell responses while the sOVA 
constructs are less effective consistent with published results (160).  
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Fig. 5. 7. Δ73 sOVA induces antibody and IFN-γ in BALB/c mice. 
BALB/c mice were infected i.n with MHV-68 recombinant viruses’ mOVA, sOVA, Δ73 
sOVA and IiOVA at 3x104 p.f.u/30µL PBS. 14 days post infection sera, were analysed for 
virus a and OVA b specific IgM and IgG responses by ELISA. Error bars show difference 
in mean (n=3 per group). Data was analysed using unpaired student 2 tailed t-test (ns, 
p>0.05; * p<0.05; *** p<0.001, **** p<0.0001). c) The frequency of IFN-γ-producing CD4+ 
T cells from pooled L, MLN, SCLN and SP upon stimulation with uninfected splenocytes in 
the presence of 5 µM OVA323-339 was determined by ELISPOT. Each symbol represents 
the number of spots per 3x104 effector cells (n=3 per group). Data are representative of 2 
independent experiments.  
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5.3 Discussion 
In this thesis chapter, the construction of Δ73 sOVA is described with the aim of 
addressing the role of ORF73 in modulating CD4+ T cell responses. The results presented 
show no observed replication defect in either BHK-21 or RAW-C2TA cells in vitro 
consistent with published data, particularly on BHK-21 (148, 149, 152). ORF73 disruption 
has however been shown to cause a replication defect in primary and in immortalised 
murine embryonic fibroblasts and NIH-3T3 cells (148, 222). Whether Δ73 sOVA shows this 
replication defect remains to be determined. Nevertheless, this suggests a cell type 
replication defect, which could be attributed to a difference in cell cycle (148). In vivo, there 
was a 1 to 2 log replication defect in the lungs of BALB/c and in C57BL/6 mice as 
previously reported (152). In the upper respiratory tract (nose) of C57BL/6 mice, an 
ORF73 replication defect was also observed. This suggests that, i) ORF73 could be 
dispensable for replication in certain cell types in vitro and in vivo particularly in mucosal 
sites during lytic replication, ii) modulates innate immune responses during lytic infection 
for example neutrophil recruitment, tumour necrosis factor alpha and interferon signalling 
or iii) restricts CD4+ T cell responses via unknown mechanism during latency (148, 152).  
In the lymph nodes and spleen, Δ73 sOVA was severely attenuated in reactivating from 
latency at early (day 6 or 7) and late (day 14 or 18) times during infection. Whether Δ73 
sOVA infected cells in these organs remains to be determined. ORF73 deletion mutant 
was however found to cause an early splenic infection that was undetectable by day 14 
following i.p infection. The virus was able to infect cells in the spleen but failed to establish 
latency and colonise germinal centre B cells (149). Thus, the observed Δ73 sOVA defect is 
consistent with the predicted role of ORF73 in plasmid episome maintenance (153) and in 
induction of latency and host colonisation (149, 152, 153). In a study by Paden et al., 
2010, ORF73 deficient virus was found to establish latency but failed to reactivate in the 
spleen of C57BL/6 mice following i.p infection. The difference in establishment of latency 
could be limited by either how the ORF73 deficient viruses were generated or the assays 
used to determine latency from reactivation. What is undisputable is the failure of ORF73 
deficient viruses to reactivate and persist regardless of the route of infection or mouse 
strain used. This implies that, viral genome in actively dividing infected cells is lost in 
ORF73 deficient infected cells. 
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Preliminary MHV-68 specific antibody response to sOVA, MHV-68 mOVA and IiOVA, 
which all have intact ORF73, showed elevated levels of IgG to MHV-68. This was more 
evident when OVA-specific IgG response was measured. The low level IgG response 
could be a reflection of viral load. Another possible reason could be limited number of 
persistently infected antigen presenting dendritic or B cells in the lymph nodes or the 
spleen even if CD4+ T cells in the lungs are primed (224). This was illustrated in a study by 
Fowler et al., 2003 who found no viral genome positive cells in the spleen of ORF73 
deficient infected mice (149, 152). The failure to establish germinal center B cell infection 
and expansion suggests affinity maturation and plasma cell differentiation is impaired. In 
C57BL/6 mice however, there was no difference in germinal centre formation between wild 
type and  ORF73 deficient virus (153) which argues against ORF73 involvement in 
germinal center formation in establishment of latency . Nevertheless, how ORF73 affects 
antibody response is still not clear.  
Another interesting feature of Δ73 sOVA virus was the ineffective stimulation of OVA323-339-
specific CD4+ T cells in BALB/c mice. MHV-68 mOVA and IiOVA provided robust OVA323-
339 specific CD4+ T cell IFN-γ response compared to the sOVA viruses as expected. In 
vitro, MHV-68 mOVA virus was more effective at stimulating CD4+ T cell hybridomas 
specific for the OVA323-339 peptide to secrete IL-2 than the IiOVA and the sOVA constructs. 
Thus, it is plausible that, the form of antigen limits stimulation of CD4+ T.  
To understand in detail how ORF73 would affect CD4+ T cell response, a virus specific 
CD4+ T IFN-γ response would be appropriate. Another effective control would be to 
generate Δ73 expressing membrane bound ovalbumin (Δ73 mOVA) as a direct 
comparison to MHV-68 mOVA. This would provide a powerful tool to study CD4+ T cell 
response during lytic infection.  
Δ73 sOVA was made to take advantage of the ovalbumin system and track OVA323-339-
specific KJ1-26 CD4+ T cells adoptively transferred in BALB/c mice. However, CD4+ T 
cells in DO11.10 transgenic mice were found to be heterogeneous to the clonotypic 
marker KJ1-26 for OVA323-339-specific CD4+ T cells (reviewed in chapter 3). This made 
tracking OVA323-339-specific CD4+ T cells in vivo difficult. The data presented in this thesis 
chapter nevertheless is consistent with the predicted role of ORF73 in induction of latency 
and host colonisation particularly in lymphoid sites. It provides a model in which OVA-
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specific CD4+ T cells can be studied to understand why CD4+ T cells are not effective at 
controlling lytic infection. It could also provide further insight into innate immunity and how 
adaptive immune response is shaped in the face of immune evasion. With the unexpected 
antibody profile to MHV-68 and OVA in Δ73 sOVA infected mice, dissecting how ORF73 
expression alters antibody response and whether this is CD4+ T cell dependent could 
provide valuable insight into vaccination.   
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CHAPTER 6: GENERAL DISCUSSION AND FUTURE DIRECTIONS 
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6.1 MHV-68 vaccination restricts lytic infection 
In this thesis, CD4+ T cell directed vaccine against MHV-68 was trialled using recombinant 
MCMV mOVA virus as a live attenuated vaccine. The results showed, lytically primed 
OVA-specific CD4+ T cells reduced lytic infection via IFN-γ and significantly reduced 
splenomegaly when OVA323-339 peptide was expressed in tandem with the ORF73 
promotor. This implied that, during latency, CD4+ T cells can engage infected cells. Why 
then, don’t these OVA323-339-specific CD4+ T cells restrict latency when ovalbumin is 
expressed under the lytic promoter M3? It is possible that M3 driven ovalbumin is below 
the threshold of detection when virus replication is shut off. Consequently, infected cells 
become undetectable by circulating memory CD4+ T cells. Alternatively, the small subset 
of primed circulating memory CD4+ T cells may not have cytolytic activity against 
predominately latently infected cells that are probably not presenting the OVA323-339 epitope 
(160).  
An attempt to track OVA323-339-specific CD4+ T cells using DO11.10 transgenic mice was 
unsuccessful. This would have provided an excellent opportunity to understand why during 
latency OVA323-339 specific CD4+ T cells become ineffective. Another setback experienced 
in tracking and mapping out the migration patterns of OVA323-339-specific CD4+ T cells was 
MHC II tetramers. None of the MHC II tetramers worked against different peptide registrars 
derived from OVA323-339 on CD4+ T cells isolated from DO11.10 transgenic mice or in 
MCMV mOVA vaccinated mice (data not shown). MHC II tetramers have inherent 
problems associated with low T-cell receptor (TCR)–MHC avidity and or low frequency of 
CD4+ T cells specific to the peptide (225-227). The latter seems unlikely in a transgenic or 
OVA primed mouse than in a naïve mice. As MHC II tetramer reagents improve, or new 
technologies such as recombinant artificial antigen presenting cells (226) or dextramers 
(228) emerge, identifying what subset of primed OVA323-339-specific CD4+ T cells drive or 
restrict B cell lymphoproliferation and splenomegaly, and when this occurs would be key to 
understanding how MHV-68 exploits CD4+ T cells.  
The vaccination results also demonstrated that OVA254-267 primed CD8+ T cells can 
effectively control MHV-68 lytic infection (7 days) and acute latent infection (13 to18 days) 
but failed during persistent infection (21 to 100 days). This effect was strain dependent. 
BALB/c and F1 mice failed to control lytic and acute latent infection. Other model systems, 
using MHV-68 lytic epitopes p65 (139) and latent epitopes M2 (140), targeting CD8+ T 
cells, have all yielded similar results, that is early reduction in virus load but no change in 
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persistent infection as infection progresses to day 21 or 30.  Antibody induced protection 
was also strain dependent. BALB/c mice given recombinant vaccinia virus expressing 
gH/gL effectively controlled lytic and acute latent infection while C75BL/6 mice failed. This 
perhaps shows that, gH/gL CD4+ T cell specific epitopes are present in BALB/c and not in 
C57BL/6 mice.  
Human vaccine trials using gp350 has shown that, targeting cell surface glycoprotein 
gp350 to prevent B cell infection and limit EBV disease is not an effective strategy at 
controlling infection. MHV-68 gp150, a positional homologue of EBV gp350 showed similar 
outcome in mice (138). The reduction in infectious mononucleosis observed with the 
gp350 vaccine has however provided an opportunity to model a vaccine that can restrict 
the severity of IM in infected young adults. This is progress. However, the challenge still 
remains to developing an effective EBV vaccine that can control infection. Identifying other 
viral genes or combinations of viral epitopes to vaccinate with requires further research.  
The use of cytomegaloviruses as potential vaccine vectors against persistent viruses like 
HIV is a recent development. In the macaque model for AIDS, Rhesus CMV provided 
robust SIV gag-specific CD8+ T cell response against a gag expressing RhCMV in CMV+ 
macaques. The ability to re-infect CMV+ animals and induce potent SIV-specific CD4+ and 
CD8+ T cell responses with complete protection in 50% of vaccinated rhesus macaques for 
over 12 months despite continual virus challenge (145, 146). This showed that CMV as 
vaccine vectors have potential. Subsequently, it was shown that RhCMV induced 
unconventional CD8+ T cell epitope targeting via MHC-E that was not replicated by any 
other conventional vaccine vector or SIV infection itself (146, 147). Re-infection of CMV+ 
macaques however raises potential questions about immunosuppression. Similarly, in this 
thesis, MCMV degraded MHC II in antigen presenting cells to protect infected cells from 
CD4+ T cell engagement. This restricted CD4+ T cell stimulation in vitro. How this affects 
vaccination is rather difficult to decipher. However, it is tempting to speculate that CD4+ T 
cell priming would be impaired particularly if infected antigen presenting cells 
endogenously present peptide.   
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